[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Wright Medical Technology, Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":350},{"warningLetters":4,"total":349},[5,30,48,71,89,112,130,148,169,191,212,229,252,271,291,312,329],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":29,"medical_device_id":19,"response_letter_date":19},1564,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-03-12T13:20:00Z\">03\u002F12\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-01-26T05:00:00Z\">01\u002F26\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnobles-medical-technology-ii-inc-673465-01262024\">Nobles Medical Technology II, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Review Board (IRB)","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Anthony A. Nobles, PhD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nobles Medical Technology II, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>17072 Newhope Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fountain Valley\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92708\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:anobles@noblesmedical.com\"> anobles@noblesmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>January 26, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Nobles:\u003C\u002Fp>\n\n\u003Cp>This Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at Nobles Medical Technology II, Inc. from October 16, 2023, to October 20, 2023, by investigators from the FDA’s Office of Bioresearch Monitoring Operations (OBIMO). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch EL versus FDA approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent ischemic stroke,” for NobleStitch EL, Investigational Device Exemption (IDE), G180296, complied with applicable federal regulations. The NobleStitch EL is a device as that term is defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited.\u003C\u002Fp>\n\n\u003Cp>The inspection was conducted under a program designed to ensure that data and information contained in requests for IDEs, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\u003C\u002Fp>\n\n\u003Cp>Our review of the inspection report prepared by the OBIMO revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions, which concerns requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an Inspectional Observations Form FDA-483 for your review and discussed the observations listed on the form with you. To date, your firm has not submitted a written response. The deviations noted on the Form FDA-483 and our subsequent review of the inspection report, are discussed below:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to ensure proper monitoring and Institutional Review Board (IRB) review and approval [21 CFR 812.40].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor, you are responsible for providing investigators with the information they need to conduct the investigation properly and for ensuring proper monitoring of the investigation. You are also responsible for ensuring that IRB review and approval are obtained and that the IRB and FDA are promptly informed of significant new information about an investigation. Examples of your failure include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>a. You failed to provide investigators with necessary information to properly conduct the study, including but not limited to, signed protocols, investigational brochures, and labeling.\u003C\u002Fp>\n\n\u003Cp>b. You failed to ensure proper monitoring of the study. Examples include, but are not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Lack of a written monitoring plan and procedures describing how you will monitor the investigation, including how to handle protocol deviations and investigator noncompliance.\u003C\u002Fli>\n\t\u003Cli>Site monitoring reports do not include the documents reviewed, associated findings, and communications with site personnel, including whether your site monitoring included a comparison of source documents with Case Report Forms (CRFs), an essential component of a monitoring plan to ensure data integrity.\u003C\u002Fli>\n\t\u003Cli>Additionally, you failed to secure investigator signatures on CRFs in a timely manner per the Investigator Agreement Section 10.1 (Trial Documentation). For example, Investigator \u003Cstrong>(b)(6)\u003C\u002Fstrong> signed four CRFs eight to twelve months after their monitoring visits, and Investigators \u003Cstrong>(b)(6)\u003C\u002Fstrong> and \u003Cstrong>(b)(6)\u003C\u002Fstrong> did not sign nine and two CRFs, respectively, for monitoring visits to their sites.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>c. You failed to provide documentation of IRB approvals and continuing review for site \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>and IRB approval for sites \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the protocol (versions 5 and 6) and the Amplatzer and NobleStitch CRFs.\u003C\u002Fp>\n\n\u003Cp>Proper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\u003C\u002Fp>\n\n\u003Cp>Furthermore, your failure to ensure that IRB review and approval was obtained at least annually, delays, or prevents the IRB from considering any changes in the research or research-related events and determining whether the human subject protection measures are adequate or need to be changed. Lastly, inadequate oversight of investigator activities can also significantly impact conduct of the study and therefore, the reliability of data generated in the study as well as the safety of study participants.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Failure to select qualified investigators and monitors by training and experience for conducting of a study [812.43(a) and (d)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor, you are responsible for selecting qualified investigators and monitors. Examples of your failure include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>a. You failed to ensure that clinical investigators were qualified by training and experience to conduct the study. During the inspection, you did not provide documentation, such as a curriculum vitae, to show that the clinical investigators were qualified to conduct this study.\u003C\u002Fp>\n\n\u003Cp>b. You did not provide documentation to support that you have the proper training and experience to appropriately monitor the study.\u003C\u002Fp>\n\n\u003Cp>The selection of qualified investigators and monitors is essential to ensure subjects’ safety and that your study is conducted properly in accordance with Good Clinical Practices.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Failure to obtain a signed agreement from each participating investigator that includes a statement of the investigator’s commitment to conduct an investigation in accordance with the agreement, investigational plan, applicable FDA regulations, conditions of approval imposed by the reviewing IRB and conditions of approval imposed by the FDA [21 CFR 812.43(c)(4)(i)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor, you are responsible for obtaining from each participating investigator a signed agreement that includes a statement of the investigator's commitment to conduct the investigation in accordance with the agreement, the investigational plan, and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB or FDA.\u003C\u002Fp>\n\n\u003Cp>While signed agreements were obtained of participating clinical investigators, they lack a statement of the investigator’s commitment to supervise all testing of the device involving human subjects. Obtaining signed agreements is important for ensuring that investigators participating in the clinical study are accountable for the conduct of the study.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Failure to obtain from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement [21 CFR 812.43(c)(5)].\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a sponsor you are responsible for obtaining from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement.\u003C\u002Fp>\n\n\u003Cp>You failed to obtain a signed agreement that includes sufficient accurate financial disclosure information from each participating investigator. Specifically, you did not provide financial disclosure records for any site during your inspection. Obtaining accurate financial disclosure information is important for ensuring that there is no financial bias by any of your clinical investigators that may impact clinical study data.\u003C\u002Fp>\n\n\u003Cp>In addition to the above objectionable conditions found during the inspection of your U.S. sites, there were similar observations noted for your site in Italy, which is your largest enrolling site. These observations include inadequate study protocols, lack of investigator agreements, inadequate informed consent, inadequate adverse event reporting, inadequate investigational device tracking, and inadequate monitoring.\u003C\u002Fp>\n\n\u003Cp>All of these failures raise significant concerns regarding whether your study will yield credible and accurate data and whether the rights, safety and well-being of subjects are adequately protected. The consequences of these failures are evidenced by the decision to suspend your study and the numerous cycles of review of your annual reports for the IDE, where discrepant and unclear information has been provided regarding fundamental aspects of your study (e.g., reviewing IRBs and sites and numbers of enrolled\u002Fimplanted subjects) as well as safety and effectiveness information.\u003C\u002Fp>\n\n\u003Cp>The violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\u003C\u002Fp>\n\n\u003Cp>Within 15 working days of receiving this letter, please provide documentation of the corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\u003C\u002Fp>\n\n\u003Cp>Your response should reference “CTS# G180296\u002FE003” and be sent via email to: Albert.Rodriguez@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>A copy of this letter has been sent to FDA’s OBIMO West via email ORABIMOW.Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\u003C\u002Fp>\n\n\u003Cp>The Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, you may contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Soma Kalb, PhD\u003Cbr>\nDirector\u003Cbr>\nDivision of Clinical Policy and Quality\u003Cbr>\nOffice of Clinical Evidence &amp; Analysis\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nAnthony A. Nobles, PhD\n\nRecipient Title\n\nChairman and CEO\n\nNobles Medical Technology II, Inc.\n\n17072 Newhope Street\n\nFountain Valley, CA 92708\n\nUnited States\n\nanobles@noblesmedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nJanuary 26, 2024\n\nDear Dr. Nobles:\n\nThis Warning Letter is to inform you of objectionable conditions observed during the Food and Drug Administration (FDA) inspection conducted at Nobles Medical Technology II, Inc. from October 16, 2023, to October 20, 2023, by investigators from the FDA’s Office of Bioresearch Monitoring Operations (OBIMO). This inspection was conducted to determine whether activities and procedures as sponsor in the significant risk clinical study “STITCH - Prospective Multi-Center Comparative Parallel Concurrent Study of the NobleStitch EL versus FDA approved Amplatzer Occluder device for closure of Patent Foramen Ovale to prevent recurrent ischemic stroke,” for NobleStitch EL, Investigational Device Exemption (IDE), G180296, complied with applicable federal regulations. The NobleStitch EL is a device as that term is defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body. This letter also requests prompt corrective action to address the violations cited.\n\nThe inspection was conducted under a program designed to ensure that data and information contained in requests for IDEs, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\n\nOur review of the inspection report prepared by the OBIMO revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 812 - Investigational Device Exemptions, which concerns requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). At the close of the inspection, the FDA investigator presented an Inspectional Observations Form FDA-483 for your review and discussed the observations listed on the form with you. To date, your firm has not submitted a written response. The deviations noted on the Form FDA-483 and our subsequent review of the inspection report, are discussed below:\n\n1. Failure to ensure proper monitoring and Institutional Review Board (IRB) review and approval [21 CFR 812.40].\n\nAs a sponsor, you are responsible for providing investigators with the information they need to conduct the investigation properly and for ensuring proper monitoring of the investigation. You are also responsible for ensuring that IRB review and approval are obtained and that the IRB and FDA are promptly informed of significant new information about an investigation. Examples of your failure include, but are not limited to, the following:\n\na. You failed to provide investigators with necessary information to properly conduct the study, including but not limited to, signed protocols, investigational brochures, and labeling.\n\nb. You failed to ensure proper monitoring of the study. Examples include, but are not limited to:\n\nLack of a written monitoring plan and procedures describing how you will monitor the investigation, including how to handle protocol deviations and investigator noncompliance.\n\nSite monitoring reports do not include the documents reviewed, associated findings, and communications with site personnel, including whether your site monitoring included a comparison of source documents with Case Report Forms (CRFs), an essential component of a monitoring plan to ensure data integrity.\n\nAdditionally, you failed to secure investigator signatures on CRFs in a timely manner per the Investigator Agreement Section 10.1 (Trial Documentation). For example, Investigator (b)(6) signed four CRFs eight to twelve months after their monitoring visits, and Investigators (b)(6) and (b)(6) did not sign nine and two CRFs, respectively, for monitoring visits to their sites.\n\nc. You failed to provide documentation of IRB approvals and continuing review for site (b)(4) and IRB approval for sites (b)(4) and (b)(4) for the protocol (versions 5 and 6) and the Amplatzer and NobleStitch CRFs.\n\nProper monitoring helps ensure that the safety, rights, and well-being of the subjects are protected, and that the data are complete and accurate. Monitoring should be an on-going program performed with the frequency necessary to ensure that the investigation is conducted according to the investigational plan, FDA regulations, and any conditions of approval required by the FDA or the reviewing IRB. Inadequate monitoring can lead to reporting of inaccurate data, missing data, enrollment of subjects that do not meet eligibility criteria, and poor adverse event reporting, among other concerns. In addition, without adequate monitoring there is no assurance that your study conduct is compliant and that any instances of noncompliance are resolved properly.\n\nFurthermore, your failure to ensure that IRB review and approval was obtained at least annually, delays, or prevents the IRB from considering any changes in the research or research-related events and determining whether the human subject protection measures are adequate or need to be changed. Lastly, inadequate oversight of investigator activities can also significantly impact conduct of the study and therefore, the reliability of data generated in the study as well as the safety of study participants.\n\n2. Failure to select qualified investigators and monitors by training and experience for conducting of a study [812.43(a) and (d)].\n\nAs a sponsor, you are responsible for selecting qualified investigators and monitors. Examples of your failure include, but are not limited to, the following:\n\na. You failed to ensure that clinical investigators were qualified by training and experience to conduct the study. During the inspection, you did not provide documentation, such as a curriculum vitae, to show that the clinical investigators were qualified to conduct this study.\n\nb. You did not provide documentation to support that you have the proper training and experience to appropriately monitor the study.\n\nThe selection of qualified investigators and monitors is essential to ensure subjects’ safety and that your study is conducted properly in accordance with Good Clinical Practices.\n\n3. Failure to obtain a signed agreement from each participating investigator that includes a statement of the investigator’s commitment to conduct an investigation in accordance with the agreement, investigational plan, applicable FDA regulations, conditions of approval imposed by the reviewing IRB and conditions of approval imposed by the FDA [21 CFR 812.43(c)(4)(i)].\n\nAs a sponsor, you are responsible for obtaining from each participating investigator a signed agreement that includes a statement of the investigator's commitment to conduct the investigation in accordance with the agreement, the investigational plan, and other applicable FDA regulations, and conditions of approval imposed by the reviewing IRB or FDA.\n\nWhile signed agreements were obtained of participating clinical investigators, they lack a statement of the investigator’s commitment to supervise all testing of the device involving human subjects. Obtaining signed agreements is important for ensuring that investigators participating in the clinical study are accountable for the conduct of the study.\n\n4. Failure to obtain from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement [21 CFR 812.43(c)(5)].\n\nAs a sponsor you are responsible for obtaining from each participating investigator a signed agreement that includes sufficient accurate financial disclosure information to allow the sponsor to submit a complete and accurate certification or disclosure statement.\n\nYou failed to obtain a signed agreement that includes sufficient accurate financial disclosure information from each participating investigator. Specifically, you did not provide financial disclosure records for any site during your inspection. Obtaining accurate financial disclosure information is important for ensuring that there is no financial bias by any of your clinical investigators that may impact clinical study data.\n\nIn addition to the above objectionable conditions found during the inspection of your U.S. sites, there were similar observations noted for your site in Italy, which is your largest enrolling site. These observations include inadequate study protocols, lack of investigator agreements, inadequate informed consent, inadequate adverse event reporting, inadequate investigational device tracking, and inadequate monitoring.\n\nAll of these failures raise significant concerns regarding whether your study will yield credible and accurate data and whether the rights, safety and well-being of subjects are adequately protected. The consequences of these failures are evidenced by the decision to suspend your study and the numerous cycles of review of your annual reports for the IDE, where discrepant and unclear information has been provided regarding fundamental aspects of your study (e.g., reviewing IRBs and sites and numbers of enrolled\u002Fimplanted subjects) as well as safety and effectiveness information.\n\nThe violations described above are not intended to be an all-inclusive list of problems that may exist with your clinical study. It is your responsibility as a study sponsor to ensure compliance with the Act and applicable regulations.\n\nWithin 15 working days of receiving this letter, please provide documentation of the corrective and preventative actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the study sponsor. Any submitted corrective action plan must include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you.\n\nYour response should reference “CTS# G180296\u002FE003” and be sent via email to: Albert.Rodriguez@fda.hhs.gov.\n\nA copy of this letter has been sent to FDA’s OBIMO West via email ORABIMOW.Correspondence@fda.hhs.gov. Please send a copy of your response to that office.\n\nThe Division of Clinical Policy and Quality has developed introductory training modules in FDA-regulated device clinical research practices, which are available on the FDA website. The modules are for persons involved in FDA-regulated device clinical research activities. These modules are located at the following website address: http:\u002F\u002Fwww.fda.gov\u002FTraining\u002FCDRHLearn.\n\nIf you have any questions, you may contact Alejandra Cambonchi by phone at (301) 796-0552 or email at Alejandra.Cambonchi@fda.hhs.gov.\n\nSincerely yours,\n\n\u002FS\u002F\n\nSoma Kalb, PhD\n\nDirector\n\nDivision of Clinical Policy and Quality\n\nOffice of Clinical Evidence & Analysis\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Nobles Medical Technology II, Inc.","nobles-medical-technology-ii-inc-673465-01262024","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnobles-medical-technology-ii-inc-673465-01262024","2026-10-26T08:09:34.338448+00:00","Warning Letter","Issued","2024-03-12","673465","Medical Devices","Anthony A. Nobles, PhD","2026-08-20T00:14:37.004+00:00","2024-01-26",{"id":31,"raw":32,"subject":36,"body_html":37,"body_text":38,"firm_name":39,"letter_id":40,"created_at":41,"fei_number":19,"letter_url":42,"updated_at":43,"action_type":22,"case_status":23,"posted_date":44,"marcs_cms_no":45,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":19,"body_fetched_at":46,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":47,"medical_device_id":19,"response_letter_date":19},3219,[33,34,35,11,36,13,13,13],"\u003Ctime datetime=\"2021-08-10T13:20:00Z\">08\u002F10\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-29T04:00:00Z\">07\u002F29\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flepu-medical-technology-beijing-co-ltd-614908-07292021\">Lepu Medical Technology -Beijing- Co., Ltd.\u003C\u002Fa>","Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Lepu Medical Technology -Beijing- Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 37 Chaoqian Rd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Changping Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Beijing Shi\u003C\u002Fspan>,\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:lee-fu@mid-link.net\"> lee-fu@mid-link.net\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: July 29, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has observed that your firm offers for sale a Neutralization Antibody Test kit (Colloidal Gold, Fluorescent, Elisa), a SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography), and a Saliva Antigen Rapid Test (hereinafter collectively referred to as “COVID-19 Test Kits”) in the United States. Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The COVID-19 Test Kits are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your COVID-19 Test Kits are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\u003C\u002Fp>\n\n\u003Cp>You should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Please direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT7: Office of In Vitro Diagnostics and Radiological\u003Cbr>\nHealth\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>_________________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) (Mar. 13, 2020), available at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nLepu Medical Technology -Beijing- Co., Ltd.\n\nNo. 37 Chaoqian Rd.\n\nChangping Qu\n\nBeijing Shi,\n\nChina\n\nlee-fu@mid-link.net\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDate: July 29, 2021\n\nRE: Adulterated and Misbranded Products Related to Coronavirus Disease 2019 (COVID-19)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has observed that your firm offers for sale a Neutralization Antibody Test kit (Colloidal Gold, Fluorescent, Elisa), a SARS-CoV-2 Antigen Rapid Test Kit (Colloidal Gold Immunochromatography), and a Saliva Antigen Rapid Test (hereinafter collectively referred to as “COVID-19 Test Kits”) in the United States. Based on our review, your COVID-19 Test Kits are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people, and thus, they are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe COVID-19 Test Kits are offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, your COVID-19 Test Kits are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). Your products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of these products into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.2 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.3 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell products that are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of such unapproved, uncleared, and unauthorized products for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices. In addition, the guidance titled “Policy for Coronavirus Disease 2019 Tests During the Public Health Emergency (Revised)”4 provides information about FDA’s policies intended to help expand testing capacity by facilitating the development and use of COVID-19 tests during the public health emergency.\n\nYou should take immediate action to address the violations cited in this letter. This letter is not meant to be an all-inclusive list of violations that exist in connection with your products or operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your products as safe and\u002For effective for a COVID-19-related use for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the products in violation of the Act. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address these violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Failure to adequately correct any violations may result in legal action, including, without limitation, seizure and injunction.\n\nFDA is advising consumers not to purchase or use certain products that are not in compliance with FDA requirements and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of your unapproved, uncleared, and unauthorized products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. If you believe that your product is not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded are subject to detention and refusal of admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nPlease direct any inquiries to FDA at COVID-19-Task-Force-CDRH@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT7: Office of In Vitro Diagnostics and Radiological\n\nHealth\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n_________________________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 Secretary of Health and Human Services Alex M. Azar II, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020 and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx).\n\n3 President Donald J. Trump, Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) (Mar. 13, 2020), available at https:\u002F\u002Fwww.whitehouse.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F).\n\n4 Accessible at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F135659\u002Fdownload.","Lepu Medical Technology -Beijing- Co., Ltd.","lepu-medical-technology-beijing-co-ltd-614908-07292021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flepu-medical-technology-beijing-co-ltd-614908-07292021","2026-10-26T08:09:13.643652+00:00","2021-08-10","614908","2026-08-20T02:42:51.907+00:00","2021-07-29",{"id":49,"raw":50,"subject":55,"body_html":57,"body_text":58,"firm_name":59,"letter_id":60,"created_at":41,"fei_number":19,"letter_url":61,"updated_at":62,"action_type":22,"case_status":63,"posted_date":64,"marcs_cms_no":65,"product_type":26,"closeout_date":66,"issuing_office":54,"recipient_name":67,"body_fetched_at":68,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":70,"medical_device_id":19,"response_letter_date":19},3079,[51,52,53,54,55,13,56,13],"\u003Ctime datetime=\"2021-10-19T13:20:00Z\">10\u002F19\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-09-17T04:00:00Z\">09\u002F17\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmagnolia-medical-technologies-inc-617922-09172021\">Magnolia Medical Technologies, Inc.\u003C\u002Fa>","Office of Medical Devices and Radiological Health, Division 3","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmagnolia-medical-technologies-inc-617922-05042022\">\u003Ctime datetime=\"2022-05-18T04:00:00Z\">05\u002F18\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Gregory J. Bullington\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Magnolia Medical Technologies, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>200 W. Mercer Street, Suite 500\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Seattle\u003C\u002Fspan>, \u003Cspan>WA\u003C\u002Fspan> \u003Cspan>98119\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Greg.bullington@magnolia-medical.com\"> Greg.bullington@magnolia-medical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Devices and Radiological Health, Division 3\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS 617922\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>September 17, 2021\u003Cbr>\n\u003Cbr>\nDear Mr. Bullington:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your medical device operations at 200 W. Mercer Street, Suite 500, Seattle, WA 98119 from June 3, 2021 through July 15, 2021. During the inspection, an FDA Investigator determined that your firm is a specification developer for the Steripath Gen 2 Blood Collection System (K192247). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that the Steripath Gen 2 device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your firm’s response dated August 5, 2021 concerning our Investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on July 15, 2021. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example,\u003C\u002Fp>\n\n\u003Cp>a. Your firm’s Corrective and Preventive Action SOP, D00011, Rev. D requires your firm to track all meetings pertaining to your CAPA activities in the product investigation section of your Corrective Action Report (CAR). Your firm’s HHE-001 Closure Memo dated January 13, 2021 references meetings held to discuss CAR C00046 on October 8, 2020 and in November 2020. However, these meetings are not described or attached to your CAR C00046.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your firm’s response dated August 5, 2021 and determined it is inadequate. Your firm’s response acknowledges these meetings were held and states the meeting minutes were never finalized. Your response states your CAPA procedures will be revised to clarify requirements for maintaining meeting minutes. However, your response does not identify that your firm has now finalized and included in your records the subject meeting minutes. Further, your response does not address how your firm evaluated other CARs for similar deficiencies. Lastly, we acknowledge your firm’s commitment to revise your CAPA procedures, however, there is insufficient detail of the proposed changes in your response to allow us to evaluate the adequacy at this time.\u003C\u002Fp>\n\n\u003Cp>b. Your firm’s CAPA C00046 includes an investigation conducted by your supplier of your butterfly retractable needles for premature retraction. This investigation identified three potential causes including 1) \u003Cstrong>(b)(4)\u003C\u002Fstrong>, 2) application of \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization, and 3) failure to adhere to shelf-life specifications assigned by the component supplier. Your firm’s CAPA C00046 includes your firm’s evaluation of the primary cause (\u003Cstrong>(b)(4)\u003C\u002Fstrong>); however, your firm did not investigate or document your evaluation of the other potential causes.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures. Your response states your firm held several meetings to discuss these causes; however, it does not identify how you have documented and included your evaluations and investigations into these cases in your CAR C00046. Additionally, your response does not address if your firm has reviewed other CARs for similar deficiencies.\u003C\u002Fp>\n\n\u003Cp>Additionally, in your response to this letter, please also include description and records of corrective actions or evaluations conducted into the acceptance activities and purchasing controls associated with your butterfly retractable needles.\u003C\u002Fp>\n\n\u003Cp>c. Your firm initiated CAR C00050 on August 20, 2020 after identifying the bill of materials for product parts \u003Cstrong>(b)(4)\u003C\u002Fstrong> (various configurations of your Steripath Gen 2 device) contained incorrect instruction for use (IFU) designations. This CAR was closed on April 29, 2021 stating it did not qualify for a CAR because it was identified prior to implementation of the changes. However, your firm identified in October 2020, two additional lots of product (\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>) were manufactured and subsequently quarantined and reworked. Additionally, our inspection identified that a third lot, 9448037, was manufactured and distributed using the incorrect IFU that your firm did not identify prior to distribution. Your firm’s CAR C00050 did not include adequate investigation to identify and correct all affected products.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures and has opened CAR C00073 to investigate the CAPA deficiencies. However, there is inadequate description of the proposed changes for us to evaluate the adequacy at this time. Additionally, your response does not address evaluations of other CARs to determine if similar deficiencies exist.\u003C\u002Fp>\n\n\u003Cp>d. Your firm initiated CAR C00055 on January 8, 2021 to investigate lack of implementation of changes to your Steripath Gen 2 labeling after receiving clearance for expanded indications for use. Your CAR C00055 does not include descriptions and records of your investigation into the cause of the nonconformance to ensure systemic corrective actions.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and determined it is inadequate. We acknowledge you have initiated a removal for this product and your response states your firm is revising your CAPA procedures. However, your response does not address what corrective actions you are taking to specifically address CAR C00055. Additionally, your response does not address reviews of other CARs to determine if similar deficiencies exist.\u003C\u002Fp>\n\n\u003Cp>2. Failure to establish and maintain adequate procedures for verifying the device design to confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm did not conduct verification testing to support the shelf life of your Steripath Gen 2 with the butterfly needle inlet accessory.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and the “Steripath Gen2 Blood Collection Set (Needle) Configuration Shelf Life Verification Report”, D00309, Rev. A dated June 11, 2021. We cannot determine the adequacy of your response at this time. Your firm’s response states your firm will conduct a retrospective review of all verifications of your Steripath Gen 2 device to assess the impact of using the \u003Cstrong>(b)(4)\u003C\u002Fstrong> inlet accessory as the model in the testing. Additionally, your response states your firm is updating your design verification procedures to require evaluation of the inlet and outlet accessories. We request you provide updates to these activities in your response to this letter. Additionally, the provided verification report shows sections 2.4.2, 2.4.3, and 2.4.4 of the test protocol were not complete. In your response to this letter, please include an explanation of why these sections were not completed.\u003C\u002Fp>\n\n\u003Cp>3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm’s supplier of the butterfly needle inlet of your Steripath Gen 2 device applies a 2-year shelf life to the component. Your firm does not have manufacturing procedures to document and control the remaining shelf life of these components when used in the manufacturing of Steripath Gen 2 finished device which you apply a 2-year shelf life.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your response dated August 5, 2021 and we cannot determine the adequacy of your response at this time. Your response commits to reviewing all components of your Steripath Gen 2 device and establish procedures to monitor and control remaining shelf life at the time of manufacturing the device. In response to this letter please include updates and supporting records of implementation of these corrective actions as they progress.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Additionally, On July 7, 2021, FDA held a conference call with your firm’s Director of Operations and your firm’s Director of Quality and Regulatory to discuss concerns pertaining to your firm’s corrective actions associated with CAR C00046. During this call it was communicated to you that your firm’s CAR C00046 did not document corrective actions to address previously distributed nonconforming products. Your firm’s Director of Operations stated that a timeline of the corrective actions and the investigation addressing these concerns would be provided to the Agency. We have reviewed your firm’s memorandum dated July 12, 2021, and we do not believe the response adequately addresses those concerns. We request a conference call to further discuss your corrective actions to CAR 00046 with our Office of Medical Device and Radiological Health Operations Division 3. Please contact Compliance Officer Jeff R. Wooley to arrange a time for this call.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at \u003Cstrong>ORADevices3 FirmResponse@fda.hhs.gov\u003C\u002Fstrong>. Please identify your response with FEI 3009976527.\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact Compliance Officer Jeff R. Wooley at 214-253-5251, or via e-mail at jeffrey.wooley@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Devices and Radiological\u003Cbr>\nHealth, Division 3\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nGregory J. Bullington\n\nRecipient Title\n\nCEO\n\nMagnolia Medical Technologies, Inc.\n\n200 W. Mercer Street, Suite 500\n\nSeattle, WA 98119\n\nUnited States\n\nGreg.bullington@magnolia-medical.com\n\nIssuing Office:\n\nOffice of Medical Devices and Radiological Health, Division 3\n\nUnited States\n\nWARNING LETTER\n\nCMS 617922\n\nSeptember 17, 2021\n\nDear Mr. Bullington:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your medical device operations at 200 W. Mercer Street, Suite 500, Seattle, WA 98119 from June 3, 2021 through July 15, 2021. During the inspection, an FDA Investigator determined that your firm is a specification developer for the Steripath Gen 2 Blood Collection System (K192247). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that the Steripath Gen 2 device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your firm’s response dated August 5, 2021 concerning our Investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on July 15, 2021. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example,\n\na. Your firm’s Corrective and Preventive Action SOP, D00011, Rev. D requires your firm to track all meetings pertaining to your CAPA activities in the product investigation section of your Corrective Action Report (CAR). Your firm’s HHE-001 Closure Memo dated January 13, 2021 references meetings held to discuss CAR C00046 on October 8, 2020 and in November 2020. However, these meetings are not described or attached to your CAR C00046.\n\nWe have reviewed your firm’s response dated August 5, 2021 and determined it is inadequate. Your firm’s response acknowledges these meetings were held and states the meeting minutes were never finalized. Your response states your CAPA procedures will be revised to clarify requirements for maintaining meeting minutes. However, your response does not identify that your firm has now finalized and included in your records the subject meeting minutes. Further, your response does not address how your firm evaluated other CARs for similar deficiencies. Lastly, we acknowledge your firm’s commitment to revise your CAPA procedures, however, there is insufficient detail of the proposed changes in your response to allow us to evaluate the adequacy at this time.\n\nb. Your firm’s CAPA C00046 includes an investigation conducted by your supplier of your butterfly retractable needles for premature retraction. This investigation identified three potential causes including 1) (b)(4), 2) application of (b)(4) sterilization, and 3) failure to adhere to shelf-life specifications assigned by the component supplier. Your firm’s CAPA C00046 includes your firm’s evaluation of the primary cause ((b)(4)); however, your firm did not investigate or document your evaluation of the other potential causes.\n\nWe have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures. Your response states your firm held several meetings to discuss these causes; however, it does not identify how you have documented and included your evaluations and investigations into these cases in your CAR C00046. Additionally, your response does not address if your firm has reviewed other CARs for similar deficiencies.\n\nAdditionally, in your response to this letter, please also include description and records of corrective actions or evaluations conducted into the acceptance activities and purchasing controls associated with your butterfly retractable needles.\n\nc. Your firm initiated CAR C00050 on August 20, 2020 after identifying the bill of materials for product parts (b)(4) (various configurations of your Steripath Gen 2 device) contained incorrect instruction for use (IFU) designations. This CAR was closed on April 29, 2021 stating it did not qualify for a CAR because it was identified prior to implementation of the changes. However, your firm identified in October 2020, two additional lots of product ((b)(4) and (b)(4)) were manufactured and subsequently quarantined and reworked. Additionally, our inspection identified that a third lot, 9448037, was manufactured and distributed using the incorrect IFU that your firm did not identify prior to distribution. Your firm’s CAR C00050 did not include adequate investigation to identify and correct all affected products.\n\nWe have reviewed your response dated August 5, 2021 and determined it is inadequate. Your response states your firm is revising your CAPA procedures and has opened CAR C00073 to investigate the CAPA deficiencies. However, there is inadequate description of the proposed changes for us to evaluate the adequacy at this time. Additionally, your response does not address evaluations of other CARs to determine if similar deficiencies exist.\n\nd. Your firm initiated CAR C00055 on January 8, 2021 to investigate lack of implementation of changes to your Steripath Gen 2 labeling after receiving clearance for expanded indications for use. Your CAR C00055 does not include descriptions and records of your investigation into the cause of the nonconformance to ensure systemic corrective actions.\n\nWe have reviewed your response dated August 5, 2021 and determined it is inadequate. We acknowledge you have initiated a removal for this product and your response states your firm is revising your CAPA procedures. However, your response does not address what corrective actions you are taking to specifically address CAR C00055. Additionally, your response does not address reviews of other CARs to determine if similar deficiencies exist.\n\n2. Failure to establish and maintain adequate procedures for verifying the device design to confirm that the design output meets the design input requirements, as required by 21 CFR 820.30(f).\n\nSpecifically, your firm did not conduct verification testing to support the shelf life of your Steripath Gen 2 with the butterfly needle inlet accessory.\n\nWe have reviewed your response dated August 5, 2021 and the “Steripath Gen2 Blood Collection Set (Needle) Configuration Shelf Life Verification Report”, D00309, Rev. A dated June 11, 2021. We cannot determine the adequacy of your response at this time. Your firm’s response states your firm will conduct a retrospective review of all verifications of your Steripath Gen 2 device to assess the impact of using the (b)(4) inlet accessory as the model in the testing. Additionally, your response states your firm is updating your design verification procedures to require evaluation of the inlet and outlet accessories. We request you provide updates to these activities in your response to this letter. Additionally, the provided verification report shows sections 2.4.2, 2.4.3, and 2.4.4 of the test protocol were not complete. In your response to this letter, please include an explanation of why these sections were not completed.\n\n3. Failure to develop, conduct, control, and monitor production processes to ensure that a device conforms to its specifications, as required by 21 CFR 820.70(a).\n\nSpecifically, your firm’s supplier of the butterfly needle inlet of your Steripath Gen 2 device applies a 2-year shelf life to the component. Your firm does not have manufacturing procedures to document and control the remaining shelf life of these components when used in the manufacturing of Steripath Gen 2 finished device which you apply a 2-year shelf life.\n\nWe have reviewed your response dated August 5, 2021 and we cannot determine the adequacy of your response at this time. Your response commits to reviewing all components of your Steripath Gen 2 device and establish procedures to monitor and control remaining shelf life at the time of manufacturing the device. In response to this letter please include updates and supporting records of implementation of these corrective actions as they progress.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nAdditionally, On July 7, 2021, FDA held a conference call with your firm’s Director of Operations and your firm’s Director of Quality and Regulatory to discuss concerns pertaining to your firm’s corrective actions associated with CAR C00046. During this call it was communicated to you that your firm’s CAR C00046 did not document corrective actions to address previously distributed nonconforming products. Your firm’s Director of Operations stated that a timeline of the corrective actions and the investigation addressing these concerns would be provided to the Agency. We have reviewed your firm’s memorandum dated July 12, 2021, and we do not believe the response adequately addresses those concerns. We request a conference call to further discuss your corrective actions to CAR 00046 with our Office of Medical Device and Radiological Health Operations Division 3. Please contact Compliance Officer Jeff R. Wooley to arrange a time for this call.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nYour response should be sent to: US Food and Drug Administration, Division 3\u002FWest, Office of Medical Device and Radiological Health Operations at ORADevices3 FirmResponse@fda.hhs.gov. Please identify your response with FEI 3009976527.\n\nIf you have any questions about the contents of this letter, please contact Compliance Officer Jeff R. Wooley at 214-253-5251, or via e-mail at jeffrey.wooley@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Devices and Radiological\n\nHealth, Division 3","Magnolia Medical Technologies, Inc.","magnolia-medical-technologies-inc-617922-09172021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmagnolia-medical-technologies-inc-617922-09172021","2026-10-26T08:09:18.447816+00:00","Closed Out","2021-10-19","617922","2022-05-18","Gregory J. Bullington","2026-08-20T02:31:05.728+00:00","VIA Electronic Mail","2021-09-17",{"id":72,"raw":73,"subject":77,"body_html":78,"body_text":79,"firm_name":80,"letter_id":81,"created_at":41,"fei_number":19,"letter_url":82,"updated_at":83,"action_type":22,"case_status":23,"posted_date":84,"marcs_cms_no":85,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":86,"body_fetched_at":87,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":88,"medical_device_id":19,"response_letter_date":19},3276,[74,75,76,11,77,13,13,13],"\u003Ctime datetime=\"2021-07-06T13:20:00Z\">07\u002F06\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-06-04T04:00:00Z\">06\u002F04\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzhejiang-xichen-medical-technology-co-ltd-612946-06042021\">Zhejiang Xichen Medical Technology Co., Ltd.\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yinlong Dong\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Zhejiang Xichen Medical Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2nd Floor, 3 Building, No. 6, Lvyuan Zhong Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Quzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Zhejiang Sheng\u003C\u002Fspan>, \u003Cspan>324000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:xs2@xicengroup.com\"> xs2@xicengroup.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Xichen001@aliyun.com\"> Xichen001@aliyun.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>DATE: June 4, 2021\u003Cbr>\n\u003Cbr>\nRe: “FFP2 NR 5-Layer KN95 Face Mask,” “Medical Face Mask,” and “Sterile Surgical Mask”\u003C\u002Fp>\n\n\u003Cp>Dear Yinlong Dong:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at the internet address https:\u002F\u002Fwww.xichen-med.com\u002F on March 23, 2021. The FDA has observed that your website offers the “FFP2 NR 5-Layer KN95 Face Mask,” “Medical Face Mask,” and “Sterile Surgical Mask” for sale in the United States. Based on our review, these products are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h). We also note that the FFP2 NR 5-Layer KN95 Face Mask is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people.\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the products are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, including but not limited to:\u003C\u002Fp>\n\n\u003Cp>• Representing the FFP2 NR 5-Layer KN95 Face Mask as a “COVID-19 Respirator” with “effective antibacterial” properties for use to “prevent…bacteria, droplets and other harmful particles,” “filter germs,” and provide “protection for your family” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fffp2-nr-5-layer-kn95-face-mask.html]\u003Cbr>\n• Representing the Medical Face Mask for use to “prevent infection,” “protect patients and other persons from the transmission of pathogenic microorganisms, body fluids, particulate matter, etc., especially in the event of an epidemic or pandemic,” and provide “protection for your family” as well as offering a “bacterial filtration efficiency [of] &gt; 98%” and “microbial cleanliness [of] &lt;30CFY\u002Fg” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fdisposable-mask.html]\u003Cbr>\n• Representing the Sterile Surgical Mask as a “Medical Surgical Mask” that is “antibacterial” and provides a “BFE above 95%” for use to “prevent the spread of body fluids and body splash content and isolate dust, particle [sic], alcohol, blood, bacteria, and virus invading.” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fsterile-surgical-mask.html]\u003C\u002Fp>\n\n\u003Cp>The FFP2 NR 5-Layer KN95 Face Mask, Medical Face Mask, and Sterile Surgical Mask (each of which your website indicates is manufactured by Zhejiang Xichen Medical Technology Co. Ltd) are offered for sale in the United States without marketing approval, clearance, or authorization from the FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>In addition, the FFP2 NR 5-Layer KN95 Face Mask is misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because its labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. 21 CFR 807.39.\u003C\u002Fp>\n\n\u003Cp>Your website contains a number of false or misleading representations, including but not limited to:\u003C\u002Fp>\n\n\u003Cp>• Displaying a “FDA REGISTRATION CERTIFICATE” also referred to as the “kn95-FDA Certificate” issued by “J &amp; F Technology Services LLC” (Certificate) under the “About Us” tab on your website. The Certificate certifies that “Zhejiang Xichen Medical Technology Co., Ltd…has completed the FDA Establishment Registration (as manufacturer, foreign exporter, contract manufacturer) and Device Listing with the US Food &amp; Drug Administration.” The Certificate has the look of an official government document, incorporating unauthorized use of the FDA logo\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and an illustration of an eagle and a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.xichen-med.com\u002Four-certificate]\u003Cbr>\n• Displaying a screenshot titled “kn-95-Registration information is available on the FDA website” of what appears to be Zhejiang Xichen Medical Technology Co., Ltd.’s previous entry in FDA’s Establishment Registration &amp; Device Listing Database. [https:\u002F\u002Fwww.xichen-med.com\u002Four-certificate]\u003C\u002Fp>\n\n\u003Cp>Taken together, display of the Certificate, bearing the FDA logo, and a screenshot from FDA’s Establishment Registration &amp; Device Listing Database positioned near images of and information about the FFP2 NR 5-Layer KN95 Face Mask are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Zhejiang Xichen Medical Technology Co., Ltd. is or was registered with the FDA and that the firm is or was in possession of a registration number. Although the Certificate appears to be intended to function as a disclaimer, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificate. We also note that you seem to reference the Certificate or some other certificate on the Sterile Surgical Mask’s webpage [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fsterilesurgical-mask.html], indicating the product has a “Certificate CE, FDA.” These representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>We remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration &amp; Device Listing Database merely denotes that the establishment has provided certain information to FDA.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID -19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>3&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>This letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the Document number CMS Case# 612946 or CTS Number CPT2001023 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donna Engleman, MS, BSN\u003Cbr>\nDirector\u003Cbr>\nDivision of Market Intelligence\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>US Agent: Fanny Zhao\u003Cbr>\nJ &amp; F Technology Services LLC\u003Cbr>\n2424 Morris Ave 818\u003Cbr>\nUnion, New Jersey 07083\u003Cbr>\nEmail Address: info@jf-yiliao.com\u003C\u002Fp>\n\n\u003Cp>Contact: Yucai.qiu\u003Cbr>\nXICEN International Gmb\u003Cbr>\nGlobal Office Center, Beethovenstr. 5\u003Cbr>\nDE-60325 Frankfurt\u002FM,Germany\u003Cbr>\nEmail Address: yucai.qiu@xicengroup.com\u003C\u002Fp>\n\n\u003Cp>XICEN International Corporation\u003Cbr>\n245 E. Main Street, Suite 107\u003Cbr>\nAlhambra, California, 91801\u003C\u002Fp>\n\n\u003Cp>_________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nYinlong Dong\n\nZhejiang Xichen Medical Technology Co., Ltd.\n\n2nd Floor, 3 Building, No. 6, Lvyuan Zhong Road\n\nQuzhou Shi\n\nZhejiang Sheng, 324000\n\nChina\n\nxs2@xicengroup.com\n\nXichen001@aliyun.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDATE: June 4, 2021\n\nRe: “FFP2 NR 5-Layer KN95 Face Mask,” “Medical Face Mask,” and “Sterile Surgical Mask”\n\nDear Yinlong Dong:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at the internet address https:\u002F\u002Fwww.xichen-med.com\u002F on March 23, 2021. The FDA has observed that your website offers the “FFP2 NR 5-Layer KN95 Face Mask,” “Medical Face Mask,” and “Sterile Surgical Mask” for sale in the United States. Based on our review, these products are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h). We also note that the FFP2 NR 5-Layer KN95 Face Mask is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people.\n\nFDA’s review of your website revealed the following statements that establish that the products are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, including but not limited to:\n\n• Representing the FFP2 NR 5-Layer KN95 Face Mask as a “COVID-19 Respirator” with “effective antibacterial” properties for use to “prevent…bacteria, droplets and other harmful particles,” “filter germs,” and provide “protection for your family” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fffp2-nr-5-layer-kn95-face-mask.html]\n\n• Representing the Medical Face Mask for use to “prevent infection,” “protect patients and other persons from the transmission of pathogenic microorganisms, body fluids, particulate matter, etc., especially in the event of an epidemic or pandemic,” and provide “protection for your family” as well as offering a “bacterial filtration efficiency [of] > 98%” and “microbial cleanliness [of] \u003C30CFY\u002Fg” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fdisposable-mask.html]\n\n• Representing the Sterile Surgical Mask as a “Medical Surgical Mask” that is “antibacterial” and provides a “BFE above 95%” for use to “prevent the spread of body fluids and body splash content and isolate dust, particle [sic], alcohol, blood, bacteria, and virus invading.” [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fsterile-surgical-mask.html]\n\nThe FFP2 NR 5-Layer KN95 Face Mask, Medical Face Mask, and Sterile Surgical Mask (each of which your website indicates is manufactured by Zhejiang Xichen Medical Technology Co. Ltd) are offered for sale in the United States without marketing approval, clearance, or authorization from the FDA. Accordingly, the products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nIn addition, the FFP2 NR 5-Layer KN95 Face Mask is misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because its labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. 21 CFR 807.39.\n\nYour website contains a number of false or misleading representations, including but not limited to:\n\n• Displaying a “FDA REGISTRATION CERTIFICATE” also referred to as the “kn95-FDA Certificate” issued by “J & F Technology Services LLC” (Certificate) under the “About Us” tab on your website. The Certificate certifies that “Zhejiang Xichen Medical Technology Co., Ltd…has completed the FDA Establishment Registration (as manufacturer, foreign exporter, contract manufacturer) and Device Listing with the US Food & Drug Administration.” The Certificate has the look of an official government document, incorporating unauthorized use of the FDA logo2 and an illustration of an eagle and a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.xichen-med.com\u002Four-certificate]\n\n• Displaying a screenshot titled “kn-95-Registration information is available on the FDA website” of what appears to be Zhejiang Xichen Medical Technology Co., Ltd.’s previous entry in FDA’s Establishment Registration & Device Listing Database. [https:\u002F\u002Fwww.xichen-med.com\u002Four-certificate]\n\nTaken together, display of the Certificate, bearing the FDA logo, and a screenshot from FDA’s Establishment Registration & Device Listing Database positioned near images of and information about the FFP2 NR 5-Layer KN95 Face Mask are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Zhejiang Xichen Medical Technology Co., Ltd. is or was registered with the FDA and that the firm is or was in possession of a registration number. Although the Certificate appears to be intended to function as a disclaimer, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificate. We also note that you seem to reference the Certificate or some other certificate on the Sterile Surgical Mask’s webpage [https:\u002F\u002Fwww.xichen-med.com\u002Fmask\u002Fsterilesurgical-mask.html], indicating the product has a “Certificate CE, FDA.” These representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nWe remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration & Device Listing Database merely denotes that the establishment has provided certain information to FDA.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID -19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.3 In addition, on March 13, 2020, the President declared a national emergency in response to COVID-19.4 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described above, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any adulterated and misbranded products for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nThis letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the Document number CMS Case# 612946 or CTS Number CPT2001023 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonna Engleman, MS, BSN\n\nDirector\n\nDivision of Market Intelligence\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nUS Agent: Fanny Zhao\n\nJ & F Technology Services LLC\n\n2424 Morris Ave 818\n\nUnion, New Jersey 07083\n\nEmail Address: info@jf-yiliao.com\n\nContact: Yucai.qiu\n\nXICEN International Gmb\n\nGlobal Office Center, Beethovenstr. 5\n\nDE-60325 Frankfurt\u002FM,Germany\n\nEmail Address: yucai.qiu@xicengroup.com\n\nXICEN International Corporation\n\n245 E. Main Street, Suite 107\n\nAlhambra, California, 91801\n\n_________________________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy).\n\n3 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n4 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamationdeclaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Zhejiang Xichen Medical Technology Co., Ltd.","zhejiang-xichen-medical-technology-co-ltd-612946-06042021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fzhejiang-xichen-medical-technology-co-ltd-612946-06042021","2026-10-26T08:10:39.291136+00:00","2021-07-06","612946","Yinlong Dong","2026-08-20T03:00:14.241+00:00","2021-06-04",{"id":90,"raw":91,"subject":96,"body_html":97,"body_text":98,"firm_name":99,"letter_id":100,"created_at":101,"fei_number":19,"letter_url":102,"updated_at":103,"action_type":22,"case_status":23,"posted_date":104,"marcs_cms_no":105,"product_type":106,"closeout_date":19,"issuing_office":95,"recipient_name":107,"body_fetched_at":108,"delivery_method":109,"recipient_title":19,"reference_number":110,"action_taken_date":111,"medical_device_id":19,"response_letter_date":19},22203,[92,93,94,95,96,13,13,13],"\u003Ctime datetime=\"2026-11-10T05:00:00Z\">11\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-29T04:00:00Z\">10\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-healthcare-medical-technology-co-ltd-736415-10292026\">Tianjin Healthcare Medical Technology Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Refusal to Provide Access to and Copying of Records","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-15\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jianyu Zhao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Firm Contact\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tianjin Healthcare Medical Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2-2066, No 88 HuanHe South Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Free Trade Pilot Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>KongGang Economic Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Shi\u003C\u002Fspan>, \u003Cspan>300000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 29, 2026\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-27-15\u003C\u002Fp>\u003Cp>To Jianyu Zhao:\u003C\u002Fp>\u003Cp>This warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>Your facility, Tianjin Healthcare Medical Technology Co., Ltd. (hereafter THM), FDA Establishment Identifier (FEI) # 3015495180 at 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>A review of import records showed multiple shipments of APIs intended for pharmacy compounding into the U.S., which declared THM, as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\u003C\u002Fp>\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>Refusal to Provide Records\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On June 17, 2026, the FDA sent an electronic records request to the contact email address provided in your registration file. You replied on June 24, 2026, that you would “discontinue the production of relevant \u003Cstrong>(b)(4)\u003C\u002Fstrong> products” for the U.S. market and refused to provide the requested documents. A follow up request was sent on June 25, 2026, informing you that APIs your firm manufactured were imported to the U.S. market and were still within expiry. Therefore, the requested records were still required. You responded that you would not provide the requested records.\u003C\u002Fp>\u003Cp>Simply ceasing commercial distribution or expressing an intent to stop production does not retroactively relieve you of your regulatory obligations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 25, 2026.\u003C\u002Fp>\u003Cp>If you no longer intend to manufacture or distribute drug products for the U.S. market, you must formally update your registration and drug listings to reflect this change in operations. Pursuant to 21 CFR 207.29(a)(3), an establishment must update its registration within 30 calendar days of ceasing operations.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>Until FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at THM, 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\u003Cp>In response to this letter, you may submit a request to schedule an FDA inspection.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015495180 and ATTN: Marva Taylor in the letter in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: U.S. agent\u003Cbr>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-15\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nJianyu Zhao\n\nRecipient Title\n\nFirm Contact\n\nTianjin Healthcare Medical Technology Co., Ltd.\n\n2-2066, No 88 HuanHe South Road\n\nTianjin Free Trade Pilot Zone\n\nKongGang Economic Zone\n\nTianjin Shi, 300000\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 29, 2026\n\nWARNING LETTER\nReference number: 320-27-15\nTo Jianyu Zhao:\nThis warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\nYour facility, Tianjin Healthcare Medical Technology Co., Ltd. (hereafter THM), FDA Establishment Identifier (FEI) # 3015495180 at 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\nA review of import records showed multiple shipments of APIs intended for pharmacy compounding into the U.S., which declared THM, as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.\nRefusal to Provide Records\nOn June 17, 2026, the FDA sent an electronic records request to the contact email address provided in your registration file. You replied on June 24, 2026, that you would “discontinue the production of relevant (b)(4) products” for the U.S. market and refused to provide the requested documents. A follow up request was sent on June 25, 2026, informing you that APIs your firm manufactured were imported to the U.S. market and were still within expiry. Therefore, the requested records were still required. You responded that you would not provide the requested records.\nSimply ceasing commercial distribution or expressing an intent to stop production does not retroactively relieve you of your regulatory obligations.\nFDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 25, 2026.\nIf you no longer intend to manufacture or distribute drug products for the U.S. market, you must formally update your registration and drug listings to reflect this change in operations. Pursuant to 21 CFR 207.29(a)(3), an establishment must update its registration within 30 calendar days of ceasing operations.\nConclusion\nThe violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\nUntil FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at THM, 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\nIn response to this letter, you may submit a request to schedule an FDA inspection.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015495180 and ATTN: Marva Taylor in the letter in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: U.S. agent\n(b)(6)","Tianjin Healthcare Medical Technology Co., Ltd.","tianjin-healthcare-medical-technology-co-ltd-736415-10292026","2026-11-17T01:02:03.701861+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-healthcare-medical-technology-co-ltd-736415-10292026","2026-11-17T01:02:49.409207+00:00","2026-11-10","736415","Drugs Over-the-Counter Drugs","Jianyu Zhao","2026-11-17T01:02:49.249+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-27-15","2026-10-29",{"id":113,"raw":114,"subject":55,"body_html":118,"body_text":119,"firm_name":120,"letter_id":121,"created_at":122,"fei_number":19,"letter_url":123,"updated_at":124,"action_type":22,"case_status":23,"posted_date":125,"marcs_cms_no":126,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":127,"body_fetched_at":128,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":129,"medical_device_id":19,"response_letter_date":19},544,[115,116,117,11,55,13,13,13],"\u003Ctime datetime=\"2025-10-07T04:00:00Z\">10\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-26T04:00:00Z\">09\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftechnological-medical-advancements-llc-712715-09262025\">Technological Medical Advancements LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Bruce R. Coren, DVM, MS\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Technological Medical Advancements LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1601 Belvedere Rd Ste E-180\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>West Palm Beach\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33406-1541\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:bcoren@diowavelaser.com\"> bcoren@diowavelaser.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>CMS # 712715\u003C\u002Fp>\u003Cp>September 26, 2025\u003C\u002Fp>\u003Cp>Dear Dr. Coren:&nbsp;\u003C\u002Fp>\u003Cp>During an inspection of your firm located in West Palm Beach, Florida from April 9, 2025, through April 21, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Diowave 250 WLS and Diowave 100 WLS laser system. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.&nbsp;\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has reviewed the information collected during the April 2025 inspection and information on your firm’s website at www.diowavelaser.com (last accessed on July 1, 2025). FDA has reviewed the Physician Brochure (TMA, Physician Brochure, February 2024), AI Instructions for Use (TMA, Diowave 100 WLS &amp; Diowave 250 WLS, IMPOS-AI User Instructions, Undated, 1 page.pdf ), Diowave Life Without Pain Brochure (Diowave Laser Treatment Center, Imagine Life Without Pain Brochure), and an Operating Manual (TWA, Diowave Stealth Micro-Pulse Laser System Operating Manual Version 2024-5), and has determined that the Diowave 100 WLS and Diowave 250 WLS devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B) because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Diowave 100 WLS and Diowave 250 WLS devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. §360(k). Specifically, the Diowave 100 WLS and the Diowave 250 WLS are in violation of the Act for the reasons discussed below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Technological Characteristics:\u003C\u002Fstrong> Devices classified under 21 CFR 890.5500 Infrared Lamp are devices intended for medical purposes that emits energy at infrared frequencies to provide topical heating and are exempt from premarket notification requirements unless they exceed the limitations on exemption at 21 CFR 890.9. However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS operate using a different fundamental scientific technology than that generic type of device. Specifically, your firm’s Care Provider Brochure states that “\u003Cem>all heat during a stealth treatment is inhibited, allowing for deep penetration as there is no heat during treatment\u003C\u002Fem>.” Further, the Diowave 100 WLS and Diowave 250 WLS appear to utilize stealth micro-pulse laser technology, which does not provide topical heating. For example, your distribution includes materials with claims such as:\u003C\u002Fp>\u003Cp>\u003Cem>o\u003C\u002Fem>&nbsp;\u003Cem> “Diowave is pleased to reveal the Stealth Micro-Pulsed Laser System™. SMPLTallows you to hold a hand piece static over a focal pathology without heating tissue..”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Our Stealth Micro-Pulse Technology allows care providers to treat various pathologies by Micro-Pulsing at appropriate power levels without introducing heat.”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“The Doctor can remove all heat from the laser beam allowing him to hold thelaser directly over the injury for an indefinite amount of time.”\u003C\u002Fem>\u003C\u002Fp>\u003Cp>As shown by the evidence, the Diowave 100 WLS and Diowave 250 WLS devices do not provide topical heating. Instead, they use a different fundamental scientific technology. Therefore, the premarket notification requirements apply.\u003C\u002Fp>\u003Cp>\u003Cstrong>Intended Use:\u003C\u002Fstrong>\u003Cbr>Generic devices classified under 21 CFR 890.5500 emit energy at infrared frequencies (approximately 700 to 50,000 nanometers) to provide topical heating and are intended for medical purposes including, but not limited to, temporary increase in local blood circulation and temporary relief of: muscle spasms, minor joint pain and stiffness, minor muscle pain and stiffness, and minor arthritis pain. Devices classified under 21 CFR 890.5500 are exempt from premarket notification unless they exceed the limitations on exemption at 21 CFR 890.9(a). However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS are intended for uses that are different from the intended use of the type of devices classified under 21 CFR 890.5500 Infrared Lamp. For example, your distribution of the Diowave 100 WLS and Diowave 250 WLS devices includes the following claims:\u003C\u002Fp>\u003Cp>\u003Cem>o &nbsp;“a painless, non-surgical, and side-effective way to treat conditions previously refractive to traditional medical care”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“treatment of various pathologies, including those refractive to traditional therapy”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Because laser therapy is the only treatment in medicine that actually heals living tissue, most conditions respond favorably to repeated laser therapy treatments. It has been proven to deliver results when all other forms of insurance-based medicine have failed.”&nbsp;&nbsp;\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“This technology has shown great promise in healing conditions which are refractive or non-responsive to all other forms of treatment and surgery, including HPLT [High Power Laser Therapy]”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“peripheral neuropathy” case study: “An 80-year-old male with advance circulatory disease in his lower extremities presents with numbness in his feet and toes. He cannot drive because he cannot feel his feet…by the end of 12 visits, his proprioception to the bottom of his feet returned”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Summation of Various Main Treatment Indications for Diowave:…abdominalpain, pelvic pain, wound care”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“Difficult to treat pathologies that are adequately treated by Diowave: post-surgical pain, implantable device pocket pain, surgically fused areas in which insurance will not cover further treatment, areas that do not respond well to nerve blocks or joint injections, “disc pathology, wounds refractory to conventional medical treatment, after regenerative medicine treatment: using laser to amplify effects of regenerative medicine treatments by kickstarting the process.”\u003C\u002Fem>\u003Cbr>\u003Cem>o &nbsp;“results come from the laser’s ability to stimulate tissue growth and repair…results in accelerated wound healing with a dramatic decrease in…inflammation, and scar tissue formation”\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Further, we note that your firm has an existing clearance (K121363) under 21 CFR 890.5500 with the following indications:\u003C\u002Fp>\u003Cp>\u003Cem>“The Diowave Laser System is intended to emit energy in the infrared spectrum to provide topical heating for the purpose of elevating tissue temperature for temporary relief of minor muscle and joint pain, muscle spasm, pain and stiffness associated with minor arthritis, promoting relaxation of muscle tissue, and to temporarily increase local blood circulation.”\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm’s promotion of the device provides evidence that the device is intended for conditions beyond the indications for which it was cleared. Examples of these claims are included above. This constitutes a major change or modification in the intended use. Thus, a new premarket notification is required. Additionally, your firm’s promotion of the device provides evidence that your firm made a technological change to the device that could significantly affect the safety or effectiveness of the device. Examples of these claims are included above. This change is a significant change or modification for which a new premarket notification is required.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>Our office requests that Technological Medical Advancements LLC cease any activities that result in the misbranding or adulteration of the Diowave 100 WLS and Diowave 250 WLS devices, such as the commercial distribution of the device, for the uses discussed above.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820. Your firm’s response dated May 23, 2025, to the Form FDA 483 (FDA 483) was not received within fifteen business days of issuance of the FDA 483 however we performed a review of your response. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish procedures to ensure that all purchased or otherwise received products and services conform to specified requirements, as required by 21 CFR 820.50.Specifically,\u003C\u002Fp>\u003Cp>A. Your firm has failed to perform supplier evaluations as required by Purchasing Control Standard Operating Procedure, TMAQSP007, Revision 2.0. These include evaluations for critical suppliers, comprised of your contract manufacturer and designer \u003Cstrong>(b)(4)\u003C\u002Fstrong> and your contract service firm \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as required by Section 3 of your procedure. Additionally, no \u003Cstrong>(b)(4)\u003C\u002Fstrong> evaluations were conducted for any suppliers despite procedural requirements, and no justification was provided for not performing them.\u003C\u002Fp>\u003Cp>B. Your firm failed to maintain supplier agreements as required by your Supplier Evaluation and Monitoring Standard Operating Procedure, TMA_QSP_023. For example, section 6.1.2 of your procedure states that “a Quality Agreement\u002FCritical Supplier Quality Agreement is drafted and signed between both parties.” However, your firm has unsigned agreements with your contract manufacturer, including both the Critical Supplier Quality Agreement and Software Agreement. During the inspection, your contract manufacturer was unable to provide required design control records for review.\u003C\u002Fp>\u003Cp>C. The inspection noted that your firm failed to have adequate purchasing controls and supplier oversight of your firm’s contract manufacturer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, responsible for design controls. Your firm's inability to retrieve basic design control records from your contract designer\u002Fmanufacturer during the FDA inspection, despite claims that these documents existed, demonstrates inadequate oversight of critical supplier activities. For example:\u003C\u002Fp>\u003Cp>i. &nbsp;Your firm could not provide the Design History File (DHF) records for the Diowave 250 WLS and Diowave 100 WLS medical devices. The inspection found no evidence of essential design control records including design planning, design inputs, design outputs, design reviews, design verification, design validation, design change or design transfer, representing a comprehensive failure to maintain adequate design control records as required by FDA regulations. As such, FDA is concerned that the medical devices will not consistently meet intended use and safety requirements, that design changes are not properly controlled and documented, and that the finished device design may not meet user needs and intended use.\u003C\u002Fp>\u003Cp>ii. &nbsp;The design risk management files for the Diowave 250 WLS and Diowave 100WLS laser device were not available for review. No records were available toreview by FDA investigators for design risk analysis despite your proceduralrequirements in section 3.4 of Risk Management Standard Operating Procedure,TMAQSP043, Revision 1.0, to incorporate risk analysis into your firm’s DesignReview. No risk assessment was available for review for the power increase from \u003Cstrong>(b)(4)\u003C\u002Fstrong>W to \u003Cstrong>(b)(4)\u003C\u002Fstrong>W. No evaluation on the potential need to submit a new premarket application was performed.\u003C\u002Fp>\u003Cp>iii. &nbsp;Your firm’s Supplier Evaluation and Monitoring Standard OperatingTMA_QSP_023, Revision 1 states in section 6.2 that “\u003Cstrong>(b)(4)\u003C\u002Fstrong>. ”There have been significant modifications to your devices without notification from critical supplier or oversight and approval of changes by your firm. This includes the review of design control records such as design verification and design validation to include risk analysis. For example, design control records for changes to software (\u003Cstrong>(b)(4)\u003C\u002Fstrong> for 250 WLS, \u003Cstrong>(b)(4)\u003C\u002Fstrong> for 100 WLS), as well as an identified power increase for the Diowave laser systems from \u003Cstrong>(b)(4)\u003C\u002Fstrong>W to \u003Cstrong>(b)(4)\u003C\u002Fstrong>W were not available for review during the inspection.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Your firm’s response does not address deficiencies with the purchasing controls and oversight of the design control activities delegated to your contract manufacturer. In addition, while your firm provided some design control records from your contract manufacturer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you did not provide records that include the changes to the Diowave Laser System 100 WLS\u002F250 WLS or design inputs, and therefore, we are unable determine if the device design outputs meet the design inputs. The design output records provided are missing complete device specifications, manufacturing specifications, software design specifications and labeling specifications. The design review documents are missing design reviews for all phases of the device design plan. There is no design change control for design changes previously described. The design transfer document does not include all required design transfer activities and any manufacturing process validations performed. Following our review of your response, you have not addressed the deficiencies in your firm’s design control subsystem and the requirement for a complete design history file (DHF) for your medical devices.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit and to maintain complaint files, as required by 21CFR 820.198(a). For example:\u003C\u002Fp>\u003Cp>A. FDA investigators reviewed ten complaints from 2025 and identified comprehensive procedural failures for the receipt, review, and evaluation of complaints. Your firm failed to implement Customer Complaints procedure, TMAQSP003, Revision 3.0,and perform required procedural activities for all complaints reviewed, including complaint investigations, failure mode analysis, Management Representative approval, and completing all fields in the complaint forms.\u003C\u002Fp>\u003Cp>B. Your firm failed to handle all complaints in a timely manner. For example, your firm has not reviewed or evaluated \u003Cstrong>(b)(4)\u003C\u002Fstrong> servicing records from the third-party supplier as specified by your procedure TMA_QSP_009 Servicing, Rev 2.0, so that the Management Representative can determine if they meet the definition of a complaint so that they can be investigated as necessary.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address this inspectional observation, and therefore is missing a corrective action plan, time frames for implementation, and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>3. Your firm has failed to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm has not adequately established CAPA Procedure, TMAQSP012, Revision 1.0. For example:\u003C\u002Fp>\u003Cp>A. Your procedure lacks requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems.\u003C\u002Fp>\u003Cp>B. Your firm has not implemented Section 3.2 of the CAPA procedure to identify actions needed to correct and prevent the recurrence of any non-conformity. For example, your firm has not opened any corrective and preventive actions, as required by your procedure, after it has been cited with the following:\u003C\u002Fp>\u003Cp>&nbsp; i. Fourteen inspectional observations from an FDA inspection conducted from August 4, 2021, to September 9, 2021;\u003Cbr>&nbsp; ii. Thirteen observations, along with seven verbal observations, from an FDA inspection conducted from February 19, 2020 to February 24, 2020;\u003Cbr>&nbsp; iii. Twelve violations cited in a letter sent to your firm on June 8, 2020, by FDA.\u003C\u002Fp>\u003Cp>This FDA inspection, along with previous FDA inspections, have identified repeat systemic deficiencies of your firm’s inability to identify actions to correct and prevent the recurrence of quality problems.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>4. Your firm has failed to establish and maintain adequate procedures for quality audits, as required by 21 CFR 820.22. Specifically, your firm did not conduct quality audits in 2023and 2024 as required by your Internal Audit Standard Operating Procedure, TMAQSP004,Revision 1.0. As of the date of the inspection, no quality audit has been conducted in 2025.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>5. Your firm has failed to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, your firm does not have a procedure for addressing nonconforming products or materials. When the FDA investigator asked about procedures for nonconforming products or materials, you stated that such procedures did not exist. Without procedures to define nonconformance criteria and disposition processes, your firm cannot effectively identify or manage quality issues that may arise during manufacturing, incoming inspection, acceptance testing activities or as part of post-market surveillance activities.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>6. Your firm has failed to adequately establish and maintain procedures for management review, as required by 21 CFR 820.20(c). Specifically, your firm did not follow Management Review Standard Operating Procedure, TMAQSP010, Revision 1.0, which requires periodic management review at least \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your firm did not conduct a management review in 2024, thereby failing to determine the effectiveness of your quality system. This inspection identified several inspectional observations and deficiencies that have gone uncorrected from the two previous FDA inspections or approximately 5 years.\u003C\u002Fp>\u003Cp>We reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identifier Regulation (UDI) Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Diowave Pure Pulse Laser System devices do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for Diowave Pure Pulse Laser System devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>A follow-up inspection will be required to assure that corrections and\u002For corrective actions are adequate. Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Melissa Michurski, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 712715” when replying. If you have any questions about the contents of this letter, please contact: Rafael Padilla at Rafael.Padilla@FDA.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDr. Bruce R. Coren, DVM, MS\n\nRecipient Title\n\nChief Executive Officer\n\nTechnological Medical Advancements LLC\n\n1601 Belvedere Rd Ste E-180\n\nWest Palm Beach, FL 33406-1541\n\nUnited States\n\nbcoren@diowavelaser.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 712715\nSeptember 26, 2025\nDear Dr. Coren:\nDuring an inspection of your firm located in West Palm Beach, Florida from April 9, 2025, through April 21, 2025, investigators from the United States Food and Drug Administration (FDA) determined that your firm manufactures the Diowave 250 WLS and Diowave 100 WLS laser system. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nUnapproved Device Violations\nFDA has reviewed the information collected during the April 2025 inspection and information on your firm’s website at www.diowavelaser.com (last accessed on July 1, 2025). FDA has reviewed the Physician Brochure (TMA, Physician Brochure, February 2024), AI Instructions for Use (TMA, Diowave 100 WLS & Diowave 250 WLS, IMPOS-AI User Instructions, Undated, 1 page.pdf ), Diowave Life Without Pain Brochure (Diowave Laser Treatment Center, Imagine Life Without Pain Brochure), and an Operating Manual (TWA, Diowave Stealth Micro-Pulse Laser System Operating Manual Version 2024-5), and has determined that the Diowave 100 WLS and Diowave 250 WLS devices are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B) because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Diowave 100 WLS and Diowave 250 WLS devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. §360(k). Specifically, the Diowave 100 WLS and the Diowave 250 WLS are in violation of the Act for the reasons discussed below.\nTechnological Characteristics: Devices classified under 21 CFR 890.5500 Infrared Lamp are devices intended for medical purposes that emits energy at infrared frequencies to provide topical heating and are exempt from premarket notification requirements unless they exceed the limitations on exemption at 21 CFR 890.9. However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS operate using a different fundamental scientific technology than that generic type of device. Specifically, your firm’s Care Provider Brochure states that “all heat during a stealth treatment is inhibited, allowing for deep penetration as there is no heat during treatment.” Further, the Diowave 100 WLS and Diowave 250 WLS appear to utilize stealth micro-pulse laser technology, which does not provide topical heating. For example, your distribution includes materials with claims such as:\no “Diowave is pleased to reveal the Stealth Micro-Pulsed Laser System™. SMPLTallows you to hold a hand piece static over a focal pathology without heating tissue..”\no “Our Stealth Micro-Pulse Technology allows care providers to treat various pathologies by Micro-Pulsing at appropriate power levels without introducing heat.”\no “The Doctor can remove all heat from the laser beam allowing him to hold thelaser directly over the injury for an indefinite amount of time.”\nAs shown by the evidence, the Diowave 100 WLS and Diowave 250 WLS devices do not provide topical heating. Instead, they use a different fundamental scientific technology. Therefore, the premarket notification requirements apply.\nIntended Use:\nGeneric devices classified under 21 CFR 890.5500 emit energy at infrared frequencies (approximately 700 to 50,000 nanometers) to provide topical heating and are intended for medical purposes including, but not limited to, temporary increase in local blood circulation and temporary relief of: muscle spasms, minor joint pain and stiffness, minor muscle pain and stiffness, and minor arthritis pain. Devices classified under 21 CFR 890.5500 are exempt from premarket notification unless they exceed the limitations on exemption at 21 CFR 890.9(a). However, there is evidence that the Diowave 250 WLS and Diowave 100 WLS are intended for uses that are different from the intended use of the type of devices classified under 21 CFR 890.5500 Infrared Lamp. For example, your distribution of the Diowave 100 WLS and Diowave 250 WLS devices includes the following claims:\no “a painless, non-surgical, and side-effective way to treat conditions previously refractive to traditional medical care”\no “treatment of various pathologies, including those refractive to traditional therapy”\no “Because laser therapy is the only treatment in medicine that actually heals living tissue, most conditions respond favorably to repeated laser therapy treatments. It has been proven to deliver results when all other forms of insurance-based medicine have failed.”\no “This technology has shown great promise in healing conditions which are refractive or non-responsive to all other forms of treatment and surgery, including HPLT [High Power Laser Therapy]”\no “peripheral neuropathy” case study: “An 80-year-old male with advance circulatory disease in his lower extremities presents with numbness in his feet and toes. He cannot drive because he cannot feel his feet…by the end of 12 visits, his proprioception to the bottom of his feet returned”\no “Summation of Various Main Treatment Indications for Diowave:…abdominalpain, pelvic pain, wound care”\no “Difficult to treat pathologies that are adequately treated by Diowave: post-surgical pain, implantable device pocket pain, surgically fused areas in which insurance will not cover further treatment, areas that do not respond well to nerve blocks or joint injections, “disc pathology, wounds refractory to conventional medical treatment, after regenerative medicine treatment: using laser to amplify effects of regenerative medicine treatments by kickstarting the process.”\no “results come from the laser’s ability to stimulate tissue growth and repair…results in accelerated wound healing with a dramatic decrease in…inflammation, and scar tissue formation”\nFurther, we note that your firm has an existing clearance (K121363) under 21 CFR 890.5500 with the following indications:\n“The Diowave Laser System is intended to emit energy in the infrared spectrum to provide topical heating for the purpose of elevating tissue temperature for temporary relief of minor muscle and joint pain, muscle spasm, pain and stiffness associated with minor arthritis, promoting relaxation of muscle tissue, and to temporarily increase local blood circulation.”\nYour firm’s promotion of the device provides evidence that the device is intended for conditions beyond the indications for which it was cleared. Examples of these claims are included above. This constitutes a major change or modification in the intended use. Thus, a new premarket notification is required. Additionally, your firm’s promotion of the device provides evidence that your firm made a technological change to the device that could significantly affect the safety or effectiveness of the device. Examples of these claims are included above. This change is a significant change or modification for which a new premarket notification is required.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fd efault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nOur office requests that Technological Medical Advancements LLC cease any activities that result in the misbranding or adulteration of the Diowave 100 WLS and Diowave 250 WLS devices, such as the commercial distribution of the device, for the uses discussed above.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. Your firm’s response dated May 23, 2025, to the Form FDA 483 (FDA 483) was not received within fifteen business days of issuance of the FDA 483 however we performed a review of your response. These violations include, but are not limited to, the following:\n1. Failure to adequately establish procedures to ensure that all purchased or otherwise received products and services conform to specified requirements, as required by 21 CFR 820.50.Specifically,\nA. Your firm has failed to perform supplier evaluations as required by Purchasing Control Standard Operating Procedure, TMAQSP007, Revision 2.0. These include evaluations for critical suppliers, comprised of your contract manufacturer and designer (b)(4) and your contract service firm (b)(4), as required by Section 3 of your procedure. Additionally, no (b)(4) evaluations were conducted for any suppliers despite procedural requirements, and no justification was provided for not performing them.\nB. Your firm failed to maintain supplier agreements as required by your Supplier Evaluation and Monitoring Standard Operating Procedure, TMA_QSP_023. For example, section 6.1.2 of your procedure states that “a Quality Agreement\u002FCritical Supplier Quality Agreement is drafted and signed between both parties.” However, your firm has unsigned agreements with your contract manufacturer, including both the Critical Supplier Quality Agreement and Software Agreement. During the inspection, your contract manufacturer was unable to provide required design control records for review.\nC. The inspection noted that your firm failed to have adequate purchasing controls and supplier oversight of your firm’s contract manufacturer, (b)(4), responsible for design controls. Your firm's inability to retrieve basic design control records from your contract designer\u002Fmanufacturer during the FDA inspection, despite claims that these documents existed, demonstrates inadequate oversight of critical supplier activities. For example:\ni. Your firm could not provide the Design History File (DHF) records for the Diowave 250 WLS and Diowave 100 WLS medical devices. The inspection found no evidence of essential design control records including design planning, design inputs, design outputs, design reviews, design verification, design validation, design change or design transfer, representing a comprehensive failure to maintain adequate design control records as required by FDA regulations. As such, FDA is concerned that the medical devices will not consistently meet intended use and safety requirements, that design changes are not properly controlled and documented, and that the finished device design may not meet user needs and intended use.\nii. The design risk management files for the Diowave 250 WLS and Diowave 100WLS laser device were not available for review. No records were available toreview by FDA investigators for design risk analysis despite your proceduralrequirements in section 3.4 of Risk Management Standard Operating Procedure,TMAQSP043, Revision 1.0, to incorporate risk analysis into your firm’s DesignReview. No risk assessment was available for review for the power increase from (b)(4)W to (b)(4)W. No evaluation on the potential need to submit a new premarket application was performed.\niii. Your firm’s Supplier Evaluation and Monitoring Standard OperatingTMA_QSP_023, Revision 1 states in section 6.2 that “(b)(4). ”There have been significant modifications to your devices without notification from critical supplier or oversight and approval of changes by your firm. This includes the review of design control records such as design verification and design validation to include risk analysis. For example, design control records for changes to software ((b)(4) for 250 WLS, (b)(4) for 100 WLS), as well as an identified power increase for the Diowave laser systems from (b)(4)W to (b)(4)W were not available for review during the inspection.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Your firm’s response does not address deficiencies with the purchasing controls and oversight of the design control activities delegated to your contract manufacturer. In addition, while your firm provided some design control records from your contract manufacturer, (b)(4), you did not provide records that include the changes to the Diowave Laser System 100 WLS\u002F250 WLS or design inputs, and therefore, we are unable determine if the device design outputs meet the design inputs. The design output records provided are missing complete device specifications, manufacturing specifications, software design specifications and labeling specifications. The design review documents are missing design reviews for all phases of the device design plan. There is no design change control for design changes previously described. The design transfer document does not include all required design transfer activities and any manufacturing process validations performed. Following our review of your response, you have not addressed the deficiencies in your firm’s design control subsystem and the requirement for a complete design history file (DHF) for your medical devices.\n2. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit and to maintain complaint files, as required by 21CFR 820.198(a). For example:\nA. FDA investigators reviewed ten complaints from 2025 and identified comprehensive procedural failures for the receipt, review, and evaluation of complaints. Your firm failed to implement Customer Complaints procedure, TMAQSP003, Revision 3.0,and perform required procedural activities for all complaints reviewed, including complaint investigations, failure mode analysis, Management Representative approval, and completing all fields in the complaint forms.\nB. Your firm failed to handle all complaints in a timely manner. For example, your firm has not reviewed or evaluated (b)(4) servicing records from the third-party supplier as specified by your procedure TMA_QSP_009 Servicing, Rev 2.0, so that the Management Representative can determine if they meet the definition of a complaint so that they can be investigated as necessary.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address this inspectional observation, and therefore is missing a corrective action plan, time frames for implementation, and documentation of activities performed to correct the underlying deficiency.\n3. Your firm has failed to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically, your firm has not adequately established CAPA Procedure, TMAQSP012, Revision 1.0. For example:\nA. Your procedure lacks requirements for analyzing processes, work operations, concessions, quality audit reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems.\nB. Your firm has not implemented Section 3.2 of the CAPA procedure to identify actions needed to correct and prevent the recurrence of any non-conformity. For example, your firm has not opened any corrective and preventive actions, as required by your procedure, after it has been cited with the following:\ni. Fourteen inspectional observations from an FDA inspection conducted from August 4, 2021, to September 9, 2021;\nii. Thirteen observations, along with seven verbal observations, from an FDA inspection conducted from February 19, 2020 to February 24, 2020;\niii. Twelve violations cited in a letter sent to your firm on June 8, 2020, by FDA.\nThis FDA inspection, along with previous FDA inspections, have identified repeat systemic deficiencies of your firm’s inability to identify actions to correct and prevent the recurrence of quality problems.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\n4. Your firm has failed to establish and maintain adequate procedures for quality audits, as required by 21 CFR 820.22. Specifically, your firm did not conduct quality audits in 2023and 2024 as required by your Internal Audit Standard Operating Procedure, TMAQSP004,Revision 1.0. As of the date of the inspection, no quality audit has been conducted in 2025.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\n5. Your firm has failed to establish procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90(a). Specifically, your firm does not have a procedure for addressing nonconforming products or materials. When the FDA investigator asked about procedures for nonconforming products or materials, you stated that such procedures did not exist. Without procedures to define nonconformance criteria and disposition processes, your firm cannot effectively identify or manage quality issues that may arise during manufacturing, incoming inspection, acceptance testing activities or as part of post-market surveillance activities.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\n6. Your firm has failed to adequately establish and maintain procedures for management review, as required by 21 CFR 820.20(c). Specifically, your firm did not follow Management Review Standard Operating Procedure, TMAQSP010, Revision 1.0, which requires periodic management review at least (b)(4). Your firm did not conduct a management review in 2024, thereby failing to determine the effectiveness of your quality system. This inspection identified several inspectional observations and deficiencies that have gone uncorrected from the two previous FDA inspections or approximately 5 years.\nWe reviewed your firm’s response dated May 23, 2025, and conclude that it is not adequate. Specifically, your firm’s response does not address the inspectional observation, and therefore is missing a corrective action plan, time frames for implementation and documentation of activities performed to correct the underlying deficiency.\nUnique Device Identifier Regulation (UDI) Violations\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the Diowave Pure Pulse Laser System devices do not bear such a UDI.\nSpecifically, the labels for Diowave Pure Pulse Laser System devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of the device (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses automatic identification and data capture (AIDC) technology on the label of the device (see 21 CFR 801.40(a)(2)).\nA follow-up inspection will be required to assure that corrections and\u002For corrective actions are adequate. Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Melissa Michurski, Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 712715” when replying. If you have any questions about the contents of this letter, please contact: Rafael Padilla at Rafael.Padilla@FDA.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Technological Medical Advancements LLC","technological-medical-advancements-llc-712715-09262025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftechnological-medical-advancements-llc-712715-09262025","2026-10-26T08:10:10.367898+00:00","2025-10-07","712715","Dr. Bruce R. Coren, DVM, MS","2026-08-19T16:15:16.641+00:00","2025-09-26",{"id":131,"raw":132,"subject":136,"body_html":137,"body_text":138,"firm_name":139,"letter_id":140,"created_at":122,"fei_number":19,"letter_url":141,"updated_at":142,"action_type":22,"case_status":23,"posted_date":143,"marcs_cms_no":144,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":145,"body_fetched_at":146,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":147,"medical_device_id":19,"response_letter_date":19},702,[133,134,135,11,136,13,13,13],"\u003Ctime datetime=\"2025-08-26T04:00:00Z\">08\u002F26\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-11T04:00:00Z\">07\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjiangsu-kerbio-medical-technology-group-co-705188-07112025\">Jiangsu Kerbio Medical Technology Group Co.\u003C\u002Fa>","Good Laboratory Practice (GLP) for Nonclinical Laboratory Studies","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Shangyou Lin\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer, General Manager \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Jiangsu Kerbio Medical Technology Group Co.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Chang yang Rd., No. 9, C4 Building\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Wujin Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Changzhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangsu Sheng\u003C\u002Fspan>, \u003Cspan>213145\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:contact@jcssmt.com\"> contact@jcssmt.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>July 11, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Lin:\u003C\u002Fp>\u003Cp>This Warning Letter is to inform you of objectionable conditions observed during the United States Food and Drug Administration (FDA) inspection conducted at Jiangsu Kerbio Medical Technology Group Co. from January 15, 2025, to January 24, 2025, by investigators from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI) Foreign Inspection Cadre. This inspection was conducted to determine whether activities and procedures related to your participation in Good Laboratory Practice (GLP) nonclinical studies complied with applicable federal regulations. Specifically, FDA investigators focused on the list of studies below including, but not limited to, guinea pig maximization sensitization (GPMT), acute systemic toxicity (AST), rabbit pyrogen, muscle implantation, hemolysis, and cytotoxicity tests conducted at your facility.\u003C\u002Fp>\u003Cp>The list of studies below is not an all-inclusive list of studies impacted by the inspection or by the violations cited in this letter.\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>Study Number\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Test\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Guinea Pig Maximization Sensitization Test (GPMT)\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Acute Systemic Toxicity (AST)\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Rabbit Pyrogen\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Hemolysis\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Muscle Implantation Test 4 and 13 Weeks\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>AST\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>MTT Cytotoxicity\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>GPMT\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>Intracutaneous Reactivity\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>These tests are used in nonclinical studies for the development of devices as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>The inspection was conducted under a program designed to ensure that data and information contained in requests for Investigational Device Exemption, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\u003C\u002Fp>\u003Cp>Our review of the inspection report prepared by the OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies, which concerns, among other things, requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). Compliance with Part 58 is intended to assure the quality and integrity of the safety data filed in a premarket submission. At the close of the inspection, the FDA investigators presented the inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you.\u003C\u002Fp>\u003Cp>We received a response from your firm dated February 21, 2025, concerning our investigators’ observations noted on the Form FDA-483. We address this response below, in relation to each of the noted violations. This letter requests prompt corrective action to address the violations cited and discusses your written response dated February 21, 2025, to the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. The study director failed to assure that (1) the protocol, including any change, is approved as provided by § 58.120 and is followed; (2) all experimental data, including observations of unanticipated responses of the test system are accurately recorded and verified; and (3) all applicable good laboratory practice regulations are followed [21 CFR 58.33(a), (b), and (e)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The study director has overall responsibility for the technical conduct of the study, as well as for the interpretation, analysis, documentation and reporting of results, and represents the single point of study control. The study director’s responsibilities include assuring that studies are conducted in accordance with the protocol, all experimental data are accurately recorded and verified, and that applicable GLP regulations are followed. Examples of the study director’s failures to adhere to these requirements include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-028 states that, “The study personnel should fill out the animal observation records in the corresponding experimental records daily.” However, based on the study records reviewed by the FDA investigators for GPMT and intracutaneous reactivity studies, there were no daily animal observations raw data included in the experimental records. Documentation of animal observations in study records is necessary to allow for the reconstruction and evaluation of the final study reports. Without these records, it is not possible to confirm that these observations, which are critical to the interpretation and analysis of study results, indeed occurred, and that the final study reports accurately reflect what was observed at the time of testing.\u003C\u002Fp>\u003Cp>b. The raw data for multiple studies conducted by two different study directors showed that the same person reportedly conducted two separate study related activities at the same or overlapping times. Additionally, the raw data for multiple studies showed that other study personnel were reportedly using the same equipment at the same time. This indicates that all experimental data were not accurately recorded and verified. Examples of discrepancies are as follows:\u003C\u002Fp>\u003Cp>1. In two intracutaneous reactivity studies, the same study personnel, \u003Cstrong>(b)(6)\u003C\u002Fstrong>, reportedly shaved all three rabbits for study \u003Cstrong>(b)(4)\u003C\u002Fstrong> and weighed all three rabbits for study \u003Cstrong>(b)(4)\u003C\u002Fstrong> at exactly 17:19 on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. It appears implausible that the same study personnel could shave and weigh multiple rabbits from two separate studies at the exact same time.\u003C\u002Fp>\u003Cp>2. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, study personnel, \u003Cstrong>(b)(6)\u003C\u002Fstrong>, completed weighing \u003Cstrong>(b)(4)\u003C\u002Fstrong> guinea pigs for the GMPT study \u003Cstrong>(b)(4)\u003C\u002Fstrong> at \u003Cstrong>(b)(4)\u003C\u002Fstrong> while study personnel, \u003Cstrong>(b)(6)\u003C\u002Fstrong>, also completed weighing \u003Cstrong>(b)(4)\u003C\u002Fstrong> animals for GMPT study \u003Cstrong>(b)(4)\u003C\u002Fstrong> at 9:12 both using scale \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The data suggests that either these two study activities were conducted at overlapping times using the same equipment or that \u003Cstrong>(b)(4)\u003C\u002Fstrong> animals were weighed within the span of two minutes, both of which appear implausible.\u003C\u002Fp>\u003Cp>c. On January 21, 2025, one of the FDA investigators directly observed study personnel, \u003Cstrong>(b)(6)\u003C\u002Fstrong>, retroactively completing records for an ongoing subacute systemic toxicity study, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including clinical observations and animal weight data from Day 1 of the study up to Day 26 (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) of the study. When asked to provide documentation that animals for this study were weighed, the records provided later that day showed that the animal weight data were incomplete as week 2 only included 5 out of 20 animal weights, and there were no weights recorded for week 3 which should have been completed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Failure to accurately record and verify experimental data as per the study protocol undermines the integrity and reliability of the study.\u003C\u002Fp>\u003Cp>d. Raw data records for ten intracutaneous reactivity studies conducted in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and two that were conducted in \u003Cstrong>(b)(4)\u003C\u002Fstrong> (refer to the table below) included an animal reuse record (document #\u003Cstrong>(b)(4)\u003C\u002Fstrong>32 Version 3.2) indicating that the studies utilized rabbits that had been previously used in other studies. This contradicts the study protocols (see protocol Section 4: Animal Care and Maintenance for each respective study) which indicate that, “Only healthy, previously unused animals were selected.”\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>e. SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-030 Skin Sensitization Test (Guinea pig maximization test) requires that guinea pigs shall be acclimatized for at least 5 days. However, the study records for GPMT studies \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> show that this SOP was not followed. The study records documented that these studies were initiated on the guinea pigs three days after the animals were received. For example, study \u003Cstrong>(b)(4)\u003C\u002Fstrong> was started on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and according to the Animal Quality Certificate, the animal was purchased on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, study \u003Cstrong>(b)(4)\u003C\u002Fstrong> was started on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the animal was purchased on \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>As the principal point of study control, the study director did not assure that studies were conducted in accordance with the protocol, that all experimental data were accurately recorded and verified, and that applicable good laboratory practice regulations were followed. When the protocol is not followed, data is erroneously recorded or analyzed, or other unforeseen circumstances occur that negatively affect the data, important findings in the study may be overlooked and the data cannot be accurately interpreted. Failure to follow the protocol impacts the quality and reliability of data contained within the final study report. This adversely impacts a manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a marketed device or for the purposes of beginning clinical trials, as applicable. Furthermore, failure to ensure accurate data such as individual animal weights, animal preparation, observations, and results, yields questionable study results and conclusions. Based on these failures, FDA has concerns about the quality and integrity of the data generated from the nonclinical laboratory studies conducted at your testing facility. Complete and accurate study data are necessary to allow FDA to fully assess the overall safety and risk of a device with an associated premarket submission. The unreliable data raises concerns about the quality and integrity of associated premarket submissions, which may put public health and safety at risk. Additionally, lack of daily observation of individual animals directly impacts the overall study integrity, as it is unclear if the animals are malnourished or sick in any way, which would have a direct impact on the interpretation of the study results\u003C\u002Fp>\u003Cp>Your written response is inadequate. The written response you provided states that the relevant standard operating procedures (SOPs) that address the concerns noted in the Form 483 will be revised and a GLP working group will be established to implement a regulatory compliance improvement plan for 21 CFR Part 58. However, the updated SOPs were not included in your response, and it is unclear whether you plan to retrain personnel on the updated SOPs.\u003C\u002Fp>\u003Cp>Additionally, your firm stated that you will conduct trainings on FDA 21 CFR Part 58 regulations to ensure thorough understanding of the compliance requirements but did not provide copies of the training materials. Given the deviations and issues cited in the violations, it is necessary to review the training materials to determine their adequacy for the trained individuals to both conduct the tests per the standards being used, and to produce accurate, traceable results.\u003C\u002Fp>\u003Cp>Furthermore, your response does not provide assurance that these violations will not occur again. Specifically, your response did not: (1) detail how your testing facility will assure that applicable SOPs will be followed to ensure the quality and integrity of data generated in a study; (2) address any planned preventive actions such as frequency (i.e., quarterly, annual) of audits to check for compliance or future training of new study directors, as applicable; and (3) detail how appropriate documentation\u002Ffollow-up will be ensured when deviations arise in the future. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Your explanation, when taken into consideration with the violations described above, which occurred in multiple studies with various study directors over many months, suggests systemic failures in study director oversight of nonclinical laboratory studies and brings into question the quality and integrity of safety data collected at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish procedures for a system for the handling of the test and control articles to ensure that (1) proper identification is maintained throughout the distribution process and (2) the receipt and distribution of each batch is documented. Such documentation shall include the date and quantity of each batch distributed or returned [21 CFR 58.107(c) and (d)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your failures to adhere to this requirement include, but are not limited to, the following examples:\u003C\u002Fp>\u003Cp>a. Verification of the lot\u002Fbatch number was not found to be documented during sample receipt, preparation, or on any other source data records.\u003C\u002Fp>\u003Cp>b. Your firm’s Sample Information Form - \u003Cstrong>(b)(4)\u003C\u002Fstrong>052 listed the sample quantity received for study \u003Cstrong>(b)(4)\u003C\u002Fstrong> (Safety Intravenous Needles for Single Use) as “3 packs” with no record of how many needles were in each pack. The form then lists 1 and ¼ of a pack were distributed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively. The same amounts were then listed as returned on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, respectively. The form goes on to list that \"3 packs\" were disposed of on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. There was no record of the number of needles used and returned.\u003C\u002Fp>\u003Cp>c. Your firm’s sample preparation form \u003Cstrong>(b)(4)\u003C\u002Fstrong>83 does not require verification or documentation of the lot number or quantity of needles used for extraction for GPMT testing.\u003C\u002Fp>\u003Cp>d. The investigators found 12 GLP studies (refer to table below) where, after completion of the testing, the study director made changes to the test article information (indicated in bold in the table) or updated the test article photo (indicated by [1] in the table) in the final study report at the sponsor's request. These changes included revisions to the test article lot #, material, and size information, suggesting that proper identification is not maintained throughout the distribution process.\u003C\u002Fp>\u003Cdiv>\u003Ctable>\u003Ctbody>\u003Ctr>\u003Ctd>\u003Cstrong>Study\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Number: \"SSMT-S\"\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Test article per protocol:\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Studies\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Completed:\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Change\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>Request date:\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>Test article per final study report:\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003Ctr>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003Ctd>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Ftd>\u003C\u002Ftr>\u003C\u002Ftbody>\u003C\u002Ftable>\u003C\u002Fdiv>\u003Cp>\u003Cem>1\u003Cstrong> \u003C\u002Fstrong>\u003C\u002Fem>The photo of the test article in the final report is not the same as the one in the protocol.\u003C\u002Fp>\u003Cp>Failure to have established procedures for the handling of the test and control articles to ensure that proper identification of the articles is maintained and that the receipt and distribution of each batch are documented as required by the regulations creates the potential for errors to occur during handling such that the incorrect information could be attributed to the article under study. This in turn could lead to testing discrepancies and inaccurate test results and conclusions. In addition, lack of these procedures adversely impacts the traceability of the test samples, reliability of the testing, and the manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a legally marketed device or for purposes of beginning clinical trials, as applicable.\u003C\u002Fp>\u003Cp>Your written response is inadequate. The written response you provided states that the relevant standard operating procedures (SOPs) addressing the concerns noted in the Form 483 will be revised, and GLP experts will be invited to provide training on FDA GLP and 510(k) regulations.\u003C\u002Fp>\u003Cp>However, your response did not: (1) include copies of revised SOPs \u003Cstrong>(b)(4)\u003C\u002Fstrong>-002 and \u003Cstrong>(b)(4)\u003C\u002Fstrong>-003 and (2) provide details regarding the proposed trainings, including information on the types of personnel that will undergo the trainings, training materials that will be used, and how the effectiveness of the training will be evaluated. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide assurance that these violations will not occur again.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Failure of the Quality Assurance Unit (QAU) to inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection and to bring any problems found during the course of an inspection which are likely to affect study integrity to the attention of the study director and management immediately [21 CFR 58.35(b)(3)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>GLP regulations require that QAU inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection showing the date of the inspection, the study inspected, the phase or segment of the study inspected, the person performing the inspection, findings and problems, action recommended and taken to resolve existing problems, and any scheduled date for reinspection. Any problems found during the course of an inspection which are likely to affect study integrity shall be brought to the attention of the study director and management immediately. Examples of the QAU’s failures include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>a. The QAU failed to identify any of the data irregularities, errors, and omissions that were observed by FDA, including those described in the examples of failures throughout this letter.\u003C\u002Fp>\u003Cp>b. There were 67 studies reviewed during the inspection, of which 63 were conducted from 2023-2024. For these 63 studies, the final study reports include a signature attesting that the QAU audited the protocol, raw data, and final study reports. However, records did not support that all reported audits were completed at the reported times. Examples are as follows:\u003C\u002Fp>\u003Cp>1. Only three (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) out of the 63 covered studies had record of a raw data audit per the QA inspection summary reports.\u003C\u002Fp>\u003Cp>2. Thirty out of the 63 covered studies did not have the reported final study report audits included on the QA inspection summary reports.\u003C\u002Fp>\u003Cp>3. Study \u003Cstrong>(b)(4)\u003C\u002Fstrong>, completed on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was observed to have an error within the printed cassette labels; however, there was no deviation or record of when this error was discovered or that it had been reported to the study director. The FDA investigators found the final report for this study was still in draft form but included the quality assurance statement reporting QAU inspections of the study protocol on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and the raw data and final study report on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, when asked to provide copies of those QA audit reports, your firm only provided a copy of a QAU inspection report for the study protocol which was dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This audit report was not recorded on the QA Summary Report of Inspections. These discrepancies, including differences between the protocol audit date recorded in the quality assurance statement of the draft study report versus in the QAU inspection report, along with the missing audit report for the final study report and raw data, and lack of related audits mentioned in the QA Summary Report of Inspections, indicate a lack of adequate monitoring by the QAU.\u003C\u002Fp>\u003Cp>A reliable QAU is integral to the successful understanding and completion of any GLP study. Without appropriate QAU oversight, neither the sponsor nor FDA reviewers have assurance that the data in the final study report are accurate and valid. Failure to perform QAU functions, such as monitoring studies to ensure protocols were followed and data are accurately recorded, over the course of multiple studies also calls into question the quality and integrity of studies conducted at your testing facility.\u003C\u002Fp>\u003Cp>Your written response is inadequate. Your written response included a document that outlines your QAU’s review of QA statements, corresponding QA inspection reports, and Summary of Inspection Report for the final study reports reviewed by the FDA investigators. You also indicated in your response that the relevant SOPs addressing the concerns noted in the Form 483 will be revised along with Form QAU-F002 “Summary of Inspection Report”, interviews will be conducted with QA personnel to clarify responsibilities, a gap analysis of the existing quality management system will be conducted, and a working group will be established to identify existing problems and make improvements. Additionally, you stated plans to have training provided by an external GLP expert. However, your response did not: (1) include copies of the revised SOPs and form such that the adequacy of the revisions can be assessed and (2) provide details regarding the proposed trainings, including the training materials that will be used and how the effectiveness of the training will be evaluated. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide reasonable assurance that QAU failures will be avoided in the future.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Failure of a testing facility to have standard operating procedures in writing setting forth nonclinical laboratory study methods that management is satisfied are adequate to ensure the quality and integrity of the data generated in the course of a study. The study director failed to authorize all deviations in the study from standard operating procedures and ensure the deviations were documented in the raw data [21 CFR 58.81(a)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>SOPs should be adequate to ensure the quality and integrity of data generated in a study. However, not all SOPs appear to be adequate. The study director also must authorize all deviations from SOPs in a study and document all study deviations in the raw data. However, the study directors at your testing facility did not adhere to these requirements. Deviations from standard operating procedures in a study also were not authorized by the study director and documented in the raw data. Examples of these issues include the following:\u003C\u002Fp>\u003Cp>a. Your firm was found to be operating under two sets of SOPs for conducting the same types of tests. One was originated for conducting testing per domestic standards and the more recent set is referred to as your GLP SOPs. There were no instructions directing which SOPs were to be used for any given study. FDA investigators found conflicting instructions between your firm’s \"domestic\" study procedures and your \"GLP\" procedures. For example, the domestic SOP, SOP-\u003Cstrong>(b)(4)\u003C\u002Fstrong>02 Animal Clinical Observation requires the use of four separate forms (\u003Cstrong>(b)(4)\u003C\u002Fstrong>: General clinical observation during study, \u003Cstrong>(b)(4)\u003C\u002Fstrong>: Detailed clinical observation during study, \u003Cstrong>(b)(4)\u003C\u002Fstrong>: General clinical observation during quarantine, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>: Detailed clinical observation during quarantine) to record clinical observations separately while animals are in quarantine versus on study. However, the corresponding GLP SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-028 only requires one form to document clinical observations while animals are in quarantine (\u003Cstrong>(b)(4)\u003C\u002Fstrong>: Animal Reception, Animal Receipt, Distribution and Quarantine Records) and does not have any requirement to use certain forms for documenting observations while on study. The lack of appropriate forms to document observations in your “GLP” procedures indicates the inadequacy of your SOPs to ensure the quality and integrity of data generated. Additionally, the GLP SOP states that, “The study personnel should fill out the animal observation records in the corresponding experimental records daily.” However, as described under violation 1 of this letter, it does not appear that daily animal observations were being recorded in accordance with this SOP. This deviation from the SOP does not appear to be authorized by the study directors nor documented in the raw data.\u003C\u002Fp>\u003Cp>b. SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-028: “Animal clinical observation and management of abnormal conditions” does not include any information on signs of abnormal conditions based on species, though GLP studies were conducted on mice, rats, and rabbits. Lack of sufficient detail within this SOP could lead to errors in identifying abnormal conditions exhibited by study animals which in turn could directly impact the quality and integrity of the data generated in the course of the studies.\u003C\u002Fp>\u003Cp>c. SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-030: “Skin Sensitization Test (Guinea Pig Maximization Test)” does not include adequate instructions for clinical observation of the animals during the studies, such as assuring that their breathing is not restricted when wrapping them with the occlusive dressings during the challenge and induction phases and that animals undergo observation daily to ensure isolation and treatment of any wounds or illness throughout the study. Additionally, the SOP and training materials for the GPMT test lacked photos to demonstrate how to use the Magnusson Kligman scores. Clinical observations are essential to the quality and integrity of the data generated from this testing, and this SOP was found to lack sufficient detail to ensure that tests can be conducted reliably and consistently.\u003C\u002Fp>\u003Cp>Failure of a testing facility to have adequate SOPs, or follow established SOPs if adequate, in multiple studies with multiple study directors over many months suggests systemic failures in the operation of your nonclinical laboratory. This failure raises questions about the reliability and accuracy of the data and does not ensure the quality and integrity of data generated in a study. Failing to follow SOPs and having inadequate SOPs yield inadequate protocols that introduce ambiguity and uncertainty as to how study requirements are to be followed, as well as inconsistent execution of studies and unreliable study results. Any deviations from the SOPs must be authorized by the study director and documented in the raw data. Failure to properly document any authorized deviations could result in study data with a high level of variability that challenges the ability to effectively interpret the study results associated with a device. This in turn adversely impacts a manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a legally marketed device or for purposes of beginning clinical trials, if applicable.\u003C\u002Fp>\u003Cp>Your written response is inadequate. Your written response acknowledged the observations cited and indicated that the relevant SOPs addressing the concerns noted in the Form 483 will be revised, a gap analysis of the existing quality management system will be conducted, and an external GLP expert will be engaged to perform an audit. However, the response did not: (1) include copies of the revised SOPs such that the adequacy of the revisions can be assessed (2) describe plans for retraining personnel on revised SOPs (3) detail how your testing facility will ensure that applicable SOPs will be followed to ensure the quality and integrity of data generated in a study; (4) address any planned preventive actions such as frequency (i.e., quarterly, annual) of audits to check for compliance or future training of new study directors, as applicable; and (5) detail how appropriate documentation\u002Ffollow-up will be ensured when deviations arise in the future. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your written response does not provide assurance that similar violations would not occur again.\u003C\u002Fp>\u003Cp>\u003Cstrong>5. Failure of the testing facility to ensure that all newly received animals from outside sources were isolated and their health status evaluated in accordance with acceptable veterinary medical practice [21 CFR 58.90(b)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>All newly received animals should be isolated and evaluated to determine health status. This can allow for early detection of potential health issues. Your failures to adhere to this requirement include, but are not limited to, the following examples:\u003C\u002Fp>\u003Cp>a. The FDA investigators reviewed guinea pig receiving and quarantine records totaling five months during 2023 and 2024. The records documented that the firm received over \u003Cstrong>(b)(4)\u003C\u002Fstrong> guinea pigs in these five months and all these guinea pigs were recorded as \"normal\" or \"okay\" with no deaths reported while in quarantine. This seems highly implausible as there were six deaths among 903 animals in the guinea pig quarantine room \u003Cstrong>(b)(4)\u003C\u002Fstrong> over a two-day period that occurred during the inspection.\u003C\u002Fp>\u003Cp>b. Your firm’s records indicate on at least one occasion while still conducting GLP rabbit studies, you received more rabbits than you have the capacity to isolate for the required time. For example, 180 New Zealand White Rabbits were received on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and these rabbits were reportedly held under quarantine from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, according to your firm, the capacity across all designated rabbit quarantine rooms in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> building (\u003Cstrong>(b)(4)\u003C\u002Fstrong> in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> building) is 141 rabbits.\u003C\u002Fp>\u003Cp>Your records raise significant concerns regarding your isolation procedures as well as your evaluation of the status of test animals. Failure to isolate newly received animals or evaluate the animal’s health status can raise serious concerns about the validity of study data. Animals may be sick upon arrival. If transferred to housing with other test animals already enrolled in another study, the newly received test animal could make the other test animals sick and impact study results. Further, test animals must be free of any disease or condition that might interfere at the beginning of a study or may significantly impact study data and\u002For results.\u003C\u002Fp>\u003Cp>Your firm’s failure to have adequate intake and isolation procedures for test animals arriving at your facility suggests systemic failures in your firm’s nonclinical laboratory practices. Further, failures that relate to test animals used in numerous studies raises questions about the quality and integrity of data collected at your facility.\u003C\u002Fp>\u003Cp>Your written response is inadequate. Your written response includes revising SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-002, issuing death reports for the six guinea pig deaths identified during the inspection, and converting Room \u003Cstrong>(b)(4)\u003C\u002Fstrong> in Building \u003Cstrong>(b)(4)\u003C\u002Fstrong> into a rabbit quarantine room, adding \u003Cstrong>(b)(4)\u003C\u002Fstrong> cages to comply with company standards. However, your response does not include: (1) copies of the revised SOP such that the adequacy of the revisions can be assessed, (2) documentation that addresses the changes to the rabbit quarantine room by adding additional cages to accommodate the animals more efficiently, and (3) documentation that demonstrates the special training for QAU personnel on SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-002 procedures was conducted and Quality Assurance Manager roles and responsibilities have been established. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Your explanation, when taken into consideration with the violations described above, which occurred over many months, suggests systemic failure in study director and veterinarian oversight of nonclinical laboratory studies and brings into question data integrity and animal care and welfare at your testing facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>6. Failure of the testing facility to ensure warm-blooded animals, excluding suckling rodents, used in laboratory procedures that require manipulations and observations over an extended period of time or in studies that require the animals to be removed from and returned to their home cages for any reason (e.g., cage cleaning, treatment, etc.) received appropriate identification [21 CFR 58.90(d)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your failures to adhere to this requirement include, but are not limited to, the following example:\u003C\u002Fp>\u003Cp>a. Your firm does not use unique or study-specific animal identification numbers to prevent mix-ups during studies that require animals be removed from their cages for study related procedures including weighing and assessments. For example, for 11 GPMT studies started on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and completed \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and 14 GPMT studies started on \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and completed \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the polar negative control group animals for each study are all identified as “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and the non-polar vehicle controls are “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” All the test animals for each study are numbered “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for the polar and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” for the non-polar. The records the FDA investigators reviewed indicated your firm has assessed and weighed guinea pigs with identical IDs from multiple studies concurrently, in the same room, and on the same scale.\u003C\u002Fp>\u003Cp>Failure to appropriately identify each animal by ensuring that they are identified with unique, study-specific identification numbers raises concerns about lack of traceability of the specific animal in the cage to the test and\u002For to the results of the testing presented in the reports. The inability to distinguish the test animals and control animals across different studies raises serious concerns about the validity of the test results. Since the ability to identify specific animals is foundational to being able to draw scientifically valid conclusions from the studies, the accuracy of study results cannot be verified.\u003C\u002Fp>\u003Cp>Your written response does not adequately address the issue of misidentification. Your written response includes revising the SOP (\u003Cstrong>(b)(4)\u003C\u002Fstrong>-002) to enforce unique animal identification numbers. It also includes revising test records for guinea pig studies to add unique ID numbers to ensure data traceability and the recruitment of external GLP experts to train staff on FDA 21 CFR Part 58. However, your response does not include copies of the revised SOP such that the adequacy of the revisions can be assessed, written documentation of the GLP training information, nor does it discuss the specific personnel that will undergo the future GLP training and\u002For newly implemented procedures as applicable. Given the deviations and issues cited in the violations above, it is necessary to review the training materials to determine their adequacy for the trained individuals to both conduct the tests per the standards being used, and to produce accurate, traceable results. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your written response does not provide assurance that misidentification of animals would not reoccur.\u003C\u002Fp>\u003Cp>\u003Cstrong>7. Failure to provide a separate laboratory space, as needed, for the performance of the routine and specialized procedures required by nonclinical laboratory studies [21 CFR 58.49].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A testing facility must provide separate laboratory space for routine and specialized procedures required by nonclinical laboratory studies, as needed. This requirement ensures that studies are conducted in a controlled environment and that potentially hazardous materials or procedures are isolated from other operations. Your failures to adhere to this requirement include, but are not limited to, the following examples:\u003C\u002Fp>\u003Cp>a. According to your firm’s floor plan for Building \u003Cstrong>(b)(4)\u003C\u002Fstrong>, rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are listed as a “Procedure Room” and “Anteroom” respectively, with \u003Cstrong>(b)(4)\u003C\u002Fstrong> connecting to Guinea Pig Room \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> connecting to Guinea Pig Room \u003Cstrong>(b)(4)\u003C\u002Fstrong>. During the inspection, study director \u003Cstrong>(b)(6)\u003C\u002Fstrong> indicated that Rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are shared as the procedure rooms for both rabbits and guinea pigs for rabbit intracutaneous reactivity studies and for guinea pig sensitization studies, respectively. Not only are they shared space for different species, according to your firm’s floor plan, these two rooms are connected, not separate. Maintaining proper separation of species or test systems is a requirement per 21 CFR 58.43(a)(1).\u003C\u002Fp>\u003Cp>b. During the inspection, it was found that scale \u003Cstrong>(b)(4)\u003C\u002Fstrong>-494 located in one of the rabbit pyrogen rooms, is shared for measuring weights of both rabbits and guinea pig species. It was also found that your firm does not have procedures for cleaning the room or equipment between studies of different species, as required per 21 CFR 58.81(b)(11).\u003C\u002Fp>\u003Cp>c. There is inadequate space in both rabbit pyrogen test rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to conduct the procedures that are required for this test. Per the United States Pharmacopeia (USP) &lt;151&gt; Pyrogenicity Test standard for the rabbit pyrogen test, it should be conducted in a separate area designated solely for pyrogen testing and under environmental conditions that are free from disturbances likely to excite the rabbits. According to study director \u003Cstrong>(b)(6)\u003C\u002Fstrong>, due to the limited space in the rooms, rabbits are transferred one at a time from the rabbit feeding rooms and put on the restrainers. This opening and closing the doors causes repeated disturbances to the rabbits already transferred to the pyrogen room as they await testing. In addition, there is extremely limited space for personnel to move around or to conduct procedures on the rabbits without disturbing the others.\u003C\u002Fp>\u003Cp>Separation of animal species during biomedical testing is important to prevent interspecies disease transmission, minimize potential anxiety and behavioral changes due to conflict, and ensure the reliability of experimental results. The presence of multiple intermixed species can introduce confounding factors into in vivo testing, making it difficult to isolate the effects of a specific treatment or intervention, which impacts data integrity. Minimizing additional stress in terms of designating adequate laboratory space for procedures and housing is also important for the health and welfare of the study animals.\u003C\u002Fp>\u003Cp>Your written response is inadequate. Your written response included an explanation of the planned corrections, including: (1) dedicating rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> to performing guinea pig studies only, (2) reducing the number of rabbit pyrogen tests in rooms \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure the number of test items matches the facility’s capacity, (3) transferring of some pyrogen testing to the backup laboratory to comply with USP &lt;151&gt;, and (4) revising SOPs \u003Cstrong>(b)(4)\u003C\u002Fstrong>-014 and \u003Cstrong>(b)(4)\u003C\u002Fstrong>-002.\u003C\u002Fp>\u003Cp>However, the response did not provide the following: (1) objective evidence that the appropriate SOPs have been revised, and (2) documentation that addresses the changes to the designation of different testing rooms to accommodate the animals more efficiently. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. In addition, your response stated that priority was given to completing a volume of studies over GLP compliance, which resulted in insufficient space to assure proper adherence to regulatory requirements. This suggests that these issues are systemic and brings into question the quality and integrity of the laboratory operation areas and data collected at your testing facility. Therefore, your response does not provide assurance that these violations will not occur again.\u003C\u002Fp>\u003Cp>\u003Cstrong>8. Failure of the Quality Assurance Unit (QAU) to maintain a copy of a master schedule sheet of all nonclinical laboratory studies conducted at the testing facility indexed by test article and containing the test system, nature of study, date study was initiated, current status of each study, identity of the sponsor, and name of the study director [21 CFR 58.35(b)(1)].\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your failures to adhere to this requirement include, but are not limited, to the following examples:\u003C\u002Fp>\u003Cp>a. There was no master schedule (MS) prior to February 12, 2022, but your firm has been conducting GLP studies since at least April 2020. Moreover, the MS does not include the sponsor or test system.\u003C\u002Fp>\u003Cp>b. Per your SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-014, the test facility manager is responsible for maintaining the master schedule, not the QAU.\u003C\u002Fp>\u003Cp>c. In addition, the FDA investigators found the following completed GLP studies were archived but were not included on the master schedule: \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Without a complete and accurate MS, the study director and QAU would not know which studies are underway, at which stages and when inspections or audits are indicated. Without appropriate QAU oversight, neither the sponsor nor FDA reviewers have assurance that the data in the final study report are accurate and valid. Failure to perform QAU functions can have a negative impact on a study because it indicates a lack of oversight to ensure compliance with all applicable GLP regulations and calls into question the quality and integrity of studies conducted.\u003C\u002Fp>\u003Cp>Your written response is inadequate. Your written response attributes these failures to inadequate planning and insufficient training to ensure that GLP requirements are fully understood. You propose to correct the MS to include all GLP studies conducted from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to present. Your corrective action includes revising “SOP \u003Cstrong>(b)(4)\u003C\u002Fstrong>-013 Project Acceptance, Distribution of Project Numbers, Assignment of Project Leaders, and Management of Master Plan Forms,” among other actions. However, it does not provide documentation that the appropriate SOPs have been revised. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide assurances that QAU failures will be avoided in the future.\u003C\u002Fp>\u003Cp>The violations described above are not intended to be an all-inclusive list of problems that may exist with your facility. It is your responsibility as a non-clinical laboratory to ensure compliance with the Act and applicable regulations.\u003C\u002Fp>\u003Cp>FDA acknowledges that your written response dated February 21, 2025, included a signed letter stating that “…due to the increasingly intense price competition within the domestic market, our institution has become unsustainable to support the basic costs associated with full system compliance. This presents significant long-term challenges and risks to our institution, as well as potential product quality risks for our customers. As a result, we hereby affirm that, effective immediately, we will suspend all FDA-related non-clinical testing for a minimum period of three years, until December 31, 2027.” Furthermore, you state that, “In the event that our company decides to resume FDA-related non-clinical testing services after January 1, 2028, we commit to the following:\u003C\u002Fp>\u003Cul>\u003Cli>Submitting a formal notification to the FDA at least six (6) months prior to any planned resumption of services, detailing our operational readiness and compliance measures.\u003C\u002Fli>\u003Cli>Resuming services only after obtaining written authorization from the FDA and ensuring alignment with current regulatory expectations.\u003C\u002Fli>\u003Cli>Ensuring that all activities are conducted in full compliance with the FDA’s most recent regulatory requirements, quality standards, and inspection protocols in effect at the time of resumption.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Within 15 working days of receiving this letter, please provide documentation of the additional corrective and preventive actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the testing facility. Any submitted corrective action plan should include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. In addition, please provide a complete list of all nonclinical laboratory studies of FDA-regulated devices for the last five years, including the name of the study, the test article, the name of the study director and sponsor, and the current status of the study. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you. In addition, FDA could initiate disqualification proceedings against you in accordance with 21 CFR 58.202. If you believe that you have complied with the FD&amp;C Act and FDA regulations, please include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Your response should reference “CTS# EC250079\u002FE001” and be sent via email to: Irfan.Khan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>A copy of this letter has been sent to FDA’s OBMI Foreign Inspection Cadre via email FDAInternationalBIMO@fda.hhs.gov. Please send a copy of your response to that office.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Angela Dixon-Allamby, by phone at (301) 796-5548 or email at Angela.Dixon-Allamby@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely yours,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Soma Kalb, PhD\u003Cbr>Director\u003Cbr>DCEA1: Division of Clinical Policy and Quality\u003Cbr>Office of Clinical Evidence &amp; Analysis\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMr. Shangyou Lin\n\nRecipient Title\n\nChief Executive Officer, General Manager\n\nJiangsu Kerbio Medical Technology Group Co.\n\nChang yang Rd., No. 9, C4 Building\n\nWujin Qu\n\nChangzhou Shi\n\nJiangsu Sheng, 213145\n\nChina\n\ncontact@jcssmt.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nJuly 11, 2025\nDear Mr. Lin:\nThis Warning Letter is to inform you of objectionable conditions observed during the United States Food and Drug Administration (FDA) inspection conducted at Jiangsu Kerbio Medical Technology Group Co. from January 15, 2025, to January 24, 2025, by investigators from the FDA’s Office of Bioresearch Monitoring Inspectorate (OBMI) Foreign Inspection Cadre. This inspection was conducted to determine whether activities and procedures related to your participation in Good Laboratory Practice (GLP) nonclinical studies complied with applicable federal regulations. Specifically, FDA investigators focused on the list of studies below including, but not limited to, guinea pig maximization sensitization (GPMT), acute systemic toxicity (AST), rabbit pyrogen, muscle implantation, hemolysis, and cytotoxicity tests conducted at your facility.\nThe list of studies below is not an all-inclusive list of studies impacted by the inspection or by the violations cited in this letter.\nStudy NumberTest\n(b)(4)Intracutaneous Reactivity\n(b)(4)Guinea Pig Maximization Sensitization Test (GPMT)\n(b)(4)Acute Systemic Toxicity (AST)\n(b)(4)Rabbit Pyrogen\n(b)(4)Hemolysis\n(b)(4)Muscle Implantation Test 4 and 13 Weeks\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n(b)(4)AST\n(b)(4)GPMT\n(b)(4)MTT Cytotoxicity\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)GPMT\n(b)(4)Intracutaneous Reactivity\n\nThese tests are used in nonclinical studies for the development of devices as that term is defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h)(1), because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nThe inspection was conducted under a program designed to ensure that data and information contained in requests for Investigational Device Exemption, Premarket Approval applications, and Premarket Notification submissions are scientifically valid and accurate. Another objective of the program is to ensure that human subjects are protected from undue hazard or risk during the course of scientific investigations.\nOur review of the inspection report prepared by the OBMI revealed serious violations of Title 21, Code of Federal Regulations (CFR) Part 58 - Good Laboratory Practice for Nonclinical Laboratory Studies, which concerns, among other things, requirements prescribed under section 520(g) of the Act, 21 U.S.C. § 360j(g). Compliance with Part 58 is intended to assure the quality and integrity of the safety data filed in a premarket submission. At the close of the inspection, the FDA investigators presented the inspectional observations Form FDA-483 for your review and discussed the observations listed on the form with you.\nWe received a response from your firm dated February 21, 2025, concerning our investigators’ observations noted on the Form FDA-483. We address this response below, in relation to each of the noted violations. This letter requests prompt corrective action to address the violations cited and discusses your written response dated February 21, 2025, to the noted violations. These violations include, but are not limited to, the following:\n1. The study director failed to assure that (1) the protocol, including any change, is approved as provided by § 58.120 and is followed; (2) all experimental data, including observations of unanticipated responses of the test system are accurately recorded and verified; and (3) all applicable good laboratory practice regulations are followed [21 CFR 58.33(a), (b), and (e)].\nThe study director has overall responsibility for the technical conduct of the study, as well as for the interpretation, analysis, documentation and reporting of results, and represents the single point of study control. The study director’s responsibilities include assuring that studies are conducted in accordance with the protocol, all experimental data are accurately recorded and verified, and that applicable GLP regulations are followed. Examples of the study director’s failures to adhere to these requirements include, but are not limited to, the following:\na. SOP (b)(4)-028 states that, “The study personnel should fill out the animal observation records in the corresponding experimental records daily.” However, based on the study records reviewed by the FDA investigators for GPMT and intracutaneous reactivity studies, there were no daily animal observations raw data included in the experimental records. Documentation of animal observations in study records is necessary to allow for the reconstruction and evaluation of the final study reports. Without these records, it is not possible to confirm that these observations, which are critical to the interpretation and analysis of study results, indeed occurred, and that the final study reports accurately reflect what was observed at the time of testing.\nb. The raw data for multiple studies conducted by two different study directors showed that the same person reportedly conducted two separate study related activities at the same or overlapping times. Additionally, the raw data for multiple studies showed that other study personnel were reportedly using the same equipment at the same time. This indicates that all experimental data were not accurately recorded and verified. Examples of discrepancies are as follows:\n1. In two intracutaneous reactivity studies, the same study personnel, (b)(6), reportedly shaved all three rabbits for study (b)(4) and weighed all three rabbits for study (b)(4) at exactly 17:19 on (b)(4). It appears implausible that the same study personnel could shave and weigh multiple rabbits from two separate studies at the exact same time.\n2. On (b)(4), study personnel, (b)(6), completed weighing (b)(4) guinea pigs for the GMPT study (b)(4) at (b)(4) while study personnel, (b)(6), also completed weighing (b)(4) animals for GMPT study (b)(4) at 9:12 both using scale (b)(4). The data suggests that either these two study activities were conducted at overlapping times using the same equipment or that (b)(4) animals were weighed within the span of two minutes, both of which appear implausible.\nc. On January 21, 2025, one of the FDA investigators directly observed study personnel, (b)(6), retroactively completing records for an ongoing subacute systemic toxicity study, (b)(4), including clinical observations and animal weight data from Day 1 of the study up to Day 26 ((b)(4)) of the study. When asked to provide documentation that animals for this study were weighed, the records provided later that day showed that the animal weight data were incomplete as week 2 only included 5 out of 20 animal weights, and there were no weights recorded for week 3 which should have been completed on (b)(4). Failure to accurately record and verify experimental data as per the study protocol undermines the integrity and reliability of the study.\nd. Raw data records for ten intracutaneous reactivity studies conducted in (b)(4) and two that were conducted in (b)(4) (refer to the table below) included an animal reuse record (document #(b)(4)32 Version 3.2) indicating that the studies utilized rabbits that had been previously used in other studies. This contradicts the study protocols (see protocol Section 4: Animal Care and Maintenance for each respective study) which indicate that, “Only healthy, previously unused animals were selected.”\n(b)(4)\ne. SOP (b)(4)-030 Skin Sensitization Test (Guinea pig maximization test) requires that guinea pigs shall be acclimatized for at least 5 days. However, the study records for GPMT studies (b)(4) and (b)(4) show that this SOP was not followed. The study records documented that these studies were initiated on the guinea pigs three days after the animals were received. For example, study (b)(4) was started on (b)(4), and according to the Animal Quality Certificate, the animal was purchased on (b)(4). In addition, study (b)(4) was started on (b)(4), and the animal was purchased on (b)(4).\nAs the principal point of study control, the study director did not assure that studies were conducted in accordance with the protocol, that all experimental data were accurately recorded and verified, and that applicable good laboratory practice regulations were followed. When the protocol is not followed, data is erroneously recorded or analyzed, or other unforeseen circumstances occur that negatively affect the data, important findings in the study may be overlooked and the data cannot be accurately interpreted. Failure to follow the protocol impacts the quality and reliability of data contained within the final study report. This adversely impacts a manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a marketed device or for the purposes of beginning clinical trials, as applicable. Furthermore, failure to ensure accurate data such as individual animal weights, animal preparation, observations, and results, yields questionable study results and conclusions. Based on these failures, FDA has concerns about the quality and integrity of the data generated from the nonclinical laboratory studies conducted at your testing facility. Complete and accurate study data are necessary to allow FDA to fully assess the overall safety and risk of a device with an associated premarket submission. The unreliable data raises concerns about the quality and integrity of associated premarket submissions, which may put public health and safety at risk. Additionally, lack of daily observation of individual animals directly impacts the overall study integrity, as it is unclear if the animals are malnourished or sick in any way, which would have a direct impact on the interpretation of the study results\nYour written response is inadequate. The written response you provided states that the relevant standard operating procedures (SOPs) that address the concerns noted in the Form 483 will be revised and a GLP working group will be established to implement a regulatory compliance improvement plan for 21 CFR Part 58. However, the updated SOPs were not included in your response, and it is unclear whether you plan to retrain personnel on the updated SOPs.\nAdditionally, your firm stated that you will conduct trainings on FDA 21 CFR Part 58 regulations to ensure thorough understanding of the compliance requirements but did not provide copies of the training materials. Given the deviations and issues cited in the violations, it is necessary to review the training materials to determine their adequacy for the trained individuals to both conduct the tests per the standards being used, and to produce accurate, traceable results.\nFurthermore, your response does not provide assurance that these violations will not occur again. Specifically, your response did not: (1) detail how your testing facility will assure that applicable SOPs will be followed to ensure the quality and integrity of data generated in a study; (2) address any planned preventive actions such as frequency (i.e., quarterly, annual) of audits to check for compliance or future training of new study directors, as applicable; and (3) detail how appropriate documentation\u002Ffollow-up will be ensured when deviations arise in the future. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Your explanation, when taken into consideration with the violations described above, which occurred in multiple studies with various study directors over many months, suggests systemic failures in study director oversight of nonclinical laboratory studies and brings into question the quality and integrity of safety data collected at your testing facility.\n2. Failure to establish procedures for a system for the handling of the test and control articles to ensure that (1) proper identification is maintained throughout the distribution process and (2) the receipt and distribution of each batch is documented. Such documentation shall include the date and quantity of each batch distributed or returned [21 CFR 58.107(c) and (d)].\nYour failures to adhere to this requirement include, but are not limited to, the following examples:\na. Verification of the lot\u002Fbatch number was not found to be documented during sample receipt, preparation, or on any other source data records.\nb. Your firm’s Sample Information Form - (b)(4)052 listed the sample quantity received for study (b)(4) (Safety Intravenous Needles for Single Use) as “3 packs” with no record of how many needles were in each pack. The form then lists 1 and ¼ of a pack were distributed on (b)(4), and (b)(4), respectively. The same amounts were then listed as returned on (b)(4), and (b)(4), respectively. The form goes on to list that \"3 packs\" were disposed of on (b)(4). There was no record of the number of needles used and returned.\nc. Your firm’s sample preparation form (b)(4)83 does not require verification or documentation of the lot number or quantity of needles used for extraction for GPMT testing.\nd. The investigators found 12 GLP studies (refer to table below) where, after completion of the testing, the study director made changes to the test article information (indicated in bold in the table) or updated the test article photo (indicated by [1] in the table) in the final study report at the sponsor's request. These changes included revisions to the test article lot #, material, and size information, suggesting that proper identification is not maintained throughout the distribution process.\nStudy\nNumber: \"SSMT-S\"Test article per protocol:Studies\nCompleted:Change\nRequest date:Test article per final study report:\n(b)(4)(b)(4)(b)(4)(b)(4)(b)(4)\n\n1 The photo of the test article in the final report is not the same as the one in the protocol.\nFailure to have established procedures for the handling of the test and control articles to ensure that proper identification of the articles is maintained and that the receipt and distribution of each batch are documented as required by the regulations creates the potential for errors to occur during handling such that the incorrect information could be attributed to the article under study. This in turn could lead to testing discrepancies and inaccurate test results and conclusions. In addition, lack of these procedures adversely impacts the traceability of the test samples, reliability of the testing, and the manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a legally marketed device or for purposes of beginning clinical trials, as applicable.\nYour written response is inadequate. The written response you provided states that the relevant standard operating procedures (SOPs) addressing the concerns noted in the Form 483 will be revised, and GLP experts will be invited to provide training on FDA GLP and 510(k) regulations.\nHowever, your response did not: (1) include copies of revised SOPs (b)(4)-002 and (b)(4)-003 and (2) provide details regarding the proposed trainings, including information on the types of personnel that will undergo the trainings, training materials that will be used, and how the effectiveness of the training will be evaluated. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide assurance that these violations will not occur again.\n3. Failure of the Quality Assurance Unit (QAU) to inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection and to bring any problems found during the course of an inspection which are likely to affect study integrity to the attention of the study director and management immediately [21 CFR 58.35(b)(3)].\nGLP regulations require that QAU inspect each nonclinical laboratory study at intervals adequate to assure the integrity of the study and maintain written and properly signed records of each periodic inspection showing the date of the inspection, the study inspected, the phase or segment of the study inspected, the person performing the inspection, findings and problems, action recommended and taken to resolve existing problems, and any scheduled date for reinspection. Any problems found during the course of an inspection which are likely to affect study integrity shall be brought to the attention of the study director and management immediately. Examples of the QAU’s failures include, but are not limited to, the following:\na. The QAU failed to identify any of the data irregularities, errors, and omissions that were observed by FDA, including those described in the examples of failures throughout this letter.\nb. There were 67 studies reviewed during the inspection, of which 63 were conducted from 2023-2024. For these 63 studies, the final study reports include a signature attesting that the QAU audited the protocol, raw data, and final study reports. However, records did not support that all reported audits were completed at the reported times. Examples are as follows:\n1. Only three ((b)(4)) out of the 63 covered studies had record of a raw data audit per the QA inspection summary reports.\n2. Thirty out of the 63 covered studies did not have the reported final study report audits included on the QA inspection summary reports.\n3. Study (b)(4), completed on (b)(4), was observed to have an error within the printed cassette labels; however, there was no deviation or record of when this error was discovered or that it had been reported to the study director. The FDA investigators found the final report for this study was still in draft form but included the quality assurance statement reporting QAU inspections of the study protocol on (b)(4), and the raw data and final study report on (b)(4). However, when asked to provide copies of those QA audit reports, your firm only provided a copy of a QAU inspection report for the study protocol which was dated (b)(4). This audit report was not recorded on the QA Summary Report of Inspections. These discrepancies, including differences between the protocol audit date recorded in the quality assurance statement of the draft study report versus in the QAU inspection report, along with the missing audit report for the final study report and raw data, and lack of related audits mentioned in the QA Summary Report of Inspections, indicate a lack of adequate monitoring by the QAU.\nA reliable QAU is integral to the successful understanding and completion of any GLP study. Without appropriate QAU oversight, neither the sponsor nor FDA reviewers have assurance that the data in the final study report are accurate and valid. Failure to perform QAU functions, such as monitoring studies to ensure protocols were followed and data are accurately recorded, over the course of multiple studies also calls into question the quality and integrity of studies conducted at your testing facility.\nYour written response is inadequate. Your written response included a document that outlines your QAU’s review of QA statements, corresponding QA inspection reports, and Summary of Inspection Report for the final study reports reviewed by the FDA investigators. You also indicated in your response that the relevant SOPs addressing the concerns noted in the Form 483 will be revised along with Form QAU-F002 “Summary of Inspection Report”, interviews will be conducted with QA personnel to clarify responsibilities, a gap analysis of the existing quality management system will be conducted, and a working group will be established to identify existing problems and make improvements. Additionally, you stated plans to have training provided by an external GLP expert. However, your response did not: (1) include copies of the revised SOPs and form such that the adequacy of the revisions can be assessed and (2) provide details regarding the proposed trainings, including the training materials that will be used and how the effectiveness of the training will be evaluated. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide reasonable assurance that QAU failures will be avoided in the future.\n4. Failure of a testing facility to have standard operating procedures in writing setting forth nonclinical laboratory study methods that management is satisfied are adequate to ensure the quality and integrity of the data generated in the course of a study. The study director failed to authorize all deviations in the study from standard operating procedures and ensure the deviations were documented in the raw data [21 CFR 58.81(a)].\nSOPs should be adequate to ensure the quality and integrity of data generated in a study. However, not all SOPs appear to be adequate. The study director also must authorize all deviations from SOPs in a study and document all study deviations in the raw data. However, the study directors at your testing facility did not adhere to these requirements. Deviations from standard operating procedures in a study also were not authorized by the study director and documented in the raw data. Examples of these issues include the following:\na. Your firm was found to be operating under two sets of SOPs for conducting the same types of tests. One was originated for conducting testing per domestic standards and the more recent set is referred to as your GLP SOPs. There were no instructions directing which SOPs were to be used for any given study. FDA investigators found conflicting instructions between your firm’s \"domestic\" study procedures and your \"GLP\" procedures. For example, the domestic SOP, SOP-(b)(4)02 Animal Clinical Observation requires the use of four separate forms ((b)(4): General clinical observation during study, (b)(4): Detailed clinical observation during study, (b)(4): General clinical observation during quarantine, and (b)(4): Detailed clinical observation during quarantine) to record clinical observations separately while animals are in quarantine versus on study. However, the corresponding GLP SOP (b)(4)-028 only requires one form to document clinical observations while animals are in quarantine ((b)(4): Animal Reception, Animal Receipt, Distribution and Quarantine Records) and does not have any requirement to use certain forms for documenting observations while on study. The lack of appropriate forms to document observations in your “GLP” procedures indicates the inadequacy of your SOPs to ensure the quality and integrity of data generated. Additionally, the GLP SOP states that, “The study personnel should fill out the animal observation records in the corresponding experimental records daily.” However, as described under violation 1 of this letter, it does not appear that daily animal observations were being recorded in accordance with this SOP. This deviation from the SOP does not appear to be authorized by the study directors nor documented in the raw data.\nb. SOP (b)(4)-028: “Animal clinical observation and management of abnormal conditions” does not include any information on signs of abnormal conditions based on species, though GLP studies were conducted on mice, rats, and rabbits. Lack of sufficient detail within this SOP could lead to errors in identifying abnormal conditions exhibited by study animals which in turn could directly impact the quality and integrity of the data generated in the course of the studies.\nc. SOP (b)(4)-030: “Skin Sensitization Test (Guinea Pig Maximization Test)” does not include adequate instructions for clinical observation of the animals during the studies, such as assuring that their breathing is not restricted when wrapping them with the occlusive dressings during the challenge and induction phases and that animals undergo observation daily to ensure isolation and treatment of any wounds or illness throughout the study. Additionally, the SOP and training materials for the GPMT test lacked photos to demonstrate how to use the Magnusson Kligman scores. Clinical observations are essential to the quality and integrity of the data generated from this testing, and this SOP was found to lack sufficient detail to ensure that tests can be conducted reliably and consistently.\nFailure of a testing facility to have adequate SOPs, or follow established SOPs if adequate, in multiple studies with multiple study directors over many months suggests systemic failures in the operation of your nonclinical laboratory. This failure raises questions about the reliability and accuracy of the data and does not ensure the quality and integrity of data generated in a study. Failing to follow SOPs and having inadequate SOPs yield inadequate protocols that introduce ambiguity and uncertainty as to how study requirements are to be followed, as well as inconsistent execution of studies and unreliable study results. Any deviations from the SOPs must be authorized by the study director and documented in the raw data. Failure to properly document any authorized deviations could result in study data with a high level of variability that challenges the ability to effectively interpret the study results associated with a device. This in turn adversely impacts a manufacturer’s and FDA’s ability to assess the overall safety and risk of the subject device prior to use in humans as a legally marketed device or for purposes of beginning clinical trials, if applicable.\nYour written response is inadequate. Your written response acknowledged the observations cited and indicated that the relevant SOPs addressing the concerns noted in the Form 483 will be revised, a gap analysis of the existing quality management system will be conducted, and an external GLP expert will be engaged to perform an audit. However, the response did not: (1) include copies of the revised SOPs such that the adequacy of the revisions can be assessed (2) describe plans for retraining personnel on revised SOPs (3) detail how your testing facility will ensure that applicable SOPs will be followed to ensure the quality and integrity of data generated in a study; (4) address any planned preventive actions such as frequency (i.e., quarterly, annual) of audits to check for compliance or future training of new study directors, as applicable; and (5) detail how appropriate documentation\u002Ffollow-up will be ensured when deviations arise in the future. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your written response does not provide assurance that similar violations would not occur again.\n5. Failure of the testing facility to ensure that all newly received animals from outside sources were isolated and their health status evaluated in accordance with acceptable veterinary medical practice [21 CFR 58.90(b)].\nAll newly received animals should be isolated and evaluated to determine health status. This can allow for early detection of potential health issues. Your failures to adhere to this requirement include, but are not limited to, the following examples:\na. The FDA investigators reviewed guinea pig receiving and quarantine records totaling five months during 2023 and 2024. The records documented that the firm received over (b)(4) guinea pigs in these five months and all these guinea pigs were recorded as \"normal\" or \"okay\" with no deaths reported while in quarantine. This seems highly implausible as there were six deaths among 903 animals in the guinea pig quarantine room (b)(4) over a two-day period that occurred during the inspection.\nb. Your firm’s records indicate on at least one occasion while still conducting GLP rabbit studies, you received more rabbits than you have the capacity to isolate for the required time. For example, 180 New Zealand White Rabbits were received on (b)(4), and these rabbits were reportedly held under quarantine from (b)(4). However, according to your firm, the capacity across all designated rabbit quarantine rooms in your (b)(4) building ((b)(4) in the (b)(4) building) is 141 rabbits.\nYour records raise significant concerns regarding your isolation procedures as well as your evaluation of the status of test animals. Failure to isolate newly received animals or evaluate the animal’s health status can raise serious concerns about the validity of study data. Animals may be sick upon arrival. If transferred to housing with other test animals already enrolled in another study, the newly received test animal could make the other test animals sick and impact study results. Further, test animals must be free of any disease or condition that might interfere at the beginning of a study or may significantly impact study data and\u002For results.\nYour firm’s failure to have adequate intake and isolation procedures for test animals arriving at your facility suggests systemic failures in your firm’s nonclinical laboratory practices. Further, failures that relate to test animals used in numerous studies raises questions about the quality and integrity of data collected at your facility.\nYour written response is inadequate. Your written response includes revising SOP (b)(4)-002, issuing death reports for the six guinea pig deaths identified during the inspection, and converting Room (b)(4) in Building (b)(4) into a rabbit quarantine room, adding (b)(4) cages to comply with company standards. However, your response does not include: (1) copies of the revised SOP such that the adequacy of the revisions can be assessed, (2) documentation that addresses the changes to the rabbit quarantine room by adding additional cages to accommodate the animals more efficiently, and (3) documentation that demonstrates the special training for QAU personnel on SOP (b)(4)-002 procedures was conducted and Quality Assurance Manager roles and responsibilities have been established. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Your explanation, when taken into consideration with the violations described above, which occurred over many months, suggests systemic failure in study director and veterinarian oversight of nonclinical laboratory studies and brings into question data integrity and animal care and welfare at your testing facility.\n6. Failure of the testing facility to ensure warm-blooded animals, excluding suckling rodents, used in laboratory procedures that require manipulations and observations over an extended period of time or in studies that require the animals to be removed from and returned to their home cages for any reason (e.g., cage cleaning, treatment, etc.) received appropriate identification [21 CFR 58.90(d)].\nYour failures to adhere to this requirement include, but are not limited to, the following example:\na. Your firm does not use unique or study-specific animal identification numbers to prevent mix-ups during studies that require animals be removed from their cages for study related procedures including weighing and assessments. For example, for 11 GPMT studies started on (b)(4), and completed (b)(4), and 14 GPMT studies started on (b)(4), and completed (b)(4), the polar negative control group animals for each study are all identified as “(b)(4)” to “(b)(4)” and the non-polar vehicle controls are “(b)(4)” to “(b)(4).” All the test animals for each study are numbered “(b)(4)” to “(b)(4)” for the polar and “(b)(4)” to “(b)(4)” for the non-polar. The records the FDA investigators reviewed indicated your firm has assessed and weighed guinea pigs with identical IDs from multiple studies concurrently, in the same room, and on the same scale.\nFailure to appropriately identify each animal by ensuring that they are identified with unique, study-specific identification numbers raises concerns about lack of traceability of the specific animal in the cage to the test and\u002For to the results of the testing presented in the reports. The inability to distinguish the test animals and control animals across different studies raises serious concerns about the validity of the test results. Since the ability to identify specific animals is foundational to being able to draw scientifically valid conclusions from the studies, the accuracy of study results cannot be verified.\nYour written response does not adequately address the issue of misidentification. Your written response includes revising the SOP ((b)(4)-002) to enforce unique animal identification numbers. It also includes revising test records for guinea pig studies to add unique ID numbers to ensure data traceability and the recruitment of external GLP experts to train staff on FDA 21 CFR Part 58. However, your response does not include copies of the revised SOP such that the adequacy of the revisions can be assessed, written documentation of the GLP training information, nor does it discuss the specific personnel that will undergo the future GLP training and\u002For newly implemented procedures as applicable. Given the deviations and issues cited in the violations above, it is necessary to review the training materials to determine their adequacy for the trained individuals to both conduct the tests per the standards being used, and to produce accurate, traceable results. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your written response does not provide assurance that misidentification of animals would not reoccur.\n7. Failure to provide a separate laboratory space, as needed, for the performance of the routine and specialized procedures required by nonclinical laboratory studies [21 CFR 58.49].\nA testing facility must provide separate laboratory space for routine and specialized procedures required by nonclinical laboratory studies, as needed. This requirement ensures that studies are conducted in a controlled environment and that potentially hazardous materials or procedures are isolated from other operations. Your failures to adhere to this requirement include, but are not limited to, the following examples:\na. According to your firm’s floor plan for Building (b)(4), rooms (b)(4) and (b)(4) are listed as a “Procedure Room” and “Anteroom” respectively, with (b)(4) connecting to Guinea Pig Room (b)(4), and (b)(4) connecting to Guinea Pig Room (b)(4). During the inspection, study director (b)(6) indicated that Rooms (b)(4) and (b)(4) are shared as the procedure rooms for both rabbits and guinea pigs for rabbit intracutaneous reactivity studies and for guinea pig sensitization studies, respectively. Not only are they shared space for different species, according to your firm’s floor plan, these two rooms are connected, not separate. Maintaining proper separation of species or test systems is a requirement per 21 CFR 58.43(a)(1).\nb. During the inspection, it was found that scale (b)(4)-494 located in one of the rabbit pyrogen rooms, is shared for measuring weights of both rabbits and guinea pig species. It was also found that your firm does not have procedures for cleaning the room or equipment between studies of different species, as required per 21 CFR 58.81(b)(11).\nc. There is inadequate space in both rabbit pyrogen test rooms (b)(4) and (b)(4) to conduct the procedures that are required for this test. Per the United States Pharmacopeia (USP) \u003C151> Pyrogenicity Test standard for the rabbit pyrogen test, it should be conducted in a separate area designated solely for pyrogen testing and under environmental conditions that are free from disturbances likely to excite the rabbits. According to study director (b)(6), due to the limited space in the rooms, rabbits are transferred one at a time from the rabbit feeding rooms and put on the restrainers. This opening and closing the doors causes repeated disturbances to the rabbits already transferred to the pyrogen room as they await testing. In addition, there is extremely limited space for personnel to move around or to conduct procedures on the rabbits without disturbing the others.\nSeparation of animal species during biomedical testing is important to prevent interspecies disease transmission, minimize potential anxiety and behavioral changes due to conflict, and ensure the reliability of experimental results. The presence of multiple intermixed species can introduce confounding factors into in vivo testing, making it difficult to isolate the effects of a specific treatment or intervention, which impacts data integrity. Minimizing additional stress in terms of designating adequate laboratory space for procedures and housing is also important for the health and welfare of the study animals.\nYour written response is inadequate. Your written response included an explanation of the planned corrections, including: (1) dedicating rooms (b)(4) to performing guinea pig studies only, (2) reducing the number of rabbit pyrogen tests in rooms (b)(4) and (b)(4) to ensure the number of test items matches the facility’s capacity, (3) transferring of some pyrogen testing to the backup laboratory to comply with USP \u003C151>, and (4) revising SOPs (b)(4)-014 and (b)(4)-002.\nHowever, the response did not provide the following: (1) objective evidence that the appropriate SOPs have been revised, and (2) documentation that addresses the changes to the designation of different testing rooms to accommodate the animals more efficiently. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. In addition, your response stated that priority was given to completing a volume of studies over GLP compliance, which resulted in insufficient space to assure proper adherence to regulatory requirements. This suggests that these issues are systemic and brings into question the quality and integrity of the laboratory operation areas and data collected at your testing facility. Therefore, your response does not provide assurance that these violations will not occur again.\n8. Failure of the Quality Assurance Unit (QAU) to maintain a copy of a master schedule sheet of all nonclinical laboratory studies conducted at the testing facility indexed by test article and containing the test system, nature of study, date study was initiated, current status of each study, identity of the sponsor, and name of the study director [21 CFR 58.35(b)(1)].\nYour failures to adhere to this requirement include, but are not limited, to the following examples:\na. There was no master schedule (MS) prior to February 12, 2022, but your firm has been conducting GLP studies since at least April 2020. Moreover, the MS does not include the sponsor or test system.\nb. Per your SOP (b)(4)-014, the test facility manager is responsible for maintaining the master schedule, not the QAU.\nc. In addition, the FDA investigators found the following completed GLP studies were archived but were not included on the master schedule: (b)(4).\nWithout a complete and accurate MS, the study director and QAU would not know which studies are underway, at which stages and when inspections or audits are indicated. Without appropriate QAU oversight, neither the sponsor nor FDA reviewers have assurance that the data in the final study report are accurate and valid. Failure to perform QAU functions can have a negative impact on a study because it indicates a lack of oversight to ensure compliance with all applicable GLP regulations and calls into question the quality and integrity of studies conducted.\nYour written response is inadequate. Your written response attributes these failures to inadequate planning and insufficient training to ensure that GLP requirements are fully understood. You propose to correct the MS to include all GLP studies conducted from (b)(4) to present. Your corrective action includes revising “SOP (b)(4)-013 Project Acceptance, Distribution of Project Numbers, Assignment of Project Leaders, and Management of Master Plan Forms,” among other actions. However, it does not provide documentation that the appropriate SOPs have been revised. Also, as your corrective action, preventative action and verification of effectiveness plans have not yet been completed, FDA cannot evaluate the adequacy of your actions in addressing this violation. Therefore, your response does not provide assurances that QAU failures will be avoided in the future.\nThe violations described above are not intended to be an all-inclusive list of problems that may exist with your facility. It is your responsibility as a non-clinical laboratory to ensure compliance with the Act and applicable regulations.\nFDA acknowledges that your written response dated February 21, 2025, included a signed letter stating that “…due to the increasingly intense price competition within the domestic market, our institution has become unsustainable to support the basic costs associated with full system compliance. This presents significant long-term challenges and risks to our institution, as well as potential product quality risks for our customers. As a result, we hereby affirm that, effective immediately, we will suspend all FDA-related non-clinical testing for a minimum period of three years, until December 31, 2027.” Furthermore, you state that, “In the event that our company decides to resume FDA-related non-clinical testing services after January 1, 2028, we commit to the following:\nSubmitting a formal notification to the FDA at least six (6) months prior to any planned resumption of services, detailing our operational readiness and compliance measures.\nResuming services only after obtaining written authorization from the FDA and ensuring alignment with current regulatory expectations.\nEnsuring that all activities are conducted in full compliance with the FDA’s most recent regulatory requirements, quality standards, and inspection protocols in effect at the time of resumption.”\nWithin 15 working days of receiving this letter, please provide documentation of the additional corrective and preventive actions that you have taken or will take to correct these violations and to prevent the recurrence of similar violations in current or future studies for which you are the testing facility. Any submitted corrective action plan should include projected completion dates for each action to be accomplished as well as a plan for monitoring the effectiveness of your corrective actions. In addition, please provide a complete list of all nonclinical laboratory studies of FDA-regulated devices for the last five years, including the name of the study, the test article, the name of the study director and sponsor, and the current status of the study. Failure to respond to this letter and take appropriate corrective action could result in the FDA taking regulatory action without further notice to you. In addition, FDA could initiate disqualification proceedings against you in accordance with 21 CFR 58.202. If you believe that you have complied with the FD&C Act and FDA regulations, please include your reasoning and any supporting information for our consideration.\nYour response should reference “CTS# EC250079\u002FE001” and be sent via email to: Irfan.Khan@fda.hhs.gov.\nA copy of this letter has been sent to FDA’s OBMI Foreign Inspection Cadre via email FDAInternationalBIMO@fda.hhs.gov. Please send a copy of your response to that office.\nIf you have any questions, please contact Angela Dixon-Allamby, by phone at (301) 796-5548 or email at Angela.Dixon-Allamby@fda.hhs.gov.\nSincerely yours,\n\u002FS\u002F\nSoma Kalb, PhD\nDirector\nDCEA1: Division of Clinical Policy and Quality\nOffice of Clinical Evidence & Analysis\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Jiangsu Kerbio Medical Technology Group Co.","jiangsu-kerbio-medical-technology-group-co-705188-07112025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fjiangsu-kerbio-medical-technology-group-co-705188-07112025","2026-10-26T08:09:04.055844+00:00","2025-08-26","705188","Mr. Shangyou Lin","2026-08-19T16:28:49.942+00:00","2025-07-11",{"id":149,"raw":150,"subject":155,"body_html":156,"body_text":157,"firm_name":158,"letter_id":159,"created_at":160,"fei_number":19,"letter_url":161,"updated_at":162,"action_type":22,"case_status":23,"posted_date":163,"marcs_cms_no":164,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":165,"body_fetched_at":166,"delivery_method":167,"recipient_title":19,"reference_number":19,"action_taken_date":168,"medical_device_id":19,"response_letter_date":19},1436,[151,152,153,11,154,13,13,13],"\u003Ctime datetime=\"2024-06-04T04:00:00Z\">06\u002F04\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-26T05:00:00Z\">12\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftechlem-medical-corporation-671395-12262023\">Techlem Medical Corporation\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Anurag Sinha, President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Techlem Medical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6890 Pacific Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mississauga\u003C\u002Fspan> \u003Cspan>ON\u003C\u002Fspan> \u003Cspan>L5T 1N8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 26, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Sinha,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Mississauga, Canada on June 19, 2023, through June 22, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures wheeled stretchers. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations \u003C\u002Fu>(CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response from your firm dated July 17, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\n\n\u003Cp>a. On June 19, 2023, your President confirmed CAPA procedures have not been established.\u003C\u002Fp>\n\n\u003Cp>b. As a result of your firm’s February 2023 audit, an observation was found that the welding equipment used in the manufacture of the devices needed to be fixed since it was “not penetrating”. The affected parts were replaced as identified on the firm’s Annual Audit Finding document. However, the following could not be provided:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Investigation into how long the welding equipment was not performing adequately,\u003C\u002Fli>\n\t\u003Cli>Testing and the effectiveness of the corrections made to the welding equipment, and\u003C\u002Fli>\n\t\u003Cli>Ensuring the adequacy of the three-month cleaning schedule.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response dated July 17, 2023, is not adequate. Your firm developed and submitted a CAPA procedure, CA-003 – Corrective and Preventive Action; however, it is deficient in several ways. The following are some, but not all areas of your CAPA procedure that are deficient:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Under Procedure, External Complaints, it states “When an external non-conformance occurs, and when applicable, Techlem Medical Corporation responds in a manner best suited to the customer’s needs.” This statement is ineffective as it gives no specific direction. The procedure should identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems. There is no mention in the CAPA procedure of verifying or validating the corrective and preventive action to ensure that the action is effective and does not adversely affect the finished device.\u003C\u002Fli>\n\t\u003Cli>There is no mention in the CAPA procedure of ensuring that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product or the prevention of such problems.\u003C\u002Fli>\n\t\u003Cli>There is no mention in the CAPA procedure of submitting relevant information on identified quality problems, as well as corrective and preventive actions, for management review.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>2. Failure to adequately establish procedures for quality audits, as required by 21 CFR 820.22. For example: You stated that you perform internal quality system audits annually; however, you lacked procedures for the internal quality audits. Your response dated July 17, 2023, is not adequate. Your firm developed and submitted your Internal Audit procedure, IA-007; however, you did not provide evidence of implementation of the newly developed procedure.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain a design history file for each type of device, as required by 21 CFR 820.30(j). For example: Your design control procedure as identified in the Quality Manual section Research and Development does not include a requirement to establish and maintain a design history file. You did not establish a design history file and you lacked the requirement to establish and maintain one.\u003C\u002Fp>\n\n\u003Cp>Your response dated July 17, 2023, is not adequate. You submitted your Quality Manual, which under the Research and Development section, on page 10, requires that a design history file be established and maintained by Quality Assurance. However, you did not provide evidence of implementation of this requirement. You also submitted your Design Control Procedure, DC-004; however, the procedure does not address the requirement to establish a design history file.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately document acceptance activities to include the signature of the individual conducting the acceptance activities, as required by 21 CFR 820.80(e). For example: On page 23 of your Quality Manual it states, “At conclusion of final inspection, the OC Inspector will sign off on the Inspection Report.” However, 16 final inspection sheets reviewed during the inspection did not have a sign off signature or release date. The adequacy of your response dated July 17, 2023, cannot be determined at this time. You submitted a blank Techlem Medical – Final QC Inspection Sheet, which contains a space for the signature and release date; however, you did not provide evidence of implementation of this revised form.\u003C\u002Fp>\n\n\u003Cp>5. Failure to adequately establish and maintain procedures to ensure that device history records for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record and the requirements of 21 CFR 820, as required by 21 CFR 820.184. For example: The Quality Manual procedure does not define where labeling for the finished devices will be maintained.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated July 17, 2023, cannot be determined at this time. The Quality Manual does not address labeling, but your firm has since developed DHR-016, Device History Record, that addresses where labeling for the finished devices will be maintained. However, you did not provide evidence of implementation of DHR-016, Device History Record.\u003C\u002Fp>\n\n\u003Cp>6. Failure to adequately establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors and consultants, as required by 21 CFR 820.50(a). For example: A Vendor Approval Form is used to gather information about a potential supplier. This form requires three references to confirm the status of the potential supplier. The procedure, Purchasing-Vendor Approval section of the Quality Manual does not include this requirement of three references. Thus, the procedure does not adequately establish and maintain the requirements used to evaluate and select potential suppliers. For example, by stating how many good references are needed for approval of the supplier.\u003C\u002Fp>\n\n\u003Cp>Your response dated July 17, 2023, is not adequate. You submitted your revised Quality Manual and a new purchasing SOP, POR-011 – Supplier Approval. In addition, you submitted a Supplier Approval Checklist.. Your purchasing SOP, POR-011 – Supplier Approval, appears to contain all the information stipulated under 21 CFR 820.50, Purchasing Controls. However, the requirements used to evaluate and select potential suppliers are still unclear. Neither the revised Quality Manual, the new Supplier Approval SOP, nor the Supplier Approval Checklist contain a requirement of three references to qualify a supplier and it is unknown whether the Approved\u002FPreferred Vendor Application Form containing the three-reference requirement is still being used or if it was superseded by one of the new documents submitted. Additionally, you did not submit evidence of implementation and you did not indicate whether you will conduct a retrospective review of your existing suppliers to determine if the suppliers have met the defined requirements.\u003C\u002Fp>\n\n\u003Cp>7. Failure to adequately establish procedures to control document changes, as required by 21 CFR 820.40(b). For example: Several of your revised documents lack a revision number, a release signature of the approving individual(s), and a date of approval.\u003C\u002Fp>\n\n\u003Cp>Your response dated July 17, 2023, is not adequate. Your firm lacked document control procedures and therefore, developed and submitted COR-002 – Control of Records. A portion of the purpose statement of this document is as follows: “To ensure the documents are Reviewed, Approved, Updated, and distributed and stored in a controlled manner.” However, the document does not address document approval, nor does it address document changes.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s wheeled stretchers are misbranded within the meaning of section 502(t)(2) [21 U.S.C. § 352(t)(2)], in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. And 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Techlem Medical Corporation is therefore a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\n\n\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21. U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S. C. § 331(q)(1)(B).\u003C\u002Fp>\n\n\u003Cp>Your response dated July 17, 2023, is not adequate. Your firm submitted evidence that you have obtained UDIs; however, a search of the GUDID database on October 17, 2023, did not reveal any entries.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993.&nbsp;\u003Cstrong>Refer to CMS case #671395 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: David Wolloscheck at 301-796-1480.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT 3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp; &nbsp;General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDr. Anurag Sinha, President\n\nRecipient Title\n\nCEO\n\nTechlem Medical Corporation\n\n6890 Pacific Circle\n\nMississauga ON L5T 1N8\n\nCanada\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDecember 26, 2023\n\nDear Dr. Sinha,\n\nDuring an inspection of your firm located in Mississauga, Canada on June 19, 2023, through June 22, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures wheeled stretchers. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response from your firm dated July 17, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example:\n\na. On June 19, 2023, your President confirmed CAPA procedures have not been established.\n\nb. As a result of your firm’s February 2023 audit, an observation was found that the welding equipment used in the manufacture of the devices needed to be fixed since it was “not penetrating”. The affected parts were replaced as identified on the firm’s Annual Audit Finding document. However, the following could not be provided:\n\nInvestigation into how long the welding equipment was not performing adequately,\n\nTesting and the effectiveness of the corrections made to the welding equipment, and\n\nEnsuring the adequacy of the three-month cleaning schedule.\n\nYour response dated July 17, 2023, is not adequate. Your firm developed and submitted a CAPA procedure, CA-003 – Corrective and Preventive Action; however, it is deficient in several ways. The following are some, but not all areas of your CAPA procedure that are deficient:\n\nUnder Procedure, External Complaints, it states “When an external non-conformance occurs, and when applicable, Techlem Medical Corporation responds in a manner best suited to the customer’s needs.” This statement is ineffective as it gives no specific direction. The procedure should identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems. There is no mention in the CAPA procedure of verifying or validating the corrective and preventive action to ensure that the action is effective and does not adversely affect the finished device.\n\nThere is no mention in the CAPA procedure of ensuring that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product or the prevention of such problems.\n\nThere is no mention in the CAPA procedure of submitting relevant information on identified quality problems, as well as corrective and preventive actions, for management review.\n\n2. Failure to adequately establish procedures for quality audits, as required by 21 CFR 820.22. For example: You stated that you perform internal quality system audits annually; however, you lacked procedures for the internal quality audits. Your response dated July 17, 2023, is not adequate. Your firm developed and submitted your Internal Audit procedure, IA-007; however, you did not provide evidence of implementation of the newly developed procedure.\n\n3. Failure to establish and maintain a design history file for each type of device, as required by 21 CFR 820.30(j). For example: Your design control procedure as identified in the Quality Manual section Research and Development does not include a requirement to establish and maintain a design history file. You did not establish a design history file and you lacked the requirement to establish and maintain one.\n\nYour response dated July 17, 2023, is not adequate. You submitted your Quality Manual, which under the Research and Development section, on page 10, requires that a design history file be established and maintained by Quality Assurance. However, you did not provide evidence of implementation of this requirement. You also submitted your Design Control Procedure, DC-004; however, the procedure does not address the requirement to establish a design history file.\n\n4. Failure to adequately document acceptance activities to include the signature of the individual conducting the acceptance activities, as required by 21 CFR 820.80(e). For example: On page 23 of your Quality Manual it states, “At conclusion of final inspection, the OC Inspector will sign off on the Inspection Report.” However, 16 final inspection sheets reviewed during the inspection did not have a sign off signature or release date. The adequacy of your response dated July 17, 2023, cannot be determined at this time. You submitted a blank Techlem Medical – Final QC Inspection Sheet, which contains a space for the signature and release date; however, you did not provide evidence of implementation of this revised form.\n\n5. Failure to adequately establish and maintain procedures to ensure that device history records for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record and the requirements of 21 CFR 820, as required by 21 CFR 820.184. For example: The Quality Manual procedure does not define where labeling for the finished devices will be maintained.\n\nThe adequacy of your response dated July 17, 2023, cannot be determined at this time. The Quality Manual does not address labeling, but your firm has since developed DHR-016, Device History Record, that addresses where labeling for the finished devices will be maintained. However, you did not provide evidence of implementation of DHR-016, Device History Record.\n\n6. Failure to adequately establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors and consultants, as required by 21 CFR 820.50(a). For example: A Vendor Approval Form is used to gather information about a potential supplier. This form requires three references to confirm the status of the potential supplier. The procedure, Purchasing-Vendor Approval section of the Quality Manual does not include this requirement of three references. Thus, the procedure does not adequately establish and maintain the requirements used to evaluate and select potential suppliers. For example, by stating how many good references are needed for approval of the supplier.\n\nYour response dated July 17, 2023, is not adequate. You submitted your revised Quality Manual and a new purchasing SOP, POR-011 – Supplier Approval. In addition, you submitted a Supplier Approval Checklist.. Your purchasing SOP, POR-011 – Supplier Approval, appears to contain all the information stipulated under 21 CFR 820.50, Purchasing Controls. However, the requirements used to evaluate and select potential suppliers are still unclear. Neither the revised Quality Manual, the new Supplier Approval SOP, nor the Supplier Approval Checklist contain a requirement of three references to qualify a supplier and it is unknown whether the Approved\u002FPreferred Vendor Application Form containing the three-reference requirement is still being used or if it was superseded by one of the new documents submitted. Additionally, you did not submit evidence of implementation and you did not indicate whether you will conduct a retrospective review of your existing suppliers to determine if the suppliers have met the defined requirements.\n\n7. Failure to adequately establish procedures to control document changes, as required by 21 CFR 820.40(b). For example: Several of your revised documents lack a revision number, a release signature of the approving individual(s), and a date of approval.\n\nYour response dated July 17, 2023, is not adequate. Your firm lacked document control procedures and therefore, developed and submitted COR-002 – Control of Records. A portion of the purpose statement of this document is as follows: “To ensure the documents are Reviewed, Approved, Updated, and distributed and stored in a controlled manner.” However, the document does not address document approval, nor does it address document changes.\n\nOur inspection also revealed that your firm’s wheeled stretchers are misbranded within the meaning of section 502(t)(2) [21 U.S.C. § 352(t)(2)], in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. And 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Techlem Medical Corporation is therefore a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\n\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21. U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S. C. § 331(q)(1)(B).\n\nYour response dated July 17, 2023, is not adequate. Your firm submitted evidence that you have obtained UDIs; however, a search of the GUDID database on October 17, 2023, did not reveal any entries.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #671395 when replying. If you have any questions about the contents of this letter, please contact: David Wolloscheck at 301-796-1480.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT 3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Techlem Medical Corporation","techlem-medical-corporation-671395-12262023","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftechlem-medical-corporation-671395-12262023","2026-10-26T08:10:10.30362+00:00","2024-06-04","671395","Dr. Anurag Sinha, President","2026-08-20T00:03:33.008+00:00","VIA UNITED PARCEL SERVICE","2023-12-26",{"id":170,"raw":171,"subject":176,"body_html":177,"body_text":178,"firm_name":179,"letter_id":180,"created_at":181,"fei_number":19,"letter_url":182,"updated_at":183,"action_type":22,"case_status":23,"posted_date":184,"marcs_cms_no":185,"product_type":186,"closeout_date":19,"issuing_office":175,"recipient_name":187,"body_fetched_at":188,"delivery_method":189,"recipient_title":19,"reference_number":19,"action_taken_date":190,"medical_device_id":19,"response_letter_date":19},2156,[172,173,174,175,176,13,13,13],"\u003Ctime datetime=\"2023-03-21T13:20:00Z\">03\u002F21\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-03-16T04:00:00Z\">03\u002F16\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarina-technology-llc-652997-03162023\">Marina Technology LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Nicholas Gollust and Robert Sunderland\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Marina Technology LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6080 Center Drive, Floor 6\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Los Angeles\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>90045\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:nick@marinatech.com\"> nick@marinatech.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@marinatech.co\"> info@marinatech.co\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 16, 2023\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Nicholas Gollust and Robert Sunderland:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.marinatech.co and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see, \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\">https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our review of the website https:\u002F\u002Fwww.marinatech.co revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Aquabar Berry Blast, Aquabar Peach Ice, and Aquabar Rainbow Ice.\u003C\u002Fp>\n\n\u003Cp>The ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&amp;C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, RW2301909, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\u003C\u002Fp>\n\n\u003Cp>DPAL-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\u003Cbr>\n\u003Cbr>\nSincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>VIA UPS and Electronic Mail\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nMarina Technology, LLC\u003Cbr>\nAttn: Sam Rosenberg and Nicholas\u003Cbr>\nsam@marinavape.com\u003Cbr>\nnick@marinavape.com\u003C\u002Fp>\n\n\u003Cp>Marina Vape LLC\u003Cbr>\nAttn: Nebil Kabir\u003Cbr>\n4943 McConnell Ave Ste N\u003Cbr>\nLos Angeles, CA 90066\u003Cbr>\ninfo@marinatech.co\u003C\u002Fp>\n\n\u003Cp>Key-Systems GmbH\u003Cbr>\nabuse@key-systems.net\u003C\u002Fp>\n\n\u003Cp>Shopify, Inc.\u003Cbr>\nabuse@shopify.com\u003C\u002Fp>\n\n\u003Cp>Element Vape\u003Cbr>\n300 W. Valley Blvd, Unit 23\u003Cbr>\nAlhambra, CA 91803\u003Cbr>\ncustomerservice@elementvape.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nNicholas Gollust and Robert Sunderland\n\nMarina Technology LLC\n\n6080 Center Drive, Floor 6\n\nLos Angeles, CA 90045\n\nUnited States\n\nnick@marinatech.com\n\ninfo@marinatech.co\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nMarch 16, 2023\n\nWARNING LETTER\n\nDear Nicholas Gollust and Robert Sunderland:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https:\u002F\u002Fwww.marinatech.co and determined that electronic nicotine delivery system (ENDS) products listed there are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. Certain tobacco products, including ENDS products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including ENDS products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see, https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\n\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nNew Tobacco Products Without Required Marketing Authorization are Adulterated and Misbranded\n\nOur review of the website https:\u002F\u002Fwww.marinatech.co revealed that you manufacture and offer for sale or distribution to customers in the United States ENDS products without a marketing authorization order, including: Aquabar Berry Blast, Aquabar Peach Ice, and Aquabar Rainbow Ice.\n\nThe ENDS products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act. In addition, these products are misbranded under section 903(a)(6) of the FD&C Act because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\n\nConclusion and Requested Actions\n\nFDA has determined that your firm markets new tobacco products lacking premarket authorization in the United States. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should address any violations that are referenced above, as well as violations that are the same as or similar to those stated above, and promptly take any necessary actions to bring your tobacco products into compliance with the FD&C Act. It is your responsibility to ensure that your tobacco products and all related labeling and\u002For advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated or misbranded may be detained or refused admission.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative labeling, advertising, sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, RW2301909, in your response and direct your response via email at CTPCompliance@fda.hhs.gov and to the following address:\n\nDPAL-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Bryan Hills at (301) 796-9367 or via email at CTPCompliance@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products\n\nVIA UPS and Electronic Mail\n\ncc:\n\nMarina Technology, LLC\n\nAttn: Sam Rosenberg and Nicholas\n\nsam@marinavape.com\n\nnick@marinavape.com\n\nMarina Vape LLC\n\nAttn: Nebil Kabir\n\n4943 McConnell Ave Ste N\n\nLos Angeles, CA 90066\n\ninfo@marinatech.co\n\nKey-Systems GmbH\n\nabuse@key-systems.net\n\nShopify, Inc.\n\nabuse@shopify.com\n\nElement Vape\n\n300 W. Valley Blvd, Unit 23\n\nAlhambra, CA 91803\n\ncustomerservice@elementvape.com","Marina Technology LLC","marina-technology-llc-652997-03162023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarina-technology-llc-652997-03162023","2026-10-26T08:09:20.478436+00:00","2023-03-21","652997","Tobacco","Nicholas Gollust and Robert Sunderland","2026-08-20T01:11:27.55+00:00","VIA UPS and Electronic Mail","2023-03-16",{"id":192,"raw":193,"subject":197,"body_html":198,"body_text":199,"firm_name":200,"letter_id":201,"created_at":202,"fei_number":19,"letter_url":203,"updated_at":204,"action_type":22,"case_status":23,"posted_date":205,"marcs_cms_no":206,"product_type":106,"closeout_date":19,"issuing_office":95,"recipient_name":207,"body_fetched_at":208,"delivery_method":209,"recipient_title":19,"reference_number":210,"action_taken_date":211,"medical_device_id":19,"response_letter_date":19},486,[194,195,196,95,197,13,13,13],"\u003Ctime datetime=\"2025-11-11T05:00:00Z\">11\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-10-09T04:00:00Z\">10\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftaizhou-kangping-medical-science-and-technology-co-ltd-711081-10092025\">Taizhou Kangping Medical Science and Technology Co., Ltd.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-01\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Yuegen Wang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Taizhou Kangping Medical Science and Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Building 3, No 27 Tai’an Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hailing Industrial Park\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hailing Qu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Taizhou Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangsu Sheng\u003C\u002Fspan>, \u003Cspan>225300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-26-01\u003C\u002Fp>\u003Cp>October 9, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Wang:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Taizhou Kangping Medical Science and Technology Co., Ltd., FEI 3013321339, at Building 3, No 27 Tai’an Road, Hailing Industrial Park, Taizhou City, Jiangsu, China 225300, from March 10 to March 14, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 4, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because you failed to take corrective actions to bring your operations into compliance with CGMP.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Failure to establish procedures designed to prevent micro-contamination in products purporting to be sterile (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are labeled as “\u003Cem>Sterile unless\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not sterilized, which you confirmed in your response on May 10, 2025: “… \u003Cstrong>(b)(4)\u003C\u002Fstrong>… is \u003Cem>Nonsterile product\u003C\u002Fem> ....” Sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> may be used by healthcare practitioners as a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong>, if labeled as sterile, must have controls in place to ensure sterility. The inspection documented that you do not perform sterility testing of the drug product, and that the Specification and Analysis Method on \u003Cstrong>(b)(4)\u003C\u002Fstrong> tests the Finished Product Quality Standards to Microbial Limits USP &lt;61&gt; method, with acceptance criteria of ≤\u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fgram of total aerobic bacteria and ≤\u003Cstrong>(b)(4)\u003C\u002Fstrong> cfu\u002Fgram of mold, yeast.\u003C\u002Fp>\u003Cp>Drugs purported to be sterile must comply with applicable 21 CFR 211 CGMP requirements (including sterility assurance).\u003C\u002Fp>\u003Cp>On July 16, 2025, FDA held a teleconference with you and your U.S. agent. We acknowledge your decision to initiate a recall of all your \u003Cstrong>(b)(4)\u003C\u002Fstrong> within expiry currently in distribution to the U.S. market.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Failure to establish appropriate product specifications and scientifically sound testing procedures (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>A. Your high-performance liquid chromatography (HPLC) analyses for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Assay Content lacked an appropriate determination of system suitability, as outlined in USP &lt;621&gt;, before sample injections. Your quality approved test method, Quality Specification and Operating Procedures for Testing \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is not scientifically sound in that your Quality Control (QC) analysts are instructed to generate a chromatographic standard curve “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” This method of calculation from the standard curve has the practical effect of masking system drift and performance issues that affect the quantitative accuracy of batch-specific test results, because the frequency is conducted “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\u003Cp>In your response, you commit to revising the frequency of establishing a standard curve (linear solution test) from “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” to “\u003Cem>at the same time with each sample test\u003C\u002Fem>.” However, your response is inadequate because you have not committed to ensuring that standard curves (linear solution tests) performed “\u003Cem>at the same time with each sample test\u003C\u002Fem>” are extended to include gas chromatography (GC), which is used to determine \u003Cstrong>(b)(4)\u003C\u002Fstrong> Assay Content.\u003C\u002Fp>\u003Cp>B. Your firm lacked sufficient controls over GC and HPLC data acquisition systems that are used to test assay label claims for drug products before release. Specifically, Excel worksheets used to perform chromatogram calculations were not retained, and access accounts to the GC and HPLC workstations were shared by job title and were not attributable to the individual analyst. The inspection documented the deletion of several recent Excel spreadsheets that were used to perform suitability and assay calculations. Your QC Supervisor\u002FManager confirmed that the Excel spreadsheets that were relied upon to generate the finished product quality standards, had not been validated, controlled, retained, or quality verified for data integrity before they were used for product release. Further, this individual was the only analyst who performed testing, yet maintained administrative privileges within the system. When further questioned on this practice, the QC Supervisor\u002FManager identified that the administrative role was the only primary access point to the Gas Chromatography data acquisition software for OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> product release and stability testing.\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP-compliant data integrity practices, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity, and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan (CAPA). The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm, including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Product Specifications\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Upon further review of the records and information you provided, process controls for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> appear to be inconsistent with the applicable conditions for an OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> formulated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> as an active ingredient. For OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products marketed under 505G of the FD&amp;C Act, such as the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, the allowable concentration for the active ingredient \u003Cstrong>(b)(4)\u003C\u002Fstrong> is \u003Cstrong>(b)(4)\u003C\u002Fstrong>%-\u003Cstrong>(b)(4)\u003C\u002Fstrong>%. However, throughout the product lifecycle for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your operations seem to far exceed the allowable concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> as indicated in your process validation. For example, your Specification and Analysis Method allows for the release of products with concentrations of \u003Cstrong>(b)(4)\u003C\u002Fstrong> up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. In addition, your 2024 Annual Quality Review and 2023 Process Validation summary of Critical Quality Attributes reports also include concentrations of \u003Cstrong>(b)(4)\u003C\u002Fstrong> that are well above what is allowed with values detected at \u003Cstrong>(b)(4)\u003C\u002Fstrong>-\u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Although your \u003Cstrong>(b)(4)\u003C\u002Fstrong> are labeled with \u003Cstrong>(b)(4)\u003C\u002Fstrong> at a concentration of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, as noted, your operations and process controls appear to deviate from the proposed conditions and requirements for an OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> product. For consistent regulatory compliance it is essential that OTC \u003Cstrong>(b)(4)\u003C\u002Fstrong> products like your \u003Cstrong>(b)(4)\u003C\u002Fstrong> conform to the applicable FDA requirements and OTC monograph conditions for the lawful distribution of this OTC drug product without an approved application.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Ceased\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your written responses to date commit to cease the commercial distribution of OTC products in the U.S. market starting March 14, 2025. If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On July 16, 2025, FDA held a teleconference with you and your U.S. agent, during which you committed to the recall of all your \u003Cstrong>(b)(4)\u003C\u002Fstrong> within expiry currently in distribution to the U.S. market.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on September 18, 2025.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA’s continuing to refuse admission of articles manufactured at Taizhou Kangping Medical Science and Technology Co., Ltd., located at Building 3, No 27 Tai’an Road, Hailing Industrial Park, Taizhou City, Jiangsu, China 225300, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), and are misbranded under section 502 of the FD&amp;C Act, respectively.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013321339 and ATTN: Kara S. Quinn.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-26-01\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Yuegen Wang\n\nRecipient Title\n\nGeneral Manager\n\nTaizhou Kangping Medical Science and Technology Co., Ltd.\n\nBuilding 3, No 27 Tai’an Road\n\nHailing Industrial Park\n\nHailing Qu\n\nTaizhou Shi\n\nJiangsu Sheng, 225300\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-01\nOctober 9, 2025\nDear Mr. Wang:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Taizhou Kangping Medical Science and Technology Co., Ltd., FEI 3013321339, at Building 3, No 27 Tai’an Road, Hailing Industrial Park, Taizhou City, Jiangsu, China 225300, from March 10 to March 14, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 4, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Your response is inadequate because you failed to take corrective actions to bring your operations into compliance with CGMP.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following:\n1. Failure to establish procedures designed to prevent micro-contamination in products purporting to be sterile (21 CFR 211.113(b)).\nYour (b)(4) are labeled as “Sterile unless (b)(4).” However, your (b)(4) are not sterilized, which you confirmed in your response on May 10, 2025: “… (b)(4)… is Nonsterile product ....” Sterile (b)(4) may be used by healthcare practitioners as a (b)(4). Sterile (b)(4), if labeled as sterile, must have controls in place to ensure sterility. The inspection documented that you do not perform sterility testing of the drug product, and that the Specification and Analysis Method on (b)(4) tests the Finished Product Quality Standards to Microbial Limits USP \u003C61> method, with acceptance criteria of ≤(b)(4) cfu\u002Fgram of total aerobic bacteria and ≤(b)(4) cfu\u002Fgram of mold, yeast.\nDrugs purported to be sterile must comply with applicable 21 CFR 211 CGMP requirements (including sterility assurance).\nOn July 16, 2025, FDA held a teleconference with you and your U.S. agent. We acknowledge your decision to initiate a recall of all your (b)(4) within expiry currently in distribution to the U.S. market.\n2. Failure to establish appropriate product specifications and scientifically sound testing procedures (21 CFR 211.160(b)).\nA. Your high-performance liquid chromatography (HPLC) analyses for (b)(4) Assay Content lacked an appropriate determination of system suitability, as outlined in USP \u003C621>, before sample injections. Your quality approved test method, Quality Specification and Operating Procedures for Testing (b)(4), is not scientifically sound in that your Quality Control (QC) analysts are instructed to generate a chromatographic standard curve “(b)(4).” This method of calculation from the standard curve has the practical effect of masking system drift and performance issues that affect the quantitative accuracy of batch-specific test results, because the frequency is conducted “(b)(4).”\nIn your response, you commit to revising the frequency of establishing a standard curve (linear solution test) from “(b)(4)” to “at the same time with each sample test.” However, your response is inadequate because you have not committed to ensuring that standard curves (linear solution tests) performed “at the same time with each sample test” are extended to include gas chromatography (GC), which is used to determine (b)(4) Assay Content.\nB. Your firm lacked sufficient controls over GC and HPLC data acquisition systems that are used to test assay label claims for drug products before release. Specifically, Excel worksheets used to perform chromatogram calculations were not retained, and access accounts to the GC and HPLC workstations were shared by job title and were not attributable to the individual analyst. The inspection documented the deletion of several recent Excel spreadsheets that were used to perform suitability and assay calculations. Your QC Supervisor\u002FManager confirmed that the Excel spreadsheets that were relied upon to generate the finished product quality standards, had not been validated, controlled, retained, or quality verified for data integrity before they were used for product release. Further, this individual was the only analyst who performed testing, yet maintained administrative privileges within the system. When further questioned on this practice, the QC Supervisor\u002FManager identified that the administrative role was the only primary access point to the Gas Chromatography data acquisition software for OTC (b)(4) product release and stability testing.\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP-compliant data integrity practices, at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe acknowledge that you are using an independent third-party consultant to audit your operation and assist in meeting FDA requirements. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies in data records and reporting, including results of the data review for drugs distributed to the United States. Include a detailed description of the scope and root causes of your data integrity lapses.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity, and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan (CAPA). The detailed corrective action plan should describe how you intend to ensure the reliability and completeness of all data generated by your firm, including microbiological and analytical data, manufacturing records, and all data submitted to FDA.\nProduct Specifications\nUpon further review of the records and information you provided, process controls for the (b)(4) appear to be inconsistent with the applicable conditions for an OTC (b)(4) formulated with (b)(4) as an active ingredient. For OTC (b)(4) drug products marketed under 505G of the FD&C Act, such as the (b)(4), the allowable concentration for the active ingredient (b)(4) is (b)(4)%-(b)(4)%. However, throughout the product lifecycle for the (b)(4), your operations seem to far exceed the allowable concentration of (b)(4) as indicated in your process validation. For example, your Specification and Analysis Method allows for the release of products with concentrations of (b)(4) up to (b)(4)%. In addition, your 2024 Annual Quality Review and 2023 Process Validation summary of Critical Quality Attributes reports also include concentrations of (b)(4) that are well above what is allowed with values detected at (b)(4)-(b)(4)%. Although your (b)(4) are labeled with (b)(4) at a concentration of (b)(4)%, as noted, your operations and process controls appear to deviate from the proposed conditions and requirements for an OTC (b)(4) product. For consistent regulatory compliance it is essential that OTC (b)(4) products like your (b)(4) conform to the applicable FDA requirements and OTC monograph conditions for the lawful distribution of this OTC drug product without an approved application.\nDrug Production Ceased\nYour written responses to date commit to cease the commercial distribution of OTC products in the U.S. market starting March 14, 2025. If you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure that your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPA.\nDrug Recall\nOn July 16, 2025, FDA held a teleconference with you and your U.S. agent, during which you committed to the recall of all your (b)(4) within expiry currently in distribution to the U.S. market.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on September 18, 2025.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA’s continuing to refuse admission of articles manufactured at Taizhou Kangping Medical Science and Technology Co., Ltd., located at Building 3, No 27 Tai’an Road, Hailing Industrial Park, Taizhou City, Jiangsu, China 225300, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated or misbranded may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), and are misbranded under section 502 of the FD&C Act, respectively.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013321339 and ATTN: Kara S. Quinn.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research","Taizhou Kangping Medical Science and Technology Co., Ltd.","taizhou-kangping-medical-science-and-technology-co-ltd-711081-10092025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftaizhou-kangping-medical-science-and-technology-co-ltd-711081-10092025","2026-10-26T08:10:09.574807+00:00","2025-11-11","711081","Mr. Yuegen Wang","2026-08-19T15:28:22.766+00:00","Via Email","320-26-01","2025-10-09",{"id":213,"raw":214,"subject":55,"body_html":218,"body_text":219,"firm_name":220,"letter_id":221,"created_at":122,"fei_number":19,"letter_url":222,"updated_at":223,"action_type":22,"case_status":23,"posted_date":224,"marcs_cms_no":225,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":226,"body_fetched_at":227,"delivery_method":69,"recipient_title":19,"reference_number":19,"action_taken_date":228,"medical_device_id":19,"response_letter_date":19},826,[215,216,217,11,55,13,13,13],"\u003Ctime datetime=\"2025-06-17T04:00:00Z\">06\u002F17\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-06-09T04:00:00Z\">06\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freset-technology-corporation-704828-06092025\">Reset Technology Corporation\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mark Teufel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Acting CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Reset Technology Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4200 West Royal Lane, Suite # 125\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Irving\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75063\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 704828\u003C\u002Fp>\u003Cp>June 9, 2025\u003C\u002Fp>\u003Cp>Dear Mark Teufel:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Englewood Cliffs, NJ, from October 29, 2024, through December 20, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the ResetSmile Partial Denture Device and the at-home ResetSmile Impression Kit Device. The ResetSmile Partial Denture Device is a removeable dental appliance used to replace missing teeth and the ResetSmile Impression Kit Device is an impression kit used to help make the removeable dental appliance. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Mr. Justin S. Marks, VP Clinical Operations\u002FQuality Representative, in an email dated January 13, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\u003C\u002Fp>\u003Cp>Specifically, you failed to define and document procedures for process validation. For example, you have no objective evidence that the following manufacturing and cleaning processes for your ResetSmile Partial Denture Devices, for which specifications such as anatomical features, mechanical strength, or residue removal cannot be verified without \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, consistently produce a result or product that meets predetermined specifications with a high degree of assurance:\u003C\u002Fp>\u003Cp>a. \u003Cu>Scanning and CAD Design\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Scanner to generate an initial 3D scan of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\u003C\u002Fp>\u003Cp>ii. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to develop the patient-matched CAD design from the above 3D scan of the model cast but have no documented validation to support your intended use of this software application.\u003C\u002Fp>\u003Cp>b. \u003Cu>3-Dimensional (3D) Printing\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software to 3D print your ResetSmile Partial Denture Device based on the above CAD design but have no documented validations which establish the process parameter settings (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications alongside your intended use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software application.\u003C\u002Fp>\u003Cp>ii. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer; \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers; or \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers to 3D print the mold to trial fit your ResetSmile Partial Denture Device but have no documented validations which establish the process parameters (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications.\u003C\u002Fp>\u003Cp>c. \u003Cu>Post-printing Quality Control (QC) Validation (i.e., Test Method)\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> software, as a part of finished device acceptance, to identify conforming and nonconforming areas for your finished device through comparison of the overlay of the 3D scan of your ResetSmile Partial Denture Device (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) with the initial 3D scan (via \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Scanner software) of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\u003C\u002Fp>\u003Cp>d. \u003Cu>Cleaning\u003C\u002Fu>\u003C\u002Fp>\u003Cp>i. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to remove manufacturing material (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) applied to your ResetSmile Partial Denture Device prior to the Post-printing QC Validation above but have no documented validation that establishes the process parameter settings (e.g., clean time, water quality, degassing time, bath cycle, etc.) under which your \u003Cstrong>(b)(4)\u003C\u002Fstrong> is able to consistently meet predefined specifications for cleanliness.\u003C\u002Fp>\u003Cp>ii. You utilize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> clean your ResetSmile Partial Denture Device after \u003Cstrong>(b)(4)\u003C\u002Fstrong> but have no documented validation that this \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner is able to consistently meet predefined specifications for cleanliness.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. You state process validations are not required as they have already been performed as part of the regulatory process for the FDA cleared materials used in your devices. You also state that you use FDA listed 3D scanners and computer assisted design and manufacturing (CAD\u002FCAM) software to manufacture each patient specific device (which has been validated by the manufacturer as part of their regulatory process) and that internal validation and verification of the patient specific device is performed as part of the QC Validation Process to ensure that the partial denture fits the patient model since each product has different patient specifications. As such, no corrective actions were identified. However, it is unclear how you are able to ensure (1) that predetermined specifications are consistently met with a high degree of assurance during the scanning, 3D printing, and post-printing quality control process steps described above for your ResetSmile Partial Denture Devices without validation of the software workflow for its intended use according to an established protocol with predefined acceptance criteria and (2) quality for all devices built in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycle, \u003Cstrong>(b)(4)\u003C\u002Fstrong> cycles, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> machines, where the results of a process (output specifications) cannot be fully verified by subsequent inspection and test. In addition, you did not provide a response on how you plan to address the lack of cleaning validations for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning processes to ensure that manufacturing material is able to be consistently removed, with a high degree of assurance, from your devices which present challenges for residue removal due to the complex geometry prevalent with such devices (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> with limited or no access, etc.). Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\u003C\u002Fp>\u003Cp>Specifically, the \"Control of Nonconformity Process\" procedure (8300-01; Rev.0; Effective: 10\u002F25\u002F24) and \"Non-Confirming Material Report\" form (8300-01-01; Rev.0; Effective: 10\u002F25\u002F24), which were implemented after the preannouncement of the FDA inspection on 10\u002F24\u002F24, are inadequate in that there are no requirements to document:\u003C\u002Fp>\u003Cp> Nonconformances in sufficient detail to describe what failed to meet specification(s);\u003Cbr> Evaluations of nonconformances to determine the need for investigations; and\u003Cbr> Dispositions of nonconformances.\u003C\u002Fp>\u003Cp>For example, there were no descriptions, evaluations for the need for investigations, and dispositions documented for \u003Cstrong>(b)(4)\u003C\u002Fstrong> cases of nonconforming product identified on the \"Internal Remakes log\" from 2\u002F2\u002F22 to 10\u002F28\u002F24 under three general categories: \"Failed print\" (\u003Cstrong>(b)(4)\u003C\u002Fstrong> cases); \"Fabrication error\" (\u003Cstrong>(b)(4)\u003C\u002Fstrong> cases); and \"Failed QC\" (\u003Cstrong>(b)(4)\u003C\u002Fstrong> cases).\u003C\u002Fp>\u003Cp>We reviewed your firm's response and concluded that it is not adequate. You plan to create a new procedure to include the definition of a nonconformance, visual identification of nonconforming product, and disposition instructions; develop a new disposition log; perform a statistical analysis of the rework cases to determine if additional corrective actions are needed; and schedule training on updated procedures under corrective action report # CA011 around January 31, 2025. However, you have not identified any corrective actions to ensure that (1) your procedures and forms require that nonconformances are recorded in sufficient detail to include what failed to meet specification(s) to allow determination of potential causes and evaluations of nonconformances to determine the need for investigations and (2) retrospective review of nonconformances, for a reasonable period of time, to document what failed to meet specifications, conduct evaluations to determine the need for investigations, and record dispositions. In addition, please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain procedures for rework, including retesting and reevaluation of the nonconforming product after rework to ensure that the product meets its current approved specifications and documentation of rework and reevaluation activities, including determination of any adverse effect from the rework upon the product, in the device history record (DHR), as required by 21 CFR 820.90(b)(2).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, you failed to define and document procedures for rework which include requirements to retest and reevaluate reworked devices and document the rework and reevaluation, including adverse impact assessments on reworked devices, in the DHR. Per your VP of Clinical Operations and head Dental Technician, approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> of manufactured ResetSmile Partial Denture Devices undergo final adjustment (rework) during the Final Quality Control (QC) step of the \"Quality Control Validation Process\" (7506-01; Rev. 0; Effective: 2\u002F19\u002F24) which states that upon completion of the scan of the finished device, where \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas indicate the need for readjustment, \"\u003Cem>***the finished device is brought to the quality control technician for final QC analysis, including possible adjustments, and cleaning***\u003C\u002Fem>.\" All eleven (11) scans of the ResetSmile Partial Denture Devices reviewed (lot #: 20022199; 20023601; 20023705; 20024773; 20025934; 20026261; 20026272; 20026352; 20021720; 20018940; 20021572) revealed that these initial scans evaluated during the final QC step contained \u003Cstrong>(b)(4)\u003C\u002Fstrong> areas which required adjustment. However, none of the readjustments for these devices were treated as reworks which would require additional rescans and retention of the scans to confirm specifications are met before release and documented assessment of any adverse effects.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and concluded that it is not adequate. You state the QC Validation Process (7506-01) is designed to identify and adjust potentially ill-fitting partial dentures prior to delivery to the dentist and consumer which surpasses requirements of the regulation and is in contrast to relying on the prescribing dentist to perform their own post-delivery adjustments, which is a universally accepted method. As such, no corrective actions were identified. However, your firm is not meeting the requirements of 21 CFR 820.90(b)(2) with regards to the handling of adjustments (reworks). Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>4. Failure to adequately investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, you failed to investigate or adequately investigate complaints alleged to not meet specifications, as noted in the following examples:\u003C\u002Fp>\u003Cp>i. \u003Cu>Complaint # 22952 (lot # 20021720) dated 6\u002F26\u002F24\u003C\u002Fu>: \"\u003Cem>***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***\u003C\u002Fem>.\"\u003C\u002Fp>\u003Cp>You responded to customer by sending an adjustment kit to the patient. However, there was no documented investigation into what may have caused or contributed to the device thickness.\u003C\u002Fp>\u003Cp>ii. \u003Cu>Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F24\u003C\u002Fu>: \"\u003Cem>***The partials don't t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don't fit properly***\u003C\u002Fem>.\"\u003C\u002Fp>\u003Cp>You requested photos and information on experienced issues from the customer and sent another impression kit to the patient for a remake. However, there was no documented investigation into what may have caused or contributed to the device fit issues.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. Your firm plans to assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR under corrective action report # CA013 around January 31, 2025. However, there were no corrective actions identified to retrospectively review and evaluate complaints, for a reasonable period of time, to determine (1) the need for an investigation (including justification when an investigation was not needed) and (2) definitively investigate any complaints which allege failures of your device, labeling, or packaging to meet any of its specifications. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>5. Failure to adequately maintain complaint files and adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, including evaluation of complaints to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting, as required by 21 CFR 820.198(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your \"Complaint Handling Process\" procedure (8202-01; Rev.0; Effective: 6\u002F22\u002F22) is inadequate in that it fails to:\u003C\u002Fp>\u003Cp>a. Outline the criteria for when your follow-up questionnaire should be sent to complainants. For example, you emailed customers questionnaires (uncontrolled), which listed questions such as “\u003Cem>***Can you feel any roughness or sharp edges on the device that are contributing to sore spots in your mouth?***\u003C\u002Fem>” or “\u003Cem>***Does the device feel like it is placing too much pressure on the gums? In any specific area or overall tightness?***\u003C\u002Fem>” to attempt to obtain details on customer experienced issues for Complaints # 21161 (lot # 20026782) and # 56207 (lot # 20027010) but not for the following complaints:\u003C\u002Fp>\u003Cp>i. \u003Cu>Complaint # 22952 (lot # 20021720) dated 06\u002F26\u002F2024\u003C\u002Fu>: “\u003Cem>***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>ii. \u003Cem>Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F2024\u003C\u002Fem>: “\u003Cem>***The partials don’t t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don’t fit properly***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>b. Ensure that complaints include evaluations of whether they represent events which require reporting to the FDA under 21 CFR 803 (Medical Device Reporting) based on sufficient information obtained from customers to determine whether the complaints meet the definition of MDR reportable events. For example, your VP of Clinical Operations acknowledged that none of your complaint records included documented evaluations on whether the complaints were reportable, including Complaints # 22952 and # 55465 above as well as the following:\u003C\u002Fp>\u003Cp>i. \u003Cu>Complaint # 21161 (lot # 20026782) dated 10\u002F14\u002F24\u003C\u002Fu>: “\u003Cem>***The bottom is so tight, I have damaged the inside of my mouth after just one attempt. I tried again but my mouth was to [sic] sore.” The patient also stated that the device was “painful to clip in, cut me in the front of my lower teethbottom [sic]”. Your firm responded by sending an impression kit to the patient for a remake***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>ii. \u003Cu>Complaint # 56207 (lot # 20027010) dated 10\u002F23\u002F24\u003C\u002Fu>: “\u003Cem>***the bottom teeth are coming on contact with the partial causing it to move. This friction is very painful and has caused blistering… The pain that I feel goes from pressure to scratching to stabbing***\u003C\u002Fem>.”\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. You plan to add the definition of a complaint to your MDR and complaint procedures; include a section for MDR evaluations to the complaint form; assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR; and provide training on the revised processes under corrective action report # CA013 around January 31, 2025. In addition, you reported that none of the 1,840 complaints as of 11\u002F21\u002F24 were MDR reportable. However, there were no corrective actions identified to ensure uniformity of the complaint process by establishing criteria for when complainants are sent questionnaires and ensure that sufficient information is requested from customers to determine whether complaint events meet the definition of MDR reportability under 21 CFR 820.3(o). Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\u003C\u002Fp>\u003Cp>6. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, your \"Corrective &amp; Preventive Action (CAPA) Process\" (8502-01; Rev. 0; 6\u002F22\u002F22) and \"Quality Objectives Management\" (5401-01; Rev. 0; 10\u002F7\u002F24) procedures are inadequate in that:\u003C\u002Fp>\u003Cp>a. 8502-01 (nor any other procedure) does not require internal remakes of your ResetSmile Partial Denture Devices, arising from issues during manufacturing, as inputs into the CAPA process to identify existing and potential causes of nonconforming product or other quality problems, as required by 21 CFR 820.100(a)(1). For example, you remade 64 devices during the month of October 2024 due to issues categorized as failed 3D printing, fabrication errors, and failed quality control but none of this data was analyzed to identify existing and potential causes of nonconforming product or other quality problems.\u003C\u002Fp>\u003Cp>b. Neither 8502-01 nor 5401-01 require appropriate statistical methodology to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example, you only evaluate complaint data by determining whether the \u003Cstrong>(b)(4)\u003C\u002Fstrong> percentage of rework (defined as the sum of adjustments kits, remakes, and refunds sent to customers divided by the number of customer orders received for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>) exceeds \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. However, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> percentage of rework calculation includes non-quality data such as refunds and lots which are different that the lots ordered for the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Therefore, you do not employ appropriate statistical methodology to any of your complaints, loosely categorized as \"issue with fit in mouth;\" \"design preference;\" \"incorrect bite\u002Focclusion;\" \"fabrication error;\" \"product not aesthetically pleasing;\" \"issue with fit on model;\" \"unknown;\" and \"wrong tooth shade,\" to detect recurring quality problems.\u003C\u002Fp>\u003Cp>c. 8502-01 does not require verification or validation of the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example, you did not verify or validate that the corrective action identified under CAPA # 002 (corrected date of 11\u002F6\u002F23) to use adjustment kits, to address the observed increase in adjustments and remake rates from fit issues, were effective and did not adversely affect your ResetSmile Partial Denture Devices prior to sending them to customers.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that it is not adequate. You clarify that the quality data analysis is performed as part of the \"Quality Objectives Management\" (5401-01 Rev. 0) and \"Management Review\" (5600-M1 Rev. 0) processes and that there were no trends noted between May to October 2024 for the three (3) weeks where the value for percentage for rework was above \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As such, no corrective actions were identified. Therefore, please provide a response on how you plan to address the above deficiencies.\u003C\u002Fp>\u003Cp>7. Failure to establish and maintain procedures to adequately control environmental conditions, which could reasonably be expected to have an adverse effect on product quality and periodically inspect the environmental control system to verify that the system, including necessary equipment, is adequate and functioning properly, as required by 21 CFR 820.70(c).\u003C\u002Fp>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>a. You failed to define and document procedures to control environmental conditions for your production area consisting of \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers, used to manufacture your ResetSmile Partial Denture Devices. For example:\u003C\u002Fp>\u003Cp>i. On 11\u002F6\u002F24, the investigator observed out of specification temperatures of 92.3℉ (33.50℃) and 92.4℉ (33.56℃) on two separate temperature and humidity monitors, which were above the \"Environment Requirements\" of \u003Cstrong>(b)(4)\u003C\u002Fstrong>℃ specified in the \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer User Guide.\" In addition, the humidity value for one of the monitors was below the requirement of \u003Cstrong>(b)(4)\u003C\u002Fstrong> in this same guide. These out of specification values affected \u003Cstrong>(b)(4)\u003C\u002Fstrong> production lots that were being printed across \u003Cstrong>(b)(4)\u003C\u002Fstrong> different \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers at the time.\u003C\u002Fp>\u003Cp>ii. On 11\u002F19\u002F24, the investigator also observed an out of specification temperature of 95.1℉ (35.06℃) and 14.4% humidity on one temperature and humidity monitor, which were outside the temperature (\u003Cstrong>(b)(4)\u003C\u002Fstrong>℃) and humidity (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) ranges specified in the \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer User Guide.\" This out of specification temperature and humidity affected \u003Cstrong>(b)(4)\u003C\u002Fstrong> production lots that were being printed across \u003Cstrong>(b)(4)\u003C\u002Fstrong> different \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers at the time.\u003C\u002Fp>\u003Cp>Moreover, you do not regularly log the temperature and humidity values or regulate the temperature in the production area.\u003C\u002Fp>\u003Cp>b. You failed to periodically inspect your temperature and humidity monitors to ensure that they are suitable for their intended use and calibrated or evaluated for accuracy.\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to calibrate your temperature and humidity sensor; set up alerts when values exceed specified requirements; control ambient humidity and temperature of the room; and develop an \"Environmental Requirements\" procedure under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\u003C\u002Fp>\u003Cp>8. Failure to ensure that all equipment used in the manufacturing process meets specified requirements and is appropriately designed, constructed, placed, and installed to facilitate maintenance, adjustment, cleaning, and use, as required by 21 CFR 820.70(g).&nbsp;\u003C\u002Fp>\u003Cp>Specifically, you failed to meet specified placement requirements for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printers, which are used to manufacture your ResetSmile Partial Denture Devices. For example, on 11\u002F19\u002F24, the investigator observed that the distance between the sides of 3D printers \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> was approximately 8 cm and the distances between the corresponding \u003Cstrong>(b)(4)\u003C\u002Fstrong> and backs of 3D printers \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> were approximately 5.5 cm and 6 cm, respectively, which are all below the specified placement requirements noted in the \"\u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printer User Guide\" which requires that \"\u003Cem>***the distances of the left, right and back [sic] side space should be at least 20cm***\u003C\u002Fem>.\"\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to rearrange the printers and printer racks to accommodate the recommended spacing guidelines in the manufacturer's instructions for use; reposition the \u003Cstrong>(b)(4)\u003C\u002Fstrong>; and document these parameters in \"Environmental Requirements\" under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\u003C\u002Fp>\u003Cp>9. Failure to establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, including documentation of training, as required by 21 CFR 820.25(b).\u003C\u002Fp>\u003Cp>Specifically, you failed to implement your \"New Hire\u002FTraining of Personnel Process\" (SOP 6202-01; Rev. 0; Effective: 6\u002F17\u002F24) which requires both acknowledgment of training on the \"Training Acknowledgment Form\" (6202-01-04; Rev. 0; Effective: none) and identification of training needs by the senior manager on the \"Training Needs Assessment\" form (6202-01-03). For example, there were no training forms completed for the following procedures:\u003C\u002Fp>\u003Cp> \"Control of Nonconformity Process\" (SOP 8300-01; Rev. 0; Effective: 10\u002F25\u002F24)\u003Cbr> \"Complaint Handling Process\" (SOP 8202-01; Rev. 0; Effective: 06\u002F22\u002F22)\u003Cbr> \"Internal Rework Process\" (SOP 8304-01; Rev. 0, Effective: 6\u002F22\u002F24)\u003Cbr> \"External Rework Process\" (SOP 8304-02; Rev. 0, Effective: 6\u002F22\u002F24)\u003C\u002Fp>\u003Cp>In addition, there was no documented training on the 6201-01-04 form from before 10\u002F28\u002F24, which is between the dates of preannouncement (10\u002F24\u002F24) and the start of the inspection (10\u002F29\u002F24) for procedures such as (but not limited to) \"QC Validation\" (7506-01), \"Device Fabrication\" (7501-01), and \"Calibration Process\" (7600-01). This applies to \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees, including your VP of Clinical Operations; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Customer Service Representatives; \u003Cstrong>(b)(4)\u003C\u002Fstrong> CAD Technician; \u003Cstrong>(b)(4)\u003C\u002Fstrong> 3D Printing Technicians; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Technicians; \u003Cstrong>(b)(4)\u003C\u002Fstrong> Dental Lab Technicians; and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Shipping\u002FReceiving personnel.&nbsp;\u003C\u002Fp>\u003Cp>We reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to conduct a review in which 6202-01-03 will be completed for all employees and additional training will be scheduled for all affected personnel for procedures noted, including completion of the 6202-01-04 form under corrective action report # CA014 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA014, and any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your ResetSmile Partial Denture Devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\u003C\u002Fp>\u003Cp>Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>Failure to submit any report required within 10 working days of initiating a correction or removal, initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR 806.10.\u003C\u002Fp>\u003Cp>Your firm initiated a medical device correction by providing “adjustment kits” as a corrective measure, allowing customers to modify their ResetSmile Partial Denture Devices at home. This correction was initiated to remedy dentures that do not perform as intended, i.e., cause irritation or do not fit the patient. The adjustment kit is comprised of four items: a pink emery board, a blue emery board, a sanding stick, and a transfer stick to highlight problem areas. Your firm is instructing customers to use this kit to adjust the dentures that cause gum irritation or do not fit well. CDRH determined that the gum irritation being caused by the ResetSmile Partial Denture Devices may cause temporary or medically reversible adverse health consequences. Also, in some cases, there is a reasonable probability that ill-fitting dentures will cause serious adverse health consequences. Your firm’s actions thus meet the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health. Therefore, this action is a medical device correction for which your firm is required to submit a Report of Correction or Removal to FDA.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our inspection also revealed that your ResetSmile Partial Denture and the at-home ResetSmile Impression Kit Devices, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>For your ResetSmile Partial Denture Devices, the inspection determined that you use \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing to produce ResetSmile Partial Denture Devices, comprised of a resin denture base material and preformed plastic denture teeth. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process includes the following specific steps: customers take at-home impressions using your firm’s impression kit; a dentist virtually reviews the scans of these at-home impressions; your firm uses the resin denture base material to make the denture bases with a 3D printer; your firm chemically bonds the preformed plastic teeth to the denture bases to fabricate the dentures; and your firm ships approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> percent of these dentures directly to customers.\u003C\u002Fp>\u003Cp>We note that (1) partial denture devices and resin denture base material are class II devices classified under 21 CFR 872.3760 and require 510(k) clearance and (2) preformed plastic teeth are class II devices classified under 21 CFR 872.3590 and generally do not require 510(k) clearance. In your response, you do not identify a 510(k) clearance for your partial denture devices. Rather, your response seems to suggest that clearance for your partial denture devices is not required because your firm uses only cleared and 510(k) exempt materials in its manufacturing process and that the resin denture base material has a clearance. However, your firm did not provide a 510(k) number for the resin denture base material intended for use in a 3D printer—rather, your firm only provided a 510(k) number for preformed plastic teeth (K060507). Therefore, premarket notification or premarket approval is required for your ResetSmile Partial Denture Devices.\u003C\u002Fp>\u003Cp>Your response did not address your at-home ResetSmile Impression Kit Devices, which the inspection revealed are shipped from your headquarters facility, located in Irving TX, directly to customers for them to use without the supervision of a dentist or other practitioner to take their own impressions for the partial dentures. Specifically, your firm’s impression kits include impression material, a retractor, a tray, and instructions which explain to customers how to take their own impressions.\u003C\u002Fp>\u003Cp>Impression material is a class II device classified under 21 CFR 872.3660 and required to have 510(k) clearance, whereas retractors and trays are class I devices and generally 510(k) exempt. Your firm claims that it has a clearance for its impression material (K221668). The 510(k) summary for K221668 states that it is “intended for use with all crowns, bridges, and orthodontic impression techniques to reproduce the structure of a patient’s teeth and gums,” and is for prescription use only. Your impression material is intended to be used by customers to take their own impression without the supervision of a dentist, and thus does not fall within this cleared indication for use. This change to the device could significantly affect the safety and effectiveness of the impression material because customers who use at-home impression kits to take their own impressions may be more likely to take improper impressions—and improper impressions can lead to improper fabrication of the denture, which can cause bone loss\u002Fresorption, irritation, sores, and TMJ dysfunction. Moreover, it is unclear whether your firm is sending the impression material to customers with a prescription from a dentist—and the labeling of the impression kit does not appear to state that it is for prescription use only. Changing a device for prescription use only to a device for over the counter use also could significantly affect the safety or effectiveness of the device.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Therefore, premarket notification or premarket approval is required for your at-home ResetSmile Impression Kit Devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unique Device Identification Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the ResetSmile devices do not bear such a UDI.\u003C\u002Fp>\u003Cp>Specifically, the labels for your ResetSmile Partial Denture and ResetSmile Impression Kit Devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> technology on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(2)).\u003C\u002Fp>\u003Cp>In addition, your ResetSmile Partial Denture and ResetSmile Impression Kit Devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Reset Technology Corporation is therefore a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Registration and Listing Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year.\u003C\u002Fp>\u003Cp>Your response states that you are exempt from registration and listing under 21 CFR 807.65(i) because you are a dental laboratory. Your response explains that your firm “manufactures patient specific restorative devices (removable partial dentures) based upon a prescription from a licensed dentist” and “use[s] FDA cleared materials . . . to manufacture each patient specific device and do[es] not commercially distribute these devices.” Your response further explains that you previously registered as a medical device manufacturer for preformed plastic denture teeth based on incorrect information from a regulatory consultant and have since deactivated your registration with the FDA for fiscal year 2025.\u003C\u002Fp>\u003Cp>21 CFR 807.65(i), among other things, exempts from registration and listing “[p]ersons who dispense devices to the ultimate consumer or whose major responsibility is to render a service necessary to provide the consumer (i.e., patient, physician, layman, etc.) with a device or the benefits to be derived from the use of the device; for example, a…dental laboratory…whose primary responsibility to the ultimate consumer is to dispense or provide a service through the use of a previously manufactured device.” Here, your firm is not providing a service through the use of previously manufactured devices. Rather, as discussed above, your firm manufactures and distributes partial denture devices using devices that lack required approval\u002Fclearance and manufactures and distributes impression kits comprised of devices that lack required approval\u002Fclearance.\u003C\u002Fp>\u003Cp>As of this date, our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2025 for your facility located in Englewood Cliffs, NJ. 21 CFR 807.22(b). Therefore, your firm’s devices at your facility located in Englewood Cliffs, NJ, are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>We also request your attendance at a virtual Regulatory Meeting to discuss the status of the specific steps you have taken since the inspection to correct the noted violations. This meeting will also give you an opportunity to ask any questions you may have and to provide FDA additional information regarding implementation of corrective actions. Please contact Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, by email at gina.brackett@fda.hhs.gov within 5 business days to set up a date and time for the meeting.\u003C\u002Fp>\u003Cp>Your firm’s response to the Warning Letter should be addressed to Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, and sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 704828” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew G. Hillebrenner\u003Cbr>Deputy Director\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>CC: Justin S. Marks, VP Clinical Operations, justin@resetsmile.com\u003C\u002Fp>\u003Cp>_____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Cem>See\u003C\u002Fem> Deciding When to Submit a 510(k) for a Change to an Existing Device – Guidance for Industry and Food and Drug Administration Staff (Oct. 2017) (“FDA has found that the directions for use necessary for health care professionals to use a device safely and effectively can be significantly different from the directions for use necessary for lay users to use that same device safely and effectively. Therefore, changing a device labeled for prescription use only to a device that is labeled for OTC use typically could significantly affect the safety or effectiveness and would likely require submission of a new 510(k).”).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nMark Teufel\n\nRecipient Title\n\nActing CEO\n\nReset Technology Corporation\n\n4200 West Royal Lane, Suite # 125\n\nIrving, TX 75063\n\nUnited States\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 704828\nJune 9, 2025\nDear Mark Teufel:\nDuring an inspection of your firm located in Englewood Cliffs, NJ, from October 29, 2024, through December 20, 2024, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the ResetSmile Partial Denture Device and the at-home ResetSmile Impression Kit Device. The ResetSmile Partial Denture Device is a removeable dental appliance used to replace missing teeth and the ResetSmile Impression Kit Device is an impression kit used to help make the removeable dental appliance. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Mr. Justin S. Marks, VP Clinical Operations\u002FQuality Representative, in an email dated January 13, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedures, as required by 21 CFR 820.75(a).\nSpecifically, you failed to define and document procedures for process validation. For example, you have no objective evidence that the following manufacturing and cleaning processes for your ResetSmile Partial Denture Devices, for which specifications such as anatomical features, mechanical strength, or residue removal cannot be verified without (b)(4) testing, consistently produce a result or product that meets predetermined specifications with a high degree of assurance:\na. Scanning and CAD Design\ni. You utilize the (b)(4) Dental Scanner to generate an initial 3D scan of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\nii. You utilize the (b)(4) to develop the patient-matched CAD design from the above 3D scan of the model cast but have no documented validation to support your intended use of this software application.\nb. 3-Dimensional (3D) Printing\ni. You utilize (b)(4) 3D Printers with the (b)(4) software to 3D print your ResetSmile Partial Denture Device based on the above CAD design but have no documented validations which establish the process parameter settings (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications alongside your intended use of the (b)(4) software application.\nii. You utilize the (b)(4) 3D Printer; (b)(4) 3D Printers; or (b)(4) 3D Printers to 3D print the mold to trial fit your ResetSmile Partial Denture Device but have no documented validations which establish the process parameters (e.g., filament diameter, fill density, extruder temperature, bed temperature, print speed, layer thickness, etc.) under which your 3D printers are able to consistently meet predefined specifications.\nc. Post-printing Quality Control (QC) Validation (i.e., Test Method)\ni. You utilize the (b)(4) software, as a part of finished device acceptance, to identify conforming and nonconforming areas for your finished device through comparison of the overlay of the 3D scan of your ResetSmile Partial Denture Device ((b)(4)) with the initial 3D scan (via (b)(4) Dental Scanner software) of the model cast from the impression taken by the customer with your at-home ResetSmile Impression Kit Device but have no documented validation to support your intended use of this software application.\nd. Cleaning\ni. You utilize the (b)(4) to remove manufacturing material (e.g., (b)(4)) applied to your ResetSmile Partial Denture Device prior to the Post-printing QC Validation above but have no documented validation that establishes the process parameter settings (e.g., clean time, water quality, degassing time, bath cycle, etc.) under which your (b)(4) is able to consistently meet predefined specifications for cleanliness.\nii. You utilize the (b)(4) to (b)(4) clean your ResetSmile Partial Denture Device after (b)(4) but have no documented validation that this (b)(4) cleaner is able to consistently meet predefined specifications for cleanliness.\nWe reviewed your firm's response and conclude that it is not adequate. You state process validations are not required as they have already been performed as part of the regulatory process for the FDA cleared materials used in your devices. You also state that you use FDA listed 3D scanners and computer assisted design and manufacturing (CAD\u002FCAM) software to manufacture each patient specific device (which has been validated by the manufacturer as part of their regulatory process) and that internal validation and verification of the patient specific device is performed as part of the QC Validation Process to ensure that the partial denture fits the patient model since each product has different patient specifications. As such, no corrective actions were identified. However, it is unclear how you are able to ensure (1) that predetermined specifications are consistently met with a high degree of assurance during the scanning, 3D printing, and post-printing quality control process steps described above for your ResetSmile Partial Denture Devices without validation of the software workflow for its intended use according to an established protocol with predefined acceptance criteria and (2) quality for all devices built in a (b)(4) cycle, (b)(4) cycles, and (b)(4) machines, where the results of a process (output specifications) cannot be fully verified by subsequent inspection and test. In addition, you did not provide a response on how you plan to address the lack of cleaning validations for your (b)(4) and (b)(4) cleaning processes to ensure that manufacturing material is able to be consistently removed, with a high degree of assurance, from your devices which present challenges for residue removal due to the complex geometry prevalent with such devices (e.g., (b)(4) with limited or no access, etc.). Therefore, please provide a response on how you plan to address the above deficiencies.\n2. Failure to adequately establish and maintain procedures to control product that does not conform to specified requirements, including the identification, documentation, evaluation, segregation, and disposition of nonconforming product, as required by 21 CFR 820.90(a).\nSpecifically, the \"Control of Nonconformity Process\" procedure (8300-01; Rev.0; Effective: 10\u002F25\u002F24) and \"Non-Confirming Material Report\" form (8300-01-01; Rev.0; Effective: 10\u002F25\u002F24), which were implemented after the preannouncement of the FDA inspection on 10\u002F24\u002F24, are inadequate in that there are no requirements to document:\n Nonconformances in sufficient detail to describe what failed to meet specification(s);\n Evaluations of nonconformances to determine the need for investigations; and\n Dispositions of nonconformances.\nFor example, there were no descriptions, evaluations for the need for investigations, and dispositions documented for (b)(4) cases of nonconforming product identified on the \"Internal Remakes log\" from 2\u002F2\u002F22 to 10\u002F28\u002F24 under three general categories: \"Failed print\" ((b)(4) cases); \"Fabrication error\" ((b)(4) cases); and \"Failed QC\" ((b)(4) cases).\nWe reviewed your firm's response and concluded that it is not adequate. You plan to create a new procedure to include the definition of a nonconformance, visual identification of nonconforming product, and disposition instructions; develop a new disposition log; perform a statistical analysis of the rework cases to determine if additional corrective actions are needed; and schedule training on updated procedures under corrective action report # CA011 around January 31, 2025. However, you have not identified any corrective actions to ensure that (1) your procedures and forms require that nonconformances are recorded in sufficient detail to include what failed to meet specification(s) to allow determination of potential causes and evaluations of nonconformances to determine the need for investigations and (2) retrospective review of nonconformances, for a reasonable period of time, to document what failed to meet specifications, conduct evaluations to determine the need for investigations, and record dispositions. In addition, please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n3. Failure to establish and maintain procedures for rework, including retesting and reevaluation of the nonconforming product after rework to ensure that the product meets its current approved specifications and documentation of rework and reevaluation activities, including determination of any adverse effect from the rework upon the product, in the device history record (DHR), as required by 21 CFR 820.90(b)(2).\nSpecifically, you failed to define and document procedures for rework which include requirements to retest and reevaluate reworked devices and document the rework and reevaluation, including adverse impact assessments on reworked devices, in the DHR. Per your VP of Clinical Operations and head Dental Technician, approximately (b)(4) of manufactured ResetSmile Partial Denture Devices undergo final adjustment (rework) during the Final Quality Control (QC) step of the \"Quality Control Validation Process\" (7506-01; Rev. 0; Effective: 2\u002F19\u002F24) which states that upon completion of the scan of the finished device, where (b)(4) areas indicate the need for readjustment, \"***the finished device is brought to the quality control technician for final QC analysis, including possible adjustments, and cleaning***.\" All eleven (11) scans of the ResetSmile Partial Denture Devices reviewed (lot #: 20022199; 20023601; 20023705; 20024773; 20025934; 20026261; 20026272; 20026352; 20021720; 20018940; 20021572) revealed that these initial scans evaluated during the final QC step contained (b)(4) areas which required adjustment. However, none of the readjustments for these devices were treated as reworks which would require additional rescans and retention of the scans to confirm specifications are met before release and documented assessment of any adverse effects.\nWe reviewed your firm's response and concluded that it is not adequate. You state the QC Validation Process (7506-01) is designed to identify and adjust potentially ill-fitting partial dentures prior to delivery to the dentist and consumer which surpasses requirements of the regulation and is in contrast to relying on the prescribing dentist to perform their own post-delivery adjustments, which is a universally accepted method. As such, no corrective actions were identified. However, your firm is not meeting the requirements of 21 CFR 820.90(b)(2) with regards to the handling of adjustments (reworks). Therefore, please provide a response on how you plan to address the above deficiencies.\n4. Failure to adequately investigate any complaint involving the possible failure of a device, labeling or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c).\nSpecifically, you failed to investigate or adequately investigate complaints alleged to not meet specifications, as noted in the following examples:\ni. Complaint # 22952 (lot # 20021720) dated 6\u002F26\u002F24: \"***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***.\"\nYou responded to customer by sending an adjustment kit to the patient. However, there was no documented investigation into what may have caused or contributed to the device thickness.\nii. Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F24: \"***The partials don't t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don't fit properly***.\"\nYou requested photos and information on experienced issues from the customer and sent another impression kit to the patient for a remake. However, there was no documented investigation into what may have caused or contributed to the device fit issues.\nWe reviewed your firm's response and conclude that it is not adequate. Your firm plans to assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR under corrective action report # CA013 around January 31, 2025. However, there were no corrective actions identified to retrospectively review and evaluate complaints, for a reasonable period of time, to determine (1) the need for an investigation (including justification when an investigation was not needed) and (2) definitively investigate any complaints which allege failures of your device, labeling, or packaging to meet any of its specifications. Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n5. Failure to adequately maintain complaint files and adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, including evaluation of complaints to determine whether the complaint represents an event which is required to be reported to FDA under part 803 of this chapter, Medical Device Reporting, as required by 21 CFR 820.198(a).\nSpecifically, your \"Complaint Handling Process\" procedure (8202-01; Rev.0; Effective: 6\u002F22\u002F22) is inadequate in that it fails to:\na. Outline the criteria for when your follow-up questionnaire should be sent to complainants. For example, you emailed customers questionnaires (uncontrolled), which listed questions such as “***Can you feel any roughness or sharp edges on the device that are contributing to sore spots in your mouth?***” or “***Does the device feel like it is placing too much pressure on the gums? In any specific area or overall tightness?***” to attempt to obtain details on customer experienced issues for Complaints # 21161 (lot # 20026782) and # 56207 (lot # 20027010) but not for the following complaints:\ni. Complaint # 22952 (lot # 20021720) dated 06\u002F26\u002F2024: “***The device is really thick and I cannot get it in with out [sic] significant pain, and once it is in, I cannot close my mouth, as the new device doesn't allow room for my bottom teeth. It also sticks out forward and leaves a \"v\" shaped gap at the bottom between the device and my natural tooth***.”\nii. Complaint # 55465 (lot # 20027016) dated 10\u002F16\u002F2024: “***The partials don’t t [sic] fit properly and made my gums hurt and bleed. My front teeth hurt, feels like my teeth [as] being pushed forward. Both my upper and lower don’t fit properly***.”\nb. Ensure that complaints include evaluations of whether they represent events which require reporting to the FDA under 21 CFR 803 (Medical Device Reporting) based on sufficient information obtained from customers to determine whether the complaints meet the definition of MDR reportable events. For example, your VP of Clinical Operations acknowledged that none of your complaint records included documented evaluations on whether the complaints were reportable, including Complaints # 22952 and # 55465 above as well as the following:\ni. Complaint # 21161 (lot # 20026782) dated 10\u002F14\u002F24: “***The bottom is so tight, I have damaged the inside of my mouth after just one attempt. I tried again but my mouth was to [sic] sore.” The patient also stated that the device was “painful to clip in, cut me in the front of my lower teethbottom [sic]”. Your firm responded by sending an impression kit to the patient for a remake***.”\nii. Complaint # 56207 (lot # 20027010) dated 10\u002F23\u002F24: “***the bottom teeth are coming on contact with the partial causing it to move. This friction is very painful and has caused blistering… The pain that I feel goes from pressure to scratching to stabbing***.”\nWe reviewed your firm's response and conclude that it is not adequate. You plan to add the definition of a complaint to your MDR and complaint procedures; include a section for MDR evaluations to the complaint form; assess all open complaints at regular intervals to determine the effectiveness of the complaint handling process, need for CAPA, and MDR; and provide training on the revised processes under corrective action report # CA013 around January 31, 2025. In addition, you reported that none of the 1,840 complaints as of 11\u002F21\u002F24 were MDR reportable. However, there were no corrective actions identified to ensure uniformity of the complaint process by establishing criteria for when complainants are sent questionnaires and ensure that sufficient information is requested from customers to determine whether complaint events meet the definition of MDR reportability under 21 CFR 820.3(o). Please provide an update on the progress of your identified corrective actions, including any supporting evidence of completion for review, timelines for completion, and plan for how you will address the inadequacies pointed out in your response.\n6. Failure to adequately establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your \"Corrective & Preventive Action (CAPA) Process\" (8502-01; Rev. 0; 6\u002F22\u002F22) and \"Quality Objectives Management\" (5401-01; Rev. 0; 10\u002F7\u002F24) procedures are inadequate in that:\na. 8502-01 (nor any other procedure) does not require internal remakes of your ResetSmile Partial Denture Devices, arising from issues during manufacturing, as inputs into the CAPA process to identify existing and potential causes of nonconforming product or other quality problems, as required by 21 CFR 820.100(a)(1). For example, you remade 64 devices during the month of October 2024 due to issues categorized as failed 3D printing, fabrication errors, and failed quality control but none of this data was analyzed to identify existing and potential causes of nonconforming product or other quality problems.\nb. Neither 8502-01 nor 5401-01 require appropriate statistical methodology to detect recurring quality problems, as required by 21 CFR 820.100(a)(1). For example, you only evaluate complaint data by determining whether the (b)(4) percentage of rework (defined as the sum of adjustments kits, remakes, and refunds sent to customers divided by the number of customer orders received for the (b)(4)) exceeds (b)(4)%. However, the (b)(4) percentage of rework calculation includes non-quality data such as refunds and lots which are different that the lots ordered for the (b)(4). Therefore, you do not employ appropriate statistical methodology to any of your complaints, loosely categorized as \"issue with fit in mouth;\" \"design preference;\" \"incorrect bite\u002Focclusion;\" \"fabrication error;\" \"product not aesthetically pleasing;\" \"issue with fit on model;\" \"unknown;\" and \"wrong tooth shade,\" to detect recurring quality problems.\nc. 8502-01 does not require verification or validation of the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as required by 21 CFR 820.100(a)(4). For example, you did not verify or validate that the corrective action identified under CAPA # 002 (corrected date of 11\u002F6\u002F23) to use adjustment kits, to address the observed increase in adjustments and remake rates from fit issues, were effective and did not adversely affect your ResetSmile Partial Denture Devices prior to sending them to customers.\nWe reviewed your firm's response and conclude that it is not adequate. You clarify that the quality data analysis is performed as part of the \"Quality Objectives Management\" (5401-01 Rev. 0) and \"Management Review\" (5600-M1 Rev. 0) processes and that there were no trends noted between May to October 2024 for the three (3) weeks where the value for percentage for rework was above (b)(4). As such, no corrective actions were identified. Therefore, please provide a response on how you plan to address the above deficiencies.\n7. Failure to establish and maintain procedures to adequately control environmental conditions, which could reasonably be expected to have an adverse effect on product quality and periodically inspect the environmental control system to verify that the system, including necessary equipment, is adequate and functioning properly, as required by 21 CFR 820.70(c).\nSpecifically:\na. You failed to define and document procedures to control environmental conditions for your production area consisting of (b)(4) 3D Printers, used to manufacture your ResetSmile Partial Denture Devices. For example:\ni. On 11\u002F6\u002F24, the investigator observed out of specification temperatures of 92.3℉ (33.50℃) and 92.4℉ (33.56℃) on two separate temperature and humidity monitors, which were above the \"Environment Requirements\" of (b)(4)℃ specified in the \"(b)(4) 3D Printer User Guide.\" In addition, the humidity value for one of the monitors was below the requirement of (b)(4) in this same guide. These out of specification values affected (b)(4) production lots that were being printed across (b)(4) different (b)(4) 3D Printers at the time.\nii. On 11\u002F19\u002F24, the investigator also observed an out of specification temperature of 95.1℉ (35.06℃) and 14.4% humidity on one temperature and humidity monitor, which were outside the temperature ((b)(4)℃) and humidity ((b)(4)) ranges specified in the \"(b)(4) 3D Printer User Guide.\" This out of specification temperature and humidity affected (b)(4) production lots that were being printed across (b)(4) different (b)(4) 3D Printers at the time.\nMoreover, you do not regularly log the temperature and humidity values or regulate the temperature in the production area.\nb. You failed to periodically inspect your temperature and humidity monitors to ensure that they are suitable for their intended use and calibrated or evaluated for accuracy.\nWe reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to calibrate your temperature and humidity sensor; set up alerts when values exceed specified requirements; control ambient humidity and temperature of the room; and develop an \"Environmental Requirements\" procedure under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\n8. Failure to ensure that all equipment used in the manufacturing process meets specified requirements and is appropriately designed, constructed, placed, and installed to facilitate maintenance, adjustment, cleaning, and use, as required by 21 CFR 820.70(g).\nSpecifically, you failed to meet specified placement requirements for your (b)(4) 3D Printers, which are used to manufacture your ResetSmile Partial Denture Devices. For example, on 11\u002F19\u002F24, the investigator observed that the distance between the sides of 3D printers (b)(4) and (b)(4) and (b)(4) and (b)(4) was approximately 8 cm and the distances between the corresponding (b)(4) and backs of 3D printers (b)(4) and (b)(4) were approximately 5.5 cm and 6 cm, respectively, which are all below the specified placement requirements noted in the \"(b)(4) 3D Printer User Guide\" which requires that \"***the distances of the left, right and back [sic] side space should be at least 20cm***.\"\nWe reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to rearrange the printers and printer racks to accommodate the recommended spacing guidelines in the manufacturer's instructions for use; reposition the (b)(4); and document these parameters in \"Environmental Requirements\" under corrective action report # CA012 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA012, and any supporting evidence.\n9. Failure to establish procedures for identifying training needs and ensure that all personnel are trained to adequately perform their assigned responsibilities, including documentation of training, as required by 21 CFR 820.25(b).\nSpecifically, you failed to implement your \"New Hire\u002FTraining of Personnel Process\" (SOP 6202-01; Rev. 0; Effective: 6\u002F17\u002F24) which requires both acknowledgment of training on the \"Training Acknowledgment Form\" (6202-01-04; Rev. 0; Effective: none) and identification of training needs by the senior manager on the \"Training Needs Assessment\" form (6202-01-03). For example, there were no training forms completed for the following procedures:\n \"Control of Nonconformity Process\" (SOP 8300-01; Rev. 0; Effective: 10\u002F25\u002F24)\n \"Complaint Handling Process\" (SOP 8202-01; Rev. 0; Effective: 06\u002F22\u002F22)\n \"Internal Rework Process\" (SOP 8304-01; Rev. 0, Effective: 6\u002F22\u002F24)\n \"External Rework Process\" (SOP 8304-02; Rev. 0, Effective: 6\u002F22\u002F24)\nIn addition, there was no documented training on the 6201-01-04 form from before 10\u002F28\u002F24, which is between the dates of preannouncement (10\u002F24\u002F24) and the start of the inspection (10\u002F29\u002F24) for procedures such as (but not limited to) \"QC Validation\" (7506-01), \"Device Fabrication\" (7501-01), and \"Calibration Process\" (7600-01). This applies to (b)(4) employees, including your VP of Clinical Operations; (b)(4) Customer Service Representatives; (b)(4) CAD Technician; (b)(4) 3D Printing Technicians; (b)(4) Dental Technicians; (b)(4) Dental Lab Technicians; and (b)(4) Shipping\u002FReceiving personnel.\nWe reviewed your firm's response and conclude that the adequacy cannot be determined at this time. You plan to conduct a review in which 6202-01-03 will be completed for all employees and additional training will be scheduled for all affected personnel for procedures noted, including completion of the 6202-01-04 form under corrective action report # CA014 around January 31, 2025. Please provide updates on the progress of these corrective actions and corrections, including # CA014, and any supporting evidence.\nCorrections and Removals Violation(s)\nOur inspection also revealed that your ResetSmile Partial Denture Devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals.\nSignificant violations include, but are not limited to, the following:\nFailure to submit any report required within 10 working days of initiating a correction or removal, initiated to reduce a risk to health posed by the device or remedy a violation which may present a risk to health, as required by 21 CFR 806.10.\nYour firm initiated a medical device correction by providing “adjustment kits” as a corrective measure, allowing customers to modify their ResetSmile Partial Denture Devices at home. This correction was initiated to remedy dentures that do not perform as intended, i.e., cause irritation or do not fit the patient. The adjustment kit is comprised of four items: a pink emery board, a blue emery board, a sanding stick, and a transfer stick to highlight problem areas. Your firm is instructing customers to use this kit to adjust the dentures that cause gum irritation or do not fit well. CDRH determined that the gum irritation being caused by the ResetSmile Partial Denture Devices may cause temporary or medically reversible adverse health consequences. Also, in some cases, there is a reasonable probability that ill-fitting dentures will cause serious adverse health consequences. Your firm’s actions thus meet the definition of a medical device correction or removal initiated to reduce a risk to health or remedy a violation which may present a risk to health. Therefore, this action is a medical device correction for which your firm is required to submit a Report of Correction or Removal to FDA.\nUnapproved Device Violation(s)\nOur inspection also revealed that your ResetSmile Partial Denture and the at-home ResetSmile Impression Kit Devices, are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have approved applications for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or approved applications for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). These devices are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at https:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nFor your ResetSmile Partial Denture Devices, the inspection determined that you use (b)(4) manufacturing to produce ResetSmile Partial Denture Devices, comprised of a resin denture base material and preformed plastic denture teeth. The (b)(4) manufacturing process includes the following specific steps: customers take at-home impressions using your firm’s impression kit; a dentist virtually reviews the scans of these at-home impressions; your firm uses the resin denture base material to make the denture bases with a 3D printer; your firm chemically bonds the preformed plastic teeth to the denture bases to fabricate the dentures; and your firm ships approximately (b)(4) percent of these dentures directly to customers.\nWe note that (1) partial denture devices and resin denture base material are class II devices classified under 21 CFR 872.3760 and require 510(k) clearance and (2) preformed plastic teeth are class II devices classified under 21 CFR 872.3590 and generally do not require 510(k) clearance. In your response, you do not identify a 510(k) clearance for your partial denture devices. Rather, your response seems to suggest that clearance for your partial denture devices is not required because your firm uses only cleared and 510(k) exempt materials in its manufacturing process and that the resin denture base material has a clearance. However, your firm did not provide a 510(k) number for the resin denture base material intended for use in a 3D printer—rather, your firm only provided a 510(k) number for preformed plastic teeth (K060507). Therefore, premarket notification or premarket approval is required for your ResetSmile Partial Denture Devices.\nYour response did not address your at-home ResetSmile Impression Kit Devices, which the inspection revealed are shipped from your headquarters facility, located in Irving TX, directly to customers for them to use without the supervision of a dentist or other practitioner to take their own impressions for the partial dentures. Specifically, your firm’s impression kits include impression material, a retractor, a tray, and instructions which explain to customers how to take their own impressions.\nImpression material is a class II device classified under 21 CFR 872.3660 and required to have 510(k) clearance, whereas retractors and trays are class I devices and generally 510(k) exempt. Your firm claims that it has a clearance for its impression material (K221668). The 510(k) summary for K221668 states that it is “intended for use with all crowns, bridges, and orthodontic impression techniques to reproduce the structure of a patient’s teeth and gums,” and is for prescription use only. Your impression material is intended to be used by customers to take their own impression without the supervision of a dentist, and thus does not fall within this cleared indication for use. This change to the device could significantly affect the safety and effectiveness of the impression material because customers who use at-home impression kits to take their own impressions may be more likely to take improper impressions—and improper impressions can lead to improper fabrication of the denture, which can cause bone loss\u002Fresorption, irritation, sores, and TMJ dysfunction. Moreover, it is unclear whether your firm is sending the impression material to customers with a prescription from a dentist—and the labeling of the impression kit does not appear to state that it is for prescription use only. Changing a device for prescription use only to a device for over the counter use also could significantly affect the safety or effectiveness of the device.1 Therefore, premarket notification or premarket approval is required for your at-home ResetSmile Impression Kit Devices.\nUnique Device Identification Violation(s)\nThe inspection revealed that your devices are misbranded within the meaning of section 502(c) of the Act, 21 U.S.C. § 352(c), because a word, statement, or other information required by or under authority of section 519 of the Act, 21 U.S.C. § 360i, to appear on the label or labeling of the devices was not prominently placed thereon with such conspicuousness (as compared with other words, statements, designs, or devices, in the labeling) and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. In particular, 21 CFR 801.20(a) – which was promulgated under authority of section 519 of the Act, among other provisions – requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. The labels of the ResetSmile devices do not bear such a UDI.\nSpecifically, the labels for your ResetSmile Partial Denture and ResetSmile Impression Kit Devices do not include a device identifier within the meaning of 21 CFR 801.3 or 830.3, and there is no UDI presented in easily readable plain-text on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(1)), and there is no UDI presented in machine-readable form that uses (b)(4) technology on the label of both of your ResetSmile devices (see 21 CFR 801.40(a)(2)).\nIn addition, your ResetSmile Partial Denture and ResetSmile Impression Kit Devices are misbranded within the meaning of section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Reset Technology Corporation is therefore a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S.C. § 331(q)(1)(B).\nRegistration and Listing Violation(s)\nUnder section 510 of the Act (21 U.S.C. § 360), manufacturers of medical devices are required to annually register with the FDA. In September 2007, section 510 of the Act was amended by the Food and Drug Administration Amendments Act of 2007 (Pub. L. 110-85) to require domestic and foreign device establishments to submit their annual establishment registration and device listing information to FDA by electronic means [section 510(p) of the Act (21 U.S.C. § 360(p))] during the period beginning October 1st and ending December 31st of each year.\nYour response states that you are exempt from registration and listing under 21 CFR 807.65(i) because you are a dental laboratory. Your response explains that your firm “manufactures patient specific restorative devices (removable partial dentures) based upon a prescription from a licensed dentist” and “use[s] FDA cleared materials . . . to manufacture each patient specific device and do[es] not commercially distribute these devices.” Your response further explains that you previously registered as a medical device manufacturer for preformed plastic denture teeth based on incorrect information from a regulatory consultant and have since deactivated your registration with the FDA for fiscal year 2025.\n21 CFR 807.65(i), among other things, exempts from registration and listing “[p]ersons who dispense devices to the ultimate consumer or whose major responsibility is to render a service necessary to provide the consumer (i.e., patient, physician, layman, etc.) with a device or the benefits to be derived from the use of the device; for example, a…dental laboratory…whose primary responsibility to the ultimate consumer is to dispense or provide a service through the use of a previously manufactured device.” Here, your firm is not providing a service through the use of previously manufactured devices. Rather, as discussed above, your firm manufactures and distributes partial denture devices using devices that lack required approval\u002Fclearance and manufactures and distributes impression kits comprised of devices that lack required approval\u002Fclearance.\nAs of this date, our records indicate that your firm has not fulfilled annual registration and listing requirements for fiscal year 2025 for your facility located in Englewood Cliffs, NJ. 21 CFR 807.22(b). Therefore, your firm’s devices at your facility located in Englewood Cliffs, NJ, are misbranded within the meaning of section 502(o) of the Act (21 U.S.C. § 352(0)), in that the devices were manufactured, prepared, propagated, compounded, or processed in an establishment not duly registered under section 510 of the Act (21 U.S.C. § 360) and were not included in a list required by section 510(j) of the Act (21 U.S.C. § 360(j)).\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing, within fifteen business days from the date you receive this letter, of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm's planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm's response should be comprehensive and address all violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nWe also request your attendance at a virtual Regulatory Meeting to discuss the status of the specific steps you have taken since the inspection to correct the noted violations. This meeting will also give you an opportunity to ask any questions you may have and to provide FDA additional information regarding implementation of corrective actions. Please contact Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, by email at gina.brackett@fda.hhs.gov within 5 business days to set up a date and time for the meeting.\nYour firm’s response to the Warning Letter should be addressed to Gina Brackett, Establishment Assessment Team (EAT) 1, Assistant Director, and sent via email to CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 704828” when replying. If you have any questions about the contents of this letter, please contact: Sargum C. Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm's facility. It is your firm's responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm's manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nMatthew G. Hillebrenner\nDeputy Director\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\nCC: Justin S. Marks, VP Clinical Operations, justin@resetsmile.com\n_____________________________\n1 See Deciding When to Submit a 510(k) for a Change to an Existing Device – Guidance for Industry and Food and Drug Administration Staff (Oct. 2017) (“FDA has found that the directions for use necessary for health care professionals to use a device safely and effectively can be significantly different from the directions for use necessary for lay users to use that same device safely and effectively. Therefore, changing a device labeled for prescription use only to a device that is labeled for OTC use typically could significantly affect the safety or effectiveness and would likely require submission of a new 510(k).”).","Reset Technology Corporation","reset-technology-corporation-704828-06092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Freset-technology-corporation-704828-06092025","2026-10-26T08:09:48.8589+00:00","2025-06-17","704828","Mark Teufel","2026-08-19T16:39:59.227+00:00","2025-06-09",{"id":230,"raw":231,"subject":237,"body_html":238,"body_text":239,"firm_name":240,"letter_id":241,"created_at":160,"fei_number":19,"letter_url":242,"updated_at":243,"action_type":22,"case_status":23,"posted_date":244,"marcs_cms_no":245,"product_type":246,"closeout_date":19,"issuing_office":235,"recipient_name":247,"body_fetched_at":248,"delivery_method":249,"recipient_title":19,"reference_number":250,"action_taken_date":251,"medical_device_id":19,"response_letter_date":19},1204,[232,233,234,235,236,13,13,13],"\u003Ctime datetime=\"2024-10-22T13:20:00Z\">10\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-10-01T04:00:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famnio-technology-llc-646460-10012024\">Amnio Technology, LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 24-646460\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Merrill B. Stromer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Amnio Technology, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>22510 N. 18th Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Phoenix\u003C\u002Fspan>, \u003Cspan>AZ\u003C\u002Fspan> \u003Cspan>85027-1363\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>October 1, 2024\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CBER 24-646460\u003C\u002Fstrong>\u003Cbr>\n\u003Cbr>\nDear Dr. Stromer:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Amnio Technology, LLC, located at 22510 N. 18th Drive, Phoenix, AZ 85027, conducted between August 15, 2022, and August 29, 2022, and your storage and distribution facility, located at \u003Cstrong>(b)(4)\u003C\u002Fstrong>, conducted between August 17, 2022, and August 29, 2022, the United States Food and Drug Administration (FDA) documented your manufacture of an amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, and an amniotic fluid derived product, PalinGen® InovōFlo® (hereinafter, your products). You have distributed your products to third-party distributors, hospitals, and medical clinics throughout the United States.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Your products are intended for injection and purported to be sterile.\u003C\u002Fp>\n\n\u003Cp>Information and records gathered prior to, during, and\u002For after the inspection, including information from your contract manufacturer, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, reflect that your products are intended for use in the cure, treatment or prevention of diseases or conditions, such as wound healing and\u002For are intended to affect the structure or function of the body. For example, your promotional materials for PalinGen Flow state, “PalinGen Flow contain[s] key growth factors, cytokines, amino acids… hyaluronic acid, extracellular matrix proteins and cellular components recognized as intrinsic to the complex wound healing process,” and “Amniotic tissue is a rich source of various biologically active factors involved in tissue regeneration and wound healing with reported anti-inflammatory, anti-bacterial, re-epithelialization and anti-fibrotic properties.” Your promotional materials for PalinGen InovoFLo state, “Amniotic fluid possesses anti-inflammatory, anti-microbial and regenerative properties that make it attractive for use in clinical applications.”\u003C\u002Fp>\n\n\u003Cp>As a result, your products are drugs as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. 321(g)(1)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\u003C\u002Fp>\n\n\u003Cp>Because PalinGen® Flow® contains amniotic membrane, in addition to being a drug and biological product, it is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, and are regulated as drugs, devices, and\u002For biological products under the FD&amp;C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\u003C\u002Fp>\n\n\u003Cp>Based on a review of the materials described above, Amnio Technology, LLC does not qualify for any exception in 21 CFR 1271.15, and PalinGen® Flow® fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, PalinGen® Flow® is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\u003C\u002Fp>\n\n\u003Cp>For example, PalinGen® Flow® fails to meet the minimal manipulation criterion set forth in section 1271.10(a)(1) and defined for structural tissue in section 1271.3(f)(1). During the manufacturing process for PalinGen® Flow®, amniotic membrane is processed \u003Cstrong>(b)(4)\u003C\u002Fstrong> to a flowable form that can be administered by injection. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength, and elasticity.\u003C\u002Fp>\n\n\u003Cp>PalinGen® Flow® also fails to meet other criteria set forth in 21 CFR 1271.10(a). For example, PalinGen® Flow® fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” PalinGen® Flow® is not intended solely to perform the same basic function or functions of amniotic membrane in the recipient as in the donor (such as serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero). Rather, PalinGen® Flow® is intended, for example, for use in wound healing and tissue regeneration, which are not homologous uses of amniotic membrane as defined in 21 CFR 1271.3(c).\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>PalinGen® InovōFlo® is not an HCT\u002FP. The definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted body fluids, such as amniotic fluid, are not considered HCT\u002FPs. Because PalinGen® InovōFlo® meets the definition of a drug under section 201(g) of the FD&amp;C Act and a biological product under section 351(i) of the PHS Act, your product is regulated as a drug under the FD&amp;C Act and a biological product under the PHS Act and requires premarket review and approval.\u003C\u002Fp>\n\n\u003Cp>To lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&amp;C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA statutory and regulatory requirements [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR part 312].\u003C\u002Fp>\n\n\u003Cp>Neither PalinGen® Flow® nor PalinGen® InovōFlo® are the subject of an approved BLA or an approved application under section 505(a) of the FD&amp;C Act. Since \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Amnio Technology, LLC \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>However, FDA’s inspection documented your distribution of PalinGen® Flow® for human use outside of a clinical investigation. Therefore, you are not exempt from the requirement to have an approved BLA or an approved application under section 505(a) in effect for PalinGen Flow. Further,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> PalinGen InovoFlo. Based on our review these products are unapproved new drugs, and your firm’s introduction or delivery for introduction of products into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&amp;C Act and section 351(a)(1) of the PHS Act.\u003C\u002Fp>\n\n\u003Cp>Additionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&amp;C Act and 21 CFR Parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (FDA-483), which described a number of significant CGMP deviations applicable to your products. These deficiencies include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. \u003Cstrong>Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)].\u003C\u002Fstrong> Specifically, your firm did not validate the manufacturing processes for PalinGen® Flow® or PalinGen® InovōFlo® with respect to identity, strength, quality, and purity.Your firm’s validation protocol is insufficient as it does not include supporting data demonstrating that your firm’s manufacturing process can consistently yield expected product characteristics.. Your firm distributed approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of PalinGen® Flow® and approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> units of PalinGen® InovFlo® since January 2020 to August 2022. These units were distributed without process validation for these products.\u003C\u002Fp>\n\n\u003Cp>2. \u003Cstrong>Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. \u003C\u002Fstrong>Specifically, your firm has assigned a two-year expiration date to your products without adequate data demonstrating the stability characteristics of the products. For example, in your study protocol for PalinGen® Flow® under PROT-ENG-148, only assessed \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and did not include tests for sterility.\u003C\u002Fp>\n\n\u003Cp>3. \u003Cstrong>Failure to follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)].\u003C\u002Fstrong> For example, the report for consumer complaint CC-000159 related to PalinGen® Flow® indicated that the incident involved a communicable disease and required medical\u002Fsurgical intervention; however, you did not report this event to FDA within 15 days, as required by your written complaint procedure.\u003C\u002Fp>\n\n\u003Cp>We acknowledge receipt of your letters dated September 16, 2022, June 7, 2023, and December 20, 2023, which respond to the FDA-483. In your response, you represent that you have corrected the deficiencies documented on the FDA-483. However, your responses and the corrective actions described are not adequate to address our concerns. For example, in your response, you reference a validation protocol completed for PalinGen® Flow; however, you failed to provide supporting data to demonstrate that your manufacturing process can consistently yield product that meets established product specifications.\u003C\u002Fp>\n\n\u003Cp>Your response also does not adequately address the inventory you still have at your facility and your specific plans for the disposition of this product inventory. Nor do you describe actions you have taken or plan to take to address the impact of the above-noted deficiencies on your products that you distributed.\u003C\u002Fp>\n\n\u003Cp>Your response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA statutory and regulatory requirements that cover such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR parts 312].\u003C\u002Fp>\n\n\u003Cp>Neither this letter nor the observations noted on the FDA-483 are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure full compliance with the FD&amp;C Act, PHS Act, and all applicable regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>For further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\u003C\u002Fp>\n\n\u003Cp>We also have concerns regarding your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized amniotic fluid derived product, ProMatrX ACF®. Based on our review, this product is a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. It is also either a drug under section 201(g) of the FD&amp;C Act or a device under section 201(h) of the FD&amp;C Act. To lawfully market a biological product, either a valid biologics license or, as applicable, an appropriate device premarket authorization must be in effect. If you would like more information on which pathway is appropriate for this product, please contact us.\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&amp;C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>_________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> You manufacture an amniotic membrane derived product for private label customers using \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process used for Palingen Flow under product names including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, ASGFluid, Cell-ECT, Gryphon Amnio Flow, SXFluid, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The instructions for use are the same as those for PalinGen Flow. You also manufacture an amniotic membrane and amniotic fluid derived product for private label customers using the same manufacturing process used for PalinGen InovoFlo under the product name \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The instructions for use are the same as those for PalinGen InovoFlo.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Because your amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, fails to meet the criterion at 21 CFR 1271.10(a)(1) and also fails to meet the criterion at 21 CFR 1271.10(a)(2), this letter does not address whether this product meets the criteria at 21 CFR 1271.10(a)(3) or (a)(4).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nCBER 24-646460\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nMerrill B. Stromer\n\nRecipient Title\n\nChairman\n\nAmnio Technology, LLC\n\n22510 N. 18th Drive\n\nPhoenix, AZ 85027-1363\n\nUnited States\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nOctober 1, 2024\n\nCBER 24-646460\n\nDear Dr. Stromer:\n\nDuring an inspection of your firm, Amnio Technology, LLC, located at 22510 N. 18th Drive, Phoenix, AZ 85027, conducted between August 15, 2022, and August 29, 2022, and your storage and distribution facility, located at (b)(4), conducted between August 17, 2022, and August 29, 2022, the United States Food and Drug Administration (FDA) documented your manufacture of an amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, and an amniotic fluid derived product, PalinGen® InovōFlo® (hereinafter, your products). You have distributed your products to third-party distributors, hospitals, and medical clinics throughout the United States.1 Your products are intended for injection and purported to be sterile.\n\nInformation and records gathered prior to, during, and\u002For after the inspection, including information from your contract manufacturer, (b)(4), reflect that your products are intended for use in the cure, treatment or prevention of diseases or conditions, such as wound healing and\u002For are intended to affect the structure or function of the body. For example, your promotional materials for PalinGen Flow state, “PalinGen Flow contain[s] key growth factors, cytokines, amino acids… hyaluronic acid, extracellular matrix proteins and cellular components recognized as intrinsic to the complex wound healing process,” and “Amniotic tissue is a rich source of various biologically active factors involved in tissue regeneration and wound healing with reported anti-inflammatory, anti-bacterial, re-epithelialization and anti-fibrotic properties.” Your promotional materials for PalinGen InovoFLo state, “Amniotic fluid possesses anti-inflammatory, anti-microbial and regenerative properties that make it attractive for use in clinical applications.”\n\nAs a result, your products are drugs as defined in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 321(g)(1)] and biological products as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)].\n\nBecause PalinGen® Flow® contains amniotic membrane, in addition to being a drug and biological product, it is also a human cell, tissue, or cellular or tissue-based product (HCT\u002FP) as defined in 21 CFR 1271.3(d) and is subject to regulation under 21 CFR Part 1271, issued under the authority of section 361 of the PHS Act [42 U.S.C. 264]. HCT\u002FPs that do not meet all the criteria in 21 CFR 1271.10(a), and when no exception in 21 CFR 1271.15 applies, are not regulated solely under section 361 of the PHS Act, and are regulated as drugs, devices, and\u002For biological products under the FD&C Act and\u002For the PHS Act, and are subject to additional regulation, including appropriate premarket review.\n\nBased on a review of the materials described above, Amnio Technology, LLC does not qualify for any exception in 21 CFR 1271.15, and PalinGen® Flow® fails to meet all the criteria in 21 CFR 1271.10(a). Therefore, PalinGen® Flow® is not regulated solely under section 361 of the PHS Act [42 U.S.C. 264] and the regulations in 21 CFR Part 1271.\n\nFor example, PalinGen® Flow® fails to meet the minimal manipulation criterion set forth in section 1271.10(a)(1) and defined for structural tissue in section 1271.3(f)(1). During the manufacturing process for PalinGen® Flow®, amniotic membrane is processed (b)(4) to a flowable form that can be administered by injection. The amniotic membrane is more than minimally manipulated because such processing alters the original relevant characteristics of the HCT\u002FP relating to its utility to serve as a barrier by effectively eliminating its physical integrity, tensile strength, and elasticity.\n\nPalinGen® Flow® also fails to meet other criteria set forth in 21 CFR 1271.10(a). For example, PalinGen® Flow® fails to meet the criterion in 21 CFR 1271.10(a)(2) that the HCT\u002FP be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer's objective intent.” PalinGen® Flow® is not intended solely to perform the same basic function or functions of amniotic membrane in the recipient as in the donor (such as serving as a selective barrier for the movement of nutrients between the external and in utero environment, protecting the fetus from the surrounding maternal environment, and serving as a covering to enclose the fetus and retain fluid in utero). Rather, PalinGen® Flow® is intended, for example, for use in wound healing and tissue regeneration, which are not homologous uses of amniotic membrane as defined in 21 CFR 1271.3(c).2\n\nPalinGen® InovōFlo® is not an HCT\u002FP. The definition of HCT\u002FPs in 21 CFR 1271.3(d) excludes secreted or extracted human products. Accordingly, secreted body fluids, such as amniotic fluid, are not considered HCT\u002FPs. Because PalinGen® InovōFlo® meets the definition of a drug under section 201(g) of the FD&C Act and a biological product under section 351(i) of the PHS Act, your product is regulated as a drug under the FD&C Act and a biological product under the PHS Act and requires premarket review and approval.\n\nTo lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. A biological product for which a biologics license application (BLA) has been approved under section 351(a) of the PHS Act is not required to have an approved application under section 505 of the FD&C Act [21 U.S.C. § 355; 42 U.S.C. § 262(j)]. Otherwise, with certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA statutory and regulatory requirements [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR part 312].\n\nNeither PalinGen® Flow® nor PalinGen® InovōFlo® are the subject of an approved BLA or an approved application under section 505(a) of the FD&C Act. Since (b)(4), Amnio Technology, LLC (b)(4) However, FDA’s inspection documented your distribution of PalinGen® Flow® for human use outside of a clinical investigation. Therefore, you are not exempt from the requirement to have an approved BLA or an approved application under section 505(a) in effect for PalinGen Flow. Further, (b)(4) PalinGen InovoFlo. Based on our review these products are unapproved new drugs, and your firm’s introduction or delivery for introduction of products into interstate commerce violates sections 301(d) [21 U.S.C. § 331(d)] and 505(a) of the FD&C Act and section 351(a)(1) of the PHS Act.\n\nAdditionally, during the inspection, FDA investigators documented evidence of significant deviations from current good manufacturing practice (CGMP) requirements, including deviations from section 501(a)(2)(B) of the FD&C Act and 21 CFR Parts 210 and 211.\n\nAt the close of the inspection, the FDA investigators issued a Form FDA-483, List of Inspectional Observations (FDA-483), which described a number of significant CGMP deviations applicable to your products. These deficiencies include, but are not limited to, the following:\n\n1. Failure to establish written procedures for production and process control designed to assure that the drug products have the identity, strength, quality, and purity they purport or are represented to possess [21 CFR 211.100(a)]. Specifically, your firm did not validate the manufacturing processes for PalinGen® Flow® or PalinGen® InovōFlo® with respect to identity, strength, quality, and purity.Your firm’s validation protocol is insufficient as it does not include supporting data demonstrating that your firm’s manufacturing process can consistently yield expected product characteristics.. Your firm distributed approximately (b)(4) units of PalinGen® Flow® and approximately (b)(4) units of PalinGen® InovFlo® since January 2020 to August 2022. These units were distributed without process validation for these products.\n\n2. Failure to establish and follow a written testing program designed to assess the stability characteristics of drug products and to use the results of such stability testing to determine appropriate storage conditions and expiration dates [21 CFR 211.166(a)]. Specifically, your firm has assigned a two-year expiration date to your products without adequate data demonstrating the stability characteristics of the products. For example, in your study protocol for PalinGen® Flow® under PROT-ENG-148, only assessed (b)(4) and (b)(4) and did not include tests for sterility.\n\n3. Failure to follow written procedures describing the handling of all written and oral complaints regarding a drug product [21 CFR 211.198(a)]. For example, the report for consumer complaint CC-000159 related to PalinGen® Flow® indicated that the incident involved a communicable disease and required medical\u002Fsurgical intervention; however, you did not report this event to FDA within 15 days, as required by your written complaint procedure.\n\nWe acknowledge receipt of your letters dated September 16, 2022, June 7, 2023, and December 20, 2023, which respond to the FDA-483. In your response, you represent that you have corrected the deficiencies documented on the FDA-483. However, your responses and the corrective actions described are not adequate to address our concerns. For example, in your response, you reference a validation protocol completed for PalinGen® Flow; however, you failed to provide supporting data to demonstrate that your manufacturing process can consistently yield product that meets established product specifications.\n\nYour response also does not adequately address the inventory you still have at your facility and your specific plans for the disposition of this product inventory. Nor do you describe actions you have taken or plan to take to address the impact of the above-noted deficiencies on your products that you distributed.\n\nYour response further does not adequately address your lack of an approved BLA to lawfully market your products. As noted above, to lawfully market a drug that is a biological product, a valid biologics license must be in effect [42 U.S.C. 262(a)]. Such licenses are issued only after showing that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an IND in effect, as specified by FDA statutory and regulatory requirements that cover such clinical use [21 U.S.C. 355(i); 42 U.S.C. 262(a)(3); 21 CFR parts 312].\n\nNeither this letter nor the observations noted on the FDA-483 are intended to be an all-inclusive list of deficiencies that may be associated with your products. It is your responsibility to ensure full compliance with the FD&C Act, PHS Act, and all applicable regulations.\n\nThis letter notifies you of our findings and provides you an opportunity to address them. Failure to adequately address these matters may lead to regulatory action without further notice. Such actions include seizure and\u002For injunction.\n\nFor further information about IND requirements for biological products, please contact the Center for Biologics Evaluation and Research (CBER), Division of Regulatory Project Management, Office of Therapeutic Products, at (240) 402-8190, or OTPRPMS@fda.hhs.gov. Please include a copy of this letter with your initial submission to CBER.\n\nWe also have concerns regarding your (b)(4) sterilized amniotic fluid derived product, ProMatrX ACF®. Based on our review, this product is a biological product as defined in section 351(i) of the Public Health Service Act (PHS Act) [42 U.S.C. 262(i)]. It is also either a drug under section 201(g) of the FD&C Act or a device under section 201(h) of the FD&C Act. To lawfully market a biological product, either a valid biologics license or, as applicable, an appropriate device premarket authorization must be in effect. If you would like more information on which pathway is appropriate for this product, please contact us.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to take to address any violations and prevent their recurrence. Include any documentation necessary to show that the matters have been addressed. If you do not believe your products are in violation of the FD&C Act, the PHS Act, or applicable regulations, include your reasoning and any supporting information for our consideration. If you cannot address these matters completely within fifteen (15) working days, please explain the reason for your delay and the time frame for completion.\n\nSend your electronic response to CBERDCMRecommendations@fda.hhs.gov. If you have questions regarding this letter, contact the Division of Case Management, CBER at (240) 402-9156.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector\n\nOffice of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\nCc:\n\n(b)(4)\n\n_________________________\n\n1 You manufacture an amniotic membrane derived product for private label customers using (b)(4) manufacturing process used for Palingen Flow under product names including (b)(4), ASGFluid, Cell-ECT, Gryphon Amnio Flow, SXFluid, and (b)(4). The instructions for use are the same as those for PalinGen Flow. You also manufacture an amniotic membrane and amniotic fluid derived product for private label customers using the same manufacturing process used for PalinGen InovoFlo under the product name (b)(4). The instructions for use are the same as those for PalinGen InovoFlo.\n\n2 Because your amniotic membrane and amniotic fluid derived product, PalinGen® Flow®, fails to meet the criterion at 21 CFR 1271.10(a)(1) and also fails to meet the criterion at 21 CFR 1271.10(a)(2), this letter does not address whether this product meets the criteria at 21 CFR 1271.10(a)(3) or (a)(4).","Amnio Technology, LLC","amnio-technology-llc-646460-10012024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famnio-technology-llc-646460-10012024","2026-10-26T08:07:55.44972+00:00","2024-10-22","646460","Biologics","Merrill B. Stromer","2026-08-19T21:55:18.541+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","CBER 24-646460","2024-10-01",{"id":253,"raw":254,"subject":55,"body_html":259,"body_text":260,"firm_name":261,"letter_id":262,"created_at":181,"fei_number":19,"letter_url":263,"updated_at":264,"action_type":22,"case_status":63,"posted_date":265,"marcs_cms_no":266,"product_type":26,"closeout_date":267,"issuing_office":11,"recipient_name":268,"body_fetched_at":269,"delivery_method":249,"recipient_title":19,"reference_number":19,"action_taken_date":270,"medical_device_id":19,"response_letter_date":19},2051,[255,256,257,11,55,13,258,13],"\u003Ctime datetime=\"2023-06-20T13:20:00Z\">06\u002F20\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-12T04:00:00Z\">06\u002F12\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-06122023\">Vitang Technology LLC\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-07232024\">\u003Ctime datetime=\"2024-07-31T04:00:00Z\">07\u002F31\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Ronald Jiang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner &amp; CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Vitang Technology LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>14662 Franklin Ave Ste H\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tustin\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>92780-7224\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ron@vitangtechnology.com\"> ron@vitangtechnology.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER \u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CMS # 653455\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 12, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Jiang:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm, Vitang Technology LLC. (Vitang or “the firm”), located in Tustin, CA on January 24, 2023 through January 31, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of The UniSmile Clear Aligner, a Class II dental aligner, cleared under 510(k) K191837and marketed as both the “UniSmile Clear Aligner System” and “2usmiles” on your firm’s websites. For example, your website (https:\u002F\u002Funismile.us\u002F) promotes the device name Unismile. Additionally, your website (https:\u002F\u002Fwww.2usmiles.com\u002F) promotes the device name 2usmiles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), the UniSmile Clear Aligner System is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>We received your response, dated February 20, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded and\u002For Unapproved Device Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm currently holds a 510(k) clearance for the “UniSmile Clear Aligner System.” This device was cleared on January 30, 2020, under K191837 for, among other things, treatment of tooth malocclusion in patients with permanent dentition by way of continuous gentle force. Your 510(k) summary dated January 29, 2020 states that “Software is used to design treatment plans. The software used with UniSmile Clear Aligner System is the Orchestrate 3D (K181112) software, version OrthoRx 4”.\u003C\u002Fp>\n\n\u003Cp>Our inspection revealed that your firm made changes to the device without submission of a new 510(k). On November 26, 2019 you changed from using the cleared Orchestrate 3D to the non-cleared iRok OrthoRx 4.0 for the development of the treatment plans for your UniSmile Clear Aligner System. You indicated that you performed verification and validation activities on iRok OrthoRx 4.0 and concluded that this software is “similar in designing clear aligner treatment plans” as Orchestrate 3D (K181112). However, note that verification and validation requirements apply for all devices subject to 21 CFR 820.30, and must be conducted regardless of whether submission of a new 510(k) is required. A change in orthodontic treatment planning software is a change that could significantly affect the safety and effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Specifically, a change from Orchestrate 3D to iRok OrthoRx 4.0 has the potential to affect the proposed treatment protocol as well as the dimensions, configurations, and applied forces of the UniSmile Clear Aligners, and affect the clinical outcome. Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified UniSmile Clear Aligner System. You did not submit any new 510(k) for the referenced modification to the UniSmile Clear Aligner System.\u003C\u002Fp>\n\n\u003Cp>Therefore, your devices are misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). Your devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Quality System Regulation (QSR) Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that the UniSmile Clear Aligner System is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198.\u003C\u002Fp>\n\n\u003Cp>Specifically, our inspection revealed that your firm has failed to establish and maintain procedures for (1) determining whether a complaint is reportable to the FDA under part 803, (2) investigating the possible failure of a device to meet any of its specifications, and (3) receiving complaints outside of your firm's complaint management system, including oral complaints. Instead, your procedure,\u003Cem> Customer complaints and refinements\u003C\u002Fem>, is used to only to provide refinement services, (e.g., rescans). For example, 11 out of 13 complaint records reviewed during our inspection did not include an evaluation for MDR reportability nor an evaluation to determine if an investigation was necessary. In addition, you did not perform an investigation into reports of broken aligners.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response, and it is inadequate. Although you stated that you recognize that your procedure lacks specific steps to report death or serious injuries, and that you will review and update procedures to comply with MDR reporting requirements within 6 weeks of your response and conduct training, you have not provided evidence of the corrective and preventive actions. Further, your response is also inadequate because it did not address corrective actions that you have taken or plan to take to establish procedures for investigating the possible failure of a device to meet any of its specifications or receiving complaints outside of your firm's complaint management system, including oral complaints.\u003C\u002Fp>\n\n\u003Cp>2. Failure to validate software used as part of the quality system for its intended use according to an established protocol, as required by 21 CFR 820.70(i).\u003C\u002Fp>\n\n\u003Cp>Specifically, you failed to validate your complaint handling system software. Your Ruby on Rails server-side web application framework, using the programming language Ruby and found at unismile.us, is used to maintain complaint files. However, your firm has failed to validate the software for its intended use.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. In your response, your firm stated that your complaint handling system has been in use for a few years and has “proven to be effective.” However, your firm has not provided evidence of the effectiveness of this complaint handling system. Additionally, your firm stated that you initiated an action plan to validate the complaint handling system. You committed to generate a software validation report, approach, testing methodology, and results of the validation within 6 weeks of your response to FDA. You have not provided a response with evidence of the corrective and preventive actions relevant to the complaint handling system effectiveness.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including evaluation of suppliers, contractors, and consultants, as required by 21 CFR 820.50(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, you are not defining the type and extent of control to be exercised over supplier services. When our investigator asked for an evaluation of your firm’s suppliers, you only provided a Manufacturing and Supply Agreement with Xi’an Henghui Technologies Co., Ltd. The August 27, 2021, manufacturing agreement with Henghui, the Chinese contract manufacturer and supplier for the uncleared software you use in the design of the dental aligners, does not identify the roles and responsibilities of both companies. Henghui has contract manufactured your devices since 2019.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you conducted comprehensive inspections of your critical supplier, Henghui, including site visits, and documented the results. You stated to look at an Attachment A. However, the response did not contain an Attachment A. Further, all supporting documents in the response are in Chinese and cannot be reviewed or assessed. You stated that you plan to review the supplier evaluation process and update necessary documents as soon as possible, and conduct auditing of all suppliers, within 12 weeks of the response. You have not provided a response with evidence of the corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR § 820.75(b), and failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, including the validation of major equipment, as required by 21 CFR 820.75(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, your \u003Cem>Validation of Process\u003C\u002Fem> procedure refers to “approval of equipment” but does not address equipment qualification to show that equipment is appropriately designed, constructed, placed, and installed. You stated during the inspection that you have documents in Chinese from the supplier that show the installation and qualifications of your 3D printer. However, since they were not in English, we were unable to verify this statement nor if your firm validated the 3D printing process used to manufacture the UniSmile Clear Aligner System. In addition, your firm’s General Manager and Engineering Manager stated that your firm documents the installation of the printers and the operational and performance qualification in the HeyGears Ultracraft A2D Quasi-Industrial Grade DLP 3D Printer operation manual when an installation occurs. However, that manual does not indicate when the qualification occurred or include evidence that it was performed.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that your response is inadequate. Your firm has not provided a procedure that addresses major equipment qualification or process validation for your 3D printing process. You stated that you will complete the necessary updates to the equipment qualification documents for all equipment within 12 weeks of the response and conduct training. We request that you provide evidence that your 3D printing process has been qualified and validated.\u003C\u002Fp>\n\n\u003Cp>5. Failure to adequately establish and maintain procedures to ensure equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\u003C\u002Fp>\n\n\u003Cp>Specifically, the Equipment Calibration List in your firm’s \u003Cem>Control of Monitoring and Measuring Equipment’s\u003C\u002Fem> procedure states that the 3D Printer should be calibrated monthly, but your firm could only provide a record of quarterly maintenance. You are not documenting the next calibration due date for your 3D printers used in the manufacture of dental aligners. Records are not readily available to the personnel using such equipment as you do not keep the records at the firm. Instead, your firm stated that they are kept with the 3D printer supplier\u002Fcalibrator.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that the equipment has been calibrated but, due to a manpower shortage, some of the records were not available. You also stated this was compounded by deficiencies in forms and procedures. You stated that you will review your forms and procedures relating to calibration and update as necessary within 10 weeks of the response. You have not provided calibration records to show all equipment was calibrated on the required schedule and have not provided a response with evidence of the corrective and preventive actions.\u003C\u002Fp>\n\n\u003Cp>6. Failure to establish procedures for device history records as required by 21 CFR 820.184.\u003C\u002Fp>\n\n\u003Cp>Specifically, your firm does not have a device history record (DHR) procedure. For example, a review of 11 out of 13 device history records (DHRs) for dental aligners did not include nor make reference to the primary identification label and labeling used for each production unit. In addition, the device history records do not contain any UDI information on its label or labeling. During our inspection, you stated that the procedure is being held at the supplier in China.\u003C\u002Fp>\n\n\u003Cp>We reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you reviewed Henghui’s procedures and quality documents and deemed them equivalent to your firm’s procedure in Attachment B. You stated that you can obtain documents from Henghui upon request and then referenced an Attachment C. Both attachments are in Chinese, and we are unable to review them. You stated that the DHR does not include or refer to the location of any UDI or UPC as you believed the devices were custom-made and exempt. In your response you stated that you plan to conduct a review and update of device history process procedures with 8 weeks of the response and provide guidance to all employees; and you will review and update shipping documentation within 4 weeks of the response and then conduct training. You stated that you will update your DHRs with regard to UDI\u002FUPC within 6 weeks of the response and provide training to employees.\u003C\u002Fp>\n\n\u003Cp>7. Failure to document the results and\u002For dates of management reviews as required by 21 CFR 820.20(c).\u003Cbr>\n\u003Cbr>\nSpecifically, you firm has no record of management reviews. Your \u003Cem>Quality Manual and Management Responsibility\u003C\u002Fem> documents both make references to the required conduct of management reviews. You provided a memo on 01\u002F30\u002F2023 that they have been conducted. However, it is generalized as to the topics covered and there are no dates of reviews documented.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate because it does not address this observation.\u003C\u002Fp>\n\n\u003Cp>8. Failure to document personnel training as required by 21 CFR 820.25(b).\u003C\u002Fp>\n\n\u003Cp>Your firm has failed to document training records. Specifically, you were unable to provide training records for General\u002FEngineering Manager and the CEO\u002FVice President of Operations\u002FHead of Shipment Tracking and Handling.\u003C\u002Fp>\n\n\u003Cp>However, your procedure that we did review indicates that new employees attend an orientation that includes training on the quality system, the quality policy, the importance of meeting regulatory, statutory and customer requirements, and the relevance and importance of their activities and how they contribute to the achievement of the quality objective. However, there is no documentation of this orientation.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response is inadequate because it does not address your firm’s failure to document personnel training.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Representations that Create an Impression of FDA Approval\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The UniSmile Clear Aligner System is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because a representation on your website creates an impression of official approval of the device and is misleading. In addition, 21 CFR 807.97 states that any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. Your website contains such representations. Specifically, your website at https:\u002F\u002Fwww.2usmiles.com\u002Fwhy-2usmiles states: “FDA APPROVED.” and incorporates the FDA logo. Statements about having active status with the FDA, and display of the FDA logo near images of and information about the respective products, is misleading because such information implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the products and\u002For establishments. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\n\n\u003Cp>In addition, we offer the following comment:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>We note that we are unable to identify whether the device covered by the above-referenced 510(k) clearance is the same as the 2usmiles your firm is currently marketing. We request that you provide to us in writing with your firm’s basis for determining the 2usmiles is the same device described in K191837.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implantation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov Refer to CMS # 653455 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Malvina B. Eydelman, M.D.\u003Cbr>\nDirector\u003Cbr>\nOHT1: Office of Ophthalmic, Anesthesia,\u003Cbr>\nRespiratory, ENT and Dental Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Shari J. Shambaugh\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nOperations Division 3\u002FWest\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nRonald Jiang\n\nRecipient Title\n\nOwner & CEO\n\nVitang Technology LLC\n\n14662 Franklin Ave Ste H\n\nTustin, CA 92780-7224\n\nUnited States\n\nron@vitangtechnology.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nCMS # 653455\n\nJune 12, 2023\n\nDear Mr. Jiang:\n\nDuring an inspection of your firm, Vitang Technology LLC. (Vitang or “the firm”), located in Tustin, CA on January 24, 2023 through January 31, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm is a manufacturer and distributor of The UniSmile Clear Aligner, a Class II dental aligner, cleared under 510(k) K191837and marketed as both the “UniSmile Clear Aligner System” and “2usmiles” on your firm’s websites. For example, your website (https:\u002F\u002Funismile.us\u002F) promotes the device name Unismile. Additionally, your website (https:\u002F\u002Fwww.2usmiles.com\u002F) promotes the device name 2usmiles. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), the UniSmile Clear Aligner System is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nWe received your response, dated February 20, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address the response below, in relation to each of the noted violations, and any additional responses will be reviewed as part of your warning letter response.\n\nMisbranded and\u002For Unapproved Device Violations\n\nOur inspection revealed that your firm currently holds a 510(k) clearance for the “UniSmile Clear Aligner System.” This device was cleared on January 30, 2020, under K191837 for, among other things, treatment of tooth malocclusion in patients with permanent dentition by way of continuous gentle force. Your 510(k) summary dated January 29, 2020 states that “Software is used to design treatment plans. The software used with UniSmile Clear Aligner System is the Orchestrate 3D (K181112) software, version OrthoRx 4”.\n\nOur inspection revealed that your firm made changes to the device without submission of a new 510(k). On November 26, 2019 you changed from using the cleared Orchestrate 3D to the non-cleared iRok OrthoRx 4.0 for the development of the treatment plans for your UniSmile Clear Aligner System. You indicated that you performed verification and validation activities on iRok OrthoRx 4.0 and concluded that this software is “similar in designing clear aligner treatment plans” as Orchestrate 3D (K181112). However, note that verification and validation requirements apply for all devices subject to 21 CFR 820.30, and must be conducted regardless of whether submission of a new 510(k) is required. A change in orthodontic treatment planning software is a change that could significantly affect the safety and effectiveness of the device within the meaning of 21 CFR 807.81(a)(3). Specifically, a change from Orchestrate 3D to iRok OrthoRx 4.0 has the potential to affect the proposed treatment protocol as well as the dimensions, configurations, and applied forces of the UniSmile Clear Aligners, and affect the clinical outcome. Accordingly, your firm was required to submit a new premarket notification submission under section 510(k) of the Act, 21 U.S.C. § 360(k), to FDA at least 90 days before you proposed to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of the modified UniSmile Clear Aligner System. You did not submit any new 510(k) for the referenced modification to the UniSmile Clear Aligner System.\n\nTherefore, your devices are misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). Your devices are also adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved Premarket Approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. 21 CFR 807.81(b). The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nQuality System Regulation (QSR) Violations\n\nOur inspection also revealed that the UniSmile Clear Aligner System is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit as required by 21 CFR 820.198.\n\nSpecifically, our inspection revealed that your firm has failed to establish and maintain procedures for (1) determining whether a complaint is reportable to the FDA under part 803, (2) investigating the possible failure of a device to meet any of its specifications, and (3) receiving complaints outside of your firm's complaint management system, including oral complaints. Instead, your procedure, Customer complaints and refinements, is used to only to provide refinement services, (e.g., rescans). For example, 11 out of 13 complaint records reviewed during our inspection did not include an evaluation for MDR reportability nor an evaluation to determine if an investigation was necessary. In addition, you did not perform an investigation into reports of broken aligners.\n\nWe reviewed your firm’s response, and it is inadequate. Although you stated that you recognize that your procedure lacks specific steps to report death or serious injuries, and that you will review and update procedures to comply with MDR reporting requirements within 6 weeks of your response and conduct training, you have not provided evidence of the corrective and preventive actions. Further, your response is also inadequate because it did not address corrective actions that you have taken or plan to take to establish procedures for investigating the possible failure of a device to meet any of its specifications or receiving complaints outside of your firm's complaint management system, including oral complaints.\n\n2. Failure to validate software used as part of the quality system for its intended use according to an established protocol, as required by 21 CFR 820.70(i).\n\nSpecifically, you failed to validate your complaint handling system software. Your Ruby on Rails server-side web application framework, using the programming language Ruby and found at unismile.us, is used to maintain complaint files. However, your firm has failed to validate the software for its intended use.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. In your response, your firm stated that your complaint handling system has been in use for a few years and has “proven to be effective.” However, your firm has not provided evidence of the effectiveness of this complaint handling system. Additionally, your firm stated that you initiated an action plan to validate the complaint handling system. You committed to generate a software validation report, approach, testing methodology, and results of the validation within 6 weeks of your response to FDA. You have not provided a response with evidence of the corrective and preventive actions relevant to the complaint handling system effectiveness.\n\n3. Failure to establish and maintain procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, including evaluation of suppliers, contractors, and consultants, as required by 21 CFR 820.50(a).\n\nSpecifically, you are not defining the type and extent of control to be exercised over supplier services. When our investigator asked for an evaluation of your firm’s suppliers, you only provided a Manufacturing and Supply Agreement with Xi’an Henghui Technologies Co., Ltd. The August 27, 2021, manufacturing agreement with Henghui, the Chinese contract manufacturer and supplier for the uncleared software you use in the design of the dental aligners, does not identify the roles and responsibilities of both companies. Henghui has contract manufactured your devices since 2019.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you conducted comprehensive inspections of your critical supplier, Henghui, including site visits, and documented the results. You stated to look at an Attachment A. However, the response did not contain an Attachment A. Further, all supporting documents in the response are in Chinese and cannot be reviewed or assessed. You stated that you plan to review the supplier evaluation process and update necessary documents as soon as possible, and conduct auditing of all suppliers, within 12 weeks of the response. You have not provided a response with evidence of the corrective and preventive actions.\n\n4. Failure to establish and maintain procedures for monitoring and control of process parameters for validated processes to ensure that the specified requirements continue to be met, as required by 21 CFR § 820.75(b), and failure to ensure that when the results of a process cannot be fully verified by subsequent inspection and test, the process shall be validated with a high degree of assurance and approved according to established procedure, including the validation of major equipment, as required by 21 CFR 820.75(a).\n\nSpecifically, your Validation of Process procedure refers to “approval of equipment” but does not address equipment qualification to show that equipment is appropriately designed, constructed, placed, and installed. You stated during the inspection that you have documents in Chinese from the supplier that show the installation and qualifications of your 3D printer. However, since they were not in English, we were unable to verify this statement nor if your firm validated the 3D printing process used to manufacture the UniSmile Clear Aligner System. In addition, your firm’s General Manager and Engineering Manager stated that your firm documents the installation of the printers and the operational and performance qualification in the HeyGears Ultracraft A2D Quasi-Industrial Grade DLP 3D Printer operation manual when an installation occurs. However, that manual does not indicate when the qualification occurred or include evidence that it was performed.\n\nWe reviewed your firm’s response and concluded that your response is inadequate. Your firm has not provided a procedure that addresses major equipment qualification or process validation for your 3D printing process. You stated that you will complete the necessary updates to the equipment qualification documents for all equipment within 12 weeks of the response and conduct training. We request that you provide evidence that your 3D printing process has been qualified and validated.\n\n5. Failure to adequately establish and maintain procedures to ensure equipment is routinely calibrated, inspected, checked, and maintained as required by 21 CFR 820.72(a).\n\nSpecifically, the Equipment Calibration List in your firm’s Control of Monitoring and Measuring Equipment’s procedure states that the 3D Printer should be calibrated monthly, but your firm could only provide a record of quarterly maintenance. You are not documenting the next calibration due date for your 3D printers used in the manufacture of dental aligners. Records are not readily available to the personnel using such equipment as you do not keep the records at the firm. Instead, your firm stated that they are kept with the 3D printer supplier\u002Fcalibrator.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that the equipment has been calibrated but, due to a manpower shortage, some of the records were not available. You also stated this was compounded by deficiencies in forms and procedures. You stated that you will review your forms and procedures relating to calibration and update as necessary within 10 weeks of the response. You have not provided calibration records to show all equipment was calibrated on the required schedule and have not provided a response with evidence of the corrective and preventive actions.\n\n6. Failure to establish procedures for device history records as required by 21 CFR 820.184.\n\nSpecifically, your firm does not have a device history record (DHR) procedure. For example, a review of 11 out of 13 device history records (DHRs) for dental aligners did not include nor make reference to the primary identification label and labeling used for each production unit. In addition, the device history records do not contain any UDI information on its label or labeling. During our inspection, you stated that the procedure is being held at the supplier in China.\n\nWe reviewed your firm’s response and concluded that the adequacy of your firm’s response cannot be determined at this time. You stated that you reviewed Henghui’s procedures and quality documents and deemed them equivalent to your firm’s procedure in Attachment B. You stated that you can obtain documents from Henghui upon request and then referenced an Attachment C. Both attachments are in Chinese, and we are unable to review them. You stated that the DHR does not include or refer to the location of any UDI or UPC as you believed the devices were custom-made and exempt. In your response you stated that you plan to conduct a review and update of device history process procedures with 8 weeks of the response and provide guidance to all employees; and you will review and update shipping documentation within 4 weeks of the response and then conduct training. You stated that you will update your DHRs with regard to UDI\u002FUPC within 6 weeks of the response and provide training to employees.\n\n7. Failure to document the results and\u002For dates of management reviews as required by 21 CFR 820.20(c).\n\nSpecifically, you firm has no record of management reviews. Your Quality Manual and Management Responsibility documents both make references to the required conduct of management reviews. You provided a memo on 01\u002F30\u002F2023 that they have been conducted. However, it is generalized as to the topics covered and there are no dates of reviews documented.\n\nYour firm’s response is inadequate because it does not address this observation.\n\n8. Failure to document personnel training as required by 21 CFR 820.25(b).\n\nYour firm has failed to document training records. Specifically, you were unable to provide training records for General\u002FEngineering Manager and the CEO\u002FVice President of Operations\u002FHead of Shipment Tracking and Handling.\n\nHowever, your procedure that we did review indicates that new employees attend an orientation that includes training on the quality system, the quality policy, the importance of meeting regulatory, statutory and customer requirements, and the relevance and importance of their activities and how they contribute to the achievement of the quality objective. However, there is no documentation of this orientation.\n\nYour firm’s response is inadequate because it does not address your firm’s failure to document personnel training.\n\nRepresentations that Create an Impression of FDA Approval\n\nThe UniSmile Clear Aligner System is also misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because a representation on your website creates an impression of official approval of the device and is misleading. In addition, 21 CFR 807.97 states that any representation that creates an impression of official approval of a device because of complying with the premarket notification regulations is misleading and constitutes misbranding. Your website contains such representations. Specifically, your website at https:\u002F\u002Fwww.2usmiles.com\u002Fwhy-2usmiles states: “FDA APPROVED.” and incorporates the FDA logo. Statements about having active status with the FDA, and display of the FDA logo near images of and information about the respective products, is misleading because such information implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the products and\u002For establishments. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\n\nIn addition, we offer the following comment:\n\nWe note that we are unable to identify whether the device covered by the above-referenced 510(k) clearance is the same as the 2usmiles your firm is currently marketing. We request that you provide to us in writing with your firm’s basis for determining the 2usmiles is the same device described in K191837.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implantation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. Please provide a translation of documentation not in English to facilitate our review. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent to: Jessica Mu, Director of Compliance Branch at oradevices3firmresponse@fda.hhs.gov Refer to CMS # 653455 when replying. If you have any questions about the contents of this letter, please contact: Raymond W. Brullo, Compliance Officer at 949-608-2918 or raymond.brullo@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely,\n\n\u002FS\u002F\n\nMalvina B. Eydelman, M.D.\n\nDirector\n\nOHT1: Office of Ophthalmic, Anesthesia,\n\nRespiratory, ENT and Dental Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\n\u002FS\u002F\n\nShari J. Shambaugh\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nOperations Division 3\u002FWest","Vitang Technology LLC","vitang-technology-llc-653455-06122023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fvitang-technology-llc-653455-06122023","2026-10-26T08:10:28.614825+00:00","2023-06-20","653455","2024-07-31","Ronald Jiang","2026-08-20T01:02:45.663+00:00","2023-06-12",{"id":272,"raw":273,"subject":277,"body_html":279,"body_text":280,"firm_name":281,"letter_id":282,"created_at":41,"fei_number":19,"letter_url":283,"updated_at":284,"action_type":22,"case_status":63,"posted_date":285,"marcs_cms_no":286,"product_type":26,"closeout_date":287,"issuing_office":11,"recipient_name":288,"body_fetched_at":289,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":290,"medical_device_id":19,"response_letter_date":19},3458,[274,275,276,11,277,13,278,13],"\u003Ctime datetime=\"2021-03-16T04:00:00Z\">03\u002F16\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-03-11T05:00:00Z\">03\u002F11\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-weifa-technology-co-ltd-609828-03112021\">Shenzhen Weifa Technology Co., Ltd\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-weifa-technology-co-ltd-609828-09272021\">\u003Ctime datetime=\"2021-09-27T04:00:00Z\">09\u002F27\u002F2021\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Huaquan Yu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Shenzhen Weifa Technology Co., Ltd\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Room 403, Building 117, Sungang Village, Baogang Road, Sungang Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shenzhen Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Guangdong Sheng\u003C\u002Fspan>, \u003Cspan>518100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@starkit.com\"> info@starkit.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>DATE: March 11, 2021\u003C\u002Fp>\n\n\u003Cp>Re: FFP1 3-ply Non-Woven EarLoop Mask and N95\u002FFFP2 Respirator\u003C\u002Fp>\n\n\u003Cp>Dear Huaquan Yu:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at the Internet address www.starkit.com, on February 2, 2021, where you offered the “FFP1 3-ply Non-Woven EarLoop Mask” and “N95\u002FFFP2 Respirator” for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>The FFP1 3-ply Non-Woven EarLoop Mask and the N95\u002FFFP2 Respirator\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> are being offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>In addition, the FFP1 3-ply Non-Woven EarLoop Mask and N95\u002FFFP2 Respirator are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. The devices are not “FDA certificated” and so express statements to the contrary are false. Moreover, FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to your firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the N95\u002FFFP2 Respirator are misleading and constitute misbranding. \u003Cem>See\u003C\u002Fem> 21 CFR 807.39.\u003C\u002Fp>\n\n\u003Cp>Your website contains a number of false and\u002For misleading representations, including but not limited to:\u003C\u002Fp>\n\n\u003Cp>• Stating that the devices are “FDA certificated” and that the devices are “official certificated…FDA.”\u003Cbr>\n• Unauthorized display of FDA’s logo\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> alongside the devices’ product information.\u003Cbr>\n• Displaying a “Certification of FDA Registration” (Certification) issued by “Shenzhen CCT Testing Technology Co. Ltd.” alongside N95\u002FFFP2 Respirator product information. The Certification “certifies that Shenzhen Weifa Technology Co., Ltd … has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” and incorporates, unauthorized use of the FDA logo\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>.\u003C\u002Fp>\n\n\u003Cp>To date, FDA has not “certificated” the FFP1 3-ply Non-Woven EarLoop Mask and the N95\u002FFFP2 Respirators, and statements to the contrary are false. In addition, taken together, display of the FDA logo and Certification positioned near images of and information about the N95\u002FFFP2 Respirator are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the N95\u002FFFP2 Respirator and\u002For establishment based on the existence of your firm’s registration and possession of a registration number. Although the Certification contains language that appears to be intended to function as a disclaimer, including a statement that the Certification does not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of the language could be easily overlooked and do not limit or otherwise mitigate the misleading impression created by the use of the Certification. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the N95\u002FFFP2 Respirator has been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>We remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue any type of device registration certificates to medical device establishments, including sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration &amp; Device Listing Database does not denote anything other than that the establishment has provided certain information to FDA.\u003C\u002Fp>\n\n\u003Cp>This letter is not meant to be an all-inclusive list of violations that exist in connection with the product or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen 15 business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you are not located in the United States, please note that products that appear to be adulterated or misbranded may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the Document number CMS Case# 609828 or CTS Number CPT2000946 when replying. We remind you that only written communication is considered as official.\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donna Engleman, MS, BSN\u003Cbr>\nDirector Division of Market Intelligence\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Angla Li\u003Cbr>\nUS Agent\u003Cbr>\n4402 Gertrude Dr\u003Cbr>\nFremont, CA 94536 xv393fbhh@sina.cn\u003C\u002Fp>\n\n\u003Cp>Alan Lin\u003Cbr>\nShenzhen CCT Testing Technology Co. Ltd.\u003Cbr>\n6F, Fazhan Building, No.04, Shangwu Road,\u003Cbr>\nShiyan Town, Bao'an District, Shenzhen, Guangdong, 518108 China\u003Cbr>\nfda@fda-test.com\u003C\u002Fp>\n\n\u003Cp>Fei Leng\u003Cbr>\nGaomishi Zhonghexiang Labor Products Industry &amp; Trade Company\u003Cbr>\n2th.Zhilan Village, Chaoyang District, Gaomi City,\u003Cbr>\nShandong Province, Weifang Shandong, CN 261500\u003C\u002Fp>\n\n\u003Cp>Medical Facility Company\u003Cbr>\nUS Agent\u003Cbr>\n555 Lexington Avenue\u003Cbr>\nFort George, NY 10040\u003Cbr>\nSpecifyA@163.com\u003C\u002Fp>\n\n\u003Cp>_____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Your website indicates the N95\u002FFFP2 Respirator is manufactured by “Gaomishi Zhonghexiang labor products industry &amp;Trade Co., Ltd.”\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nHuaquan Yu\n\nShenzhen Weifa Technology Co., Ltd\n\nRoom 403, Building 117, Sungang Village, Baogang Road, Sungang Street\n\nShenzhen Shi\n\nGuangdong Sheng, 518100\n\nChina\n\ninfo@starkit.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDATE: March 11, 2021\n\nRe: FFP1 3-ply Non-Woven EarLoop Mask and N95\u002FFFP2 Respirator\n\nDear Huaquan Yu:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website at the Internet address www.starkit.com, on February 2, 2021, where you offered the “FFP1 3-ply Non-Woven EarLoop Mask” and “N95\u002FFFP2 Respirator” for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nThe FFP1 3-ply Non-Woven EarLoop Mask and the N95\u002FFFP2 Respirator1 are being offered for sale in the United States without marketing approval, clearance, or authorization from FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nIn addition, the FFP1 3-ply Non-Woven EarLoop Mask and N95\u002FFFP2 Respirator are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. The devices are not “FDA certificated” and so express statements to the contrary are false. Moreover, FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to your firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the N95\u002FFFP2 Respirator are misleading and constitute misbranding. See 21 CFR 807.39.\n\nYour website contains a number of false and\u002For misleading representations, including but not limited to:\n\n• Stating that the devices are “FDA certificated” and that the devices are “official certificated…FDA.”\n\n• Unauthorized display of FDA’s logo2 alongside the devices’ product information.\n\n• Displaying a “Certification of FDA Registration” (Certification) issued by “Shenzhen CCT Testing Technology Co. Ltd.” alongside N95\u002FFFP2 Respirator product information. The Certification “certifies that Shenzhen Weifa Technology Co., Ltd … has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” and incorporates, unauthorized use of the FDA logo2.\n\nTo date, FDA has not “certificated” the FFP1 3-ply Non-Woven EarLoop Mask and the N95\u002FFFP2 Respirators, and statements to the contrary are false. In addition, taken together, display of the FDA logo and Certification positioned near images of and information about the N95\u002FFFP2 Respirator are misleading because they imply FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the N95\u002FFFP2 Respirator and\u002For establishment based on the existence of your firm’s registration and possession of a registration number. Although the Certification contains language that appears to be intended to function as a disclaimer, including a statement that the Certification does not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of the language could be easily overlooked and do not limit or otherwise mitigate the misleading impression created by the use of the Certification. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the N95\u002FFFP2 Respirator has been reviewed and approved by FDA.\n\nWe remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue any type of device registration certificates to medical device establishments, including sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration & Device Listing Database does not denote anything other than that the establishment has provided certain information to FDA.\n\nThis letter is not meant to be an all-inclusive list of violations that exist in connection with the product or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them.\n\nPlease notify this office in writing within fifteen 15 business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you are not located in the United States, please note that products that appear to be adulterated or misbranded may be detained or refused admission if they are offered for importation into the United States. We may advise the appropriate regulatory officials in the country from which you operate that FDA considers your products listed above to be adulterated and misbranded products that cannot be legally sold to consumers in the United States.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the Document number CMS Case# 609828 or CTS Number CPT2000946 when replying. We remind you that only written communication is considered as official.\n\nIf you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\n\n\u002FS\u002F\n\nDonna Engleman, MS, BSN\n\nDirector Division of Market Intelligence\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nAngla Li\n\nUS Agent\n\n4402 Gertrude Dr\n\nFremont, CA 94536 xv393fbhh@sina.cn\n\nAlan Lin\n\nShenzhen CCT Testing Technology Co. Ltd.\n\n6F, Fazhan Building, No.04, Shangwu Road,\n\nShiyan Town, Bao'an District, Shenzhen, Guangdong, 518108 China\n\nfda@fda-test.com\n\nFei Leng\n\nGaomishi Zhonghexiang Labor Products Industry & Trade Company\n\n2th.Zhilan Village, Chaoyang District, Gaomi City,\n\nShandong Province, Weifang Shandong, CN 261500\n\nMedical Facility Company\n\nUS Agent\n\n555 Lexington Avenue\n\nFort George, NY 10040\n\nSpecifyA@163.com\n\n_____________________\n\n1 Your website indicates the N95\u002FFFP2 Respirator is manufactured by “Gaomishi Zhonghexiang labor products industry &Trade Co., Ltd.”\n\n2 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy).","Shenzhen Weifa Technology Co., Ltd","shenzhen-weifa-technology-co-ltd-609828-03112021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fshenzhen-weifa-technology-co-ltd-609828-03112021","2026-10-26T08:09:56.748503+00:00","2021-03-16","609828","2021-09-27","Huaquan Yu","2026-08-20T03:16:48.496+00:00","2021-03-11",{"id":292,"raw":293,"subject":297,"body_html":298,"body_text":299,"firm_name":300,"letter_id":301,"created_at":160,"fei_number":19,"letter_url":302,"updated_at":303,"action_type":22,"case_status":23,"posted_date":304,"marcs_cms_no":305,"product_type":306,"closeout_date":19,"issuing_office":95,"recipient_name":307,"body_fetched_at":308,"delivery_method":309,"recipient_title":19,"reference_number":310,"action_taken_date":311,"medical_device_id":19,"response_letter_date":19},1007,[294,295,296,95,297,13,13,13],"\u003Ctime datetime=\"2025-03-18T04:00:00Z\">03\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-14T04:00:00Z\">03\u002F14\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-pharmaceutical-technology-692576-03142025\">Advanced Pharmaceutical Technology\u003C\u002Fa>","CGMP\u002FFinished Pharmaceutical\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-55\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Frank M. Bardani\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Advanced Pharmaceutical Technology\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>132 South Central Avenue\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Elmsford\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>10523\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-55\u003C\u002Fp>\u003Cp>March 14, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Bardani:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Advanced Pharmaceutical Technology Inc., FEI 3009963974, at 132 South Central Avenue, Elmsford, from July 10 to August 1, 2024. The products you manufacture at this facility are combination products under section 503(g) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 353(g) as your products include drug and device constituent parts.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for combination products\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. See Title 21 Code of Federal Regulations (CFR) part 4, 21 CFR parts 210 and 211 (drug CGMP), and 21 CFR part 820 (Quality System or QS Regulation).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to drug CGMP requirements, 21 CFR parts 210 and 211, your combination products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, information and records gathered during the course of the inspection reflect that your products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans. Therefore, these products meet the definition of drug as defined in section 201(g)(1) of the FD&amp;C Act [21 U.S.C. 321(g)(1)].\u003C\u002Fp>\u003Cp>We reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. We also acknowledge that you recently registered as a 503B Outsourcing Facility. However, you have been distributing your drug products in the United States since 2023, prior to registering as a 503B Outsourcing Facility.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You lacked appropriate controls to ensure the sterility of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products that purport to be sterile. For example, you relied on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process without monitoring pre-sterilization bioburden. In addition, you failed to establish an adequate system, as was required by your standard operating procedure (SOP), for monitoring environmental conditions (including the frequency performed) to ensure your manufacturing areas were suitable for sterile drug production.\u003C\u002Fp>\u003Cp>In your response, you state that you plan to test for bioburden, prior to release, and will reject lots that fail to meet appropriate specifications for endotoxin. You also state that environmental monitoring is not required because your drug products are \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized, and that you tested product that was manufactured more than \u003Cstrong>(b)(4)\u003C\u002Fstrong> prior for microbial content and the samples showed no signs of positive cultures.\u003C\u002Fp>\u003Cp>Your response is inadequate because you failed to include relevant details for pre-sterilization bioburden testing, including limits you have established, and the steps you will take in the event these limits are exceeded. In addition, appropriate environmental conditions for the manufacture of your drugs, including appropriate air quality, must be provided to protect products from microbiological contamination, even when \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized, in order to minimize sterilization challenges and the byproducts of excessive bioburden.\u003C\u002Fp>\u003Cp>It should be noted that although the sterility test is a critical final quality control for products that purport to be sterile, it cannot be solely relied upon as justification to release each drug product batch, as the test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Sample sizes for sterility testing are typically small compared to the total number of units in a batch and may not detect issues that result in sporadic non-sterility. For example, inadequate \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization validation studies or failure to consistently execute a \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization cycle within its validated state may go undetected for substantial periods if your firm places too much reliance on the final quality control test for sterility to identify a sterility assurance problem. It is also essential to note that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem, and prompt review of the qualification status of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization process.\u003C\u002Fp>\u003Cp>This is a repeat violation from your 2019 and 2021 inspections.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of controlled-release dosage form, appropriate laboratory determination of satisfactory conformance to the specifications for the rate of release of each active ingredient (21 CFR 211.167(c)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to provide adequate data demonstrating your drug products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, have a \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the active ingredient. For example, you claim your \u003Cstrong>(b)(4)\u003C\u002Fstrong> lasts for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products have \u003Cstrong>(b)(4)\u003C\u002Fstrong> effect for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your release and stability data for dissolution does not provide data that drug \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Drug products should not be released without appropriate determination of conformance to final specifications and intended use. There is a lack of assurance of appropriate quality and that your drug will have the intended effect it purports to possess.\u003C\u002Fp>\u003Cp>In your response, you state that you estimated the therapeutic duration and that you will remove \u003Cstrong>(b)(4)\u003C\u002Fstrong> claims until you perform adequate studies. Your response is inadequate because you did not provide a retrospective assessment of your drug products on the U.S. market within expiry to identify and take appropriate action on any product quality or patient safety risks.\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilized, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You lacked adequate scientific rationale to demonstrate that your drug manufacturing processes are appropriately validated, reproducible, and controlled to consistently yield drug products of uniform character and quality. For example, you increased the commercial production batch size and released drug product without appropriate validation. You also failed to include critical process parameters in your batch records.\u003C\u002Fp>\u003Cp>In your response, you plan to revalidate manufacturing processes and include more detailed production steps. Your response is inadequate because you failed to provide a detailed plan or supportive documentation for adequately validating your drug production process.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\u003C\u002Fp>\u003Cp>Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\u003Cp>This is a repeat violation from your 2019 and 2021 inspections.\u003C\u002Fp>\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Contract Testing Laboratories\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your quality unit (QU) did not exercise its responsibility to oversee your contract testing laboratory to ensure the appropriate finish product testing was being conducted. For example, you failed to ensure your contract testing laboratory completed the method validation protocol for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The Method Validation Report did not identify potential impurities of \u003Cstrong>(b)(4)\u003C\u002Fstrong> referenced in the method validation protocol. You did not adequately ensure the executed test method was suitable to monitor all potential impurities.\u003C\u002Fp>\u003Cp>In your response, you provided an impurity method that did not adequately identify and characterize the potential impurities of your drug products. Your response is inadequate because the method validation protocol should include all potential impurities with the scientific justification for which ones would be included in the test method. You did not commit to performing a retrospective assessment of all the product lots currently on the market within expiry once new method validations are completed.\u003C\u002Fp>\u003Cp>In addition, your contract testing laboratory was conducting a single dissolution test point for your drug products without scientific justification that a single time point demonstrates a consistent drug absorption over an extended period of time.\u003C\u002Fp>\u003Cp>Your response states that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> label claims were removed. Your response is inadequate because you did not provide sufficient scientific justification to support inadequately testing your finished drug product.\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. See the FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cem>Contract Manufacturing Organizations\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm utilizes a contract manufacturing organization (CMO) to manufacture your prescription sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You stated to our investigators that you received a batch of \u003Cstrong>(b)(4)\u003C\u002Fstrong> from \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You received this drug product without performing an evaluation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You do not have adequate procedures to ensure that the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> produced for your firm met appropriate quality attributes.\u003C\u002Fp>\u003Cp>In your response, you provide documentation indicating that the CMO of \u003Cstrong>(b)(4)\u003C\u002Fstrong> is \u003Cstrong>(b)(4)\u003C\u002Fstrong> and provided documentation of an audit performed at this facility. Your response is inadequate because your QU did not ensure the drug product was manufactured in accordance with CGMP requirements.\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the FD&amp;C Act, 21 U.S.C. 374(a)(4) to your CMO of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Injection USP), \u003Cstrong>(b)(4)\u003C\u002Fstrong>. After multiple follow-up requests, your CMO failed to respond to these attempted communications or otherwise provide the requested records or other information. It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your CMO failed to respond to the section 704(a)(4) records requests and associated communication attempts, FDA placed all drugs and drug products manufactured by your CMO on Import Alert 66-79. Drugs manufactured by facilities on Import Alert 66-79 are subject to refusal of admission pursuant to section 801(a)(3) of the FD&amp;C Act in that all drugs from their facility appear to be adulterated under section 501(j) because they have been manufactured, processed, packed, or held in any factory, warehouse, or establishment and the owner, operator or agent of such factory, warehouse, or establishment delays, denies, or limits an inspection, or refuses to permit entry or inspection.\u003C\u002Fp>\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as well as your \u003Cstrong>(b)(4)\u003C\u002Fstrong> injection product are listed in FDA’s electronic Drug Registration and Listing System (eDRLS) as “Export Only.” However, information obtained during the inspection of your firm indicates that your firm plans to distribute these products commercially in the United States. Please be advised that, based on review of the product labeling collected during the inspection of your firm and the labeling that your firm submitted to FDA’s eDRLS, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act and require FDA premarket approval under section 505 of the FD&amp;C Act [21 U.S.C. 355]. Distribution of an unapproved new drug in the United States is prohibited under section 301(d) of the FD&amp;C Act [21 U.S.C. 331(d)].\u003C\u002Fp>\u003Cp>We encourage you to contact FDA’s Office of New Drugs at ONDCommunications@fda.hhs.gov for assistance with the application process for your unapproved drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>503B Registration\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FD&amp;C Act, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FD&amp;C Act [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FD&amp;C Act [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements in section 582 of the FD&amp;C Act [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FD&amp;C Act are met. However, outsourcing facilities must comply with other applicable provisions of the FD&amp;C Act, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding CGMP requirements.\u003Cem>\u003Cstrong>\u003Csup>2,3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cstrong>Drugs Manufactured for Importation into the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drug products imported into the United States must comply with all applicable requirements under the FD&amp;C Act and the corresponding regulations set forth in Title 21 of the Code of Federal Regulations. These requirements include compliance with labeling requirements, firm registration and drug listing, and adherence to CGMP. Facilities that manufacture drug products and drug components intended for importation into the United States are subject to inspection by the FDA to determine compliance with these regulatory standards. For drugs requiring NDA or ANDA approval, the application must be submitted to and approved by the FDA’s Center for Drug Evaluation and Research (CDER) prior to importation, as required by section 505(a) of the FD&amp;C Act and 21 CFR part 314.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drugs Manufactured for Exportation out of the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drug products exported from the United States under section 802 of the FD&amp;C Act, must comply with applicable requirements under the FD&amp;C Act, including those specified in section 802(f) [21 U.S.C. § 382(f)]. Under this provision, a drug may not be exported if it is not “manufactured, processed, packaged, and held in substantial conformity with current good manufacturing practice requirements.” Furthermore, a drug is considered adulterated under section 501(a)(2)(B) of the FD&amp;C Act [21 U.S.C. § 351(a)(2)(B)] if the methods, facilities, or controls used in its manufacture, processing, packaging, or holding do not conform to CGMP standards.\u003C\u002Fp>\u003Cp>We therefore encourage you to review your manufacturing processes to ensure that unapproved new drugs intended for export comply with CGMP requirements. Non-compliance with these requirements prevents your ability to export these drugs under section 802(f) of the FD&amp;C Act [21 U.S.C. § 382(f)].\u003C\u002Fp>\u003Cp>\u003Cstrong>Repeat Violations at Facility\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In previous inspections from September 10 to 27, 2019, and August 5 to 23, 2021, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Because you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009963974 and ATTN: Kevin Maguire.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Jill P. Furman\u003Cbr>Director\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1 \u003C\u002Fstrong>\u003C\u002Fem>The terms combination product and drug are used interchangeably in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> For additional information, please see FDA’s “Information for Outsourcing Facilities” webpage, available at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Finformation-outsourcing-facilities. Furthermore, FDA’s Compounding Quality Center Of Excellence (CQCOE) supports outsourcing facilities’ efforts to improve the quality of drugs they produce through training, research and engagement activities with FDA and other supporting stakeholders. For additional information on the CQCOE, please visit https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fcompounding-quality-center-excellence.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nReference #:\n\n320-25-55\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Frank M. Bardani\n\nRecipient Title\n\nPresident\n\nAdvanced Pharmaceutical Technology\n\n132 South Central Avenue\n\nElmsford, NY 10523\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-55\nMarch 14, 2025\nDear Mr. Bardani:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Advanced Pharmaceutical Technology Inc., FEI 3009963974, at 132 South Central Avenue, Elmsford, from July 10 to August 1, 2024. The products you manufacture at this facility are combination products under section 503(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 353(g) as your products include drug and device constituent parts.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) requirements for combination products1. See Title 21 Code of Federal Regulations (CFR) part 4, 21 CFR parts 210 and 211 (drug CGMP), and 21 CFR part 820 (Quality System or QS Regulation).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to drug CGMP requirements, 21 CFR parts 210 and 211, your combination products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nIn addition, information and records gathered during the course of the inspection reflect that your products, (b)(4), are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in humans. Therefore, these products meet the definition of drug as defined in section 201(g)(1) of the FD&C Act [21 U.S.C. 321(g)(1)].\nWe reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. We also acknowledge that you recently registered as a 503B Outsourcing Facility. However, you have been distributing your drug products in the United States since 2023, prior to registering as a 503B Outsourcing Facility.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all sterilization processes (21 CFR 211.113(b)).\nYou lacked appropriate controls to ensure the sterility of (b)(4) drug products that purport to be sterile. For example, you relied on the (b)(4) sterilization process without monitoring pre-sterilization bioburden. In addition, you failed to establish an adequate system, as was required by your standard operating procedure (SOP), for monitoring environmental conditions (including the frequency performed) to ensure your manufacturing areas were suitable for sterile drug production.\nIn your response, you state that you plan to test for bioburden, prior to release, and will reject lots that fail to meet appropriate specifications for endotoxin. You also state that environmental monitoring is not required because your drug products are (b)(4) sterilized, and that you tested product that was manufactured more than (b)(4) prior for microbial content and the samples showed no signs of positive cultures.\nYour response is inadequate because you failed to include relevant details for pre-sterilization bioburden testing, including limits you have established, and the steps you will take in the event these limits are exceeded. In addition, appropriate environmental conditions for the manufacture of your drugs, including appropriate air quality, must be provided to protect products from microbiological contamination, even when (b)(4) sterilized, in order to minimize sterilization challenges and the byproducts of excessive bioburden.\nIt should be noted that although the sterility test is a critical final quality control for products that purport to be sterile, it cannot be solely relied upon as justification to release each drug product batch, as the test is only the last in a series of design and control provisions intended to protect the consumer from distribution of an unsafe batch. Sample sizes for sterility testing are typically small compared to the total number of units in a batch and may not detect issues that result in sporadic non-sterility. For example, inadequate (b)(4) sterilization validation studies or failure to consistently execute a (b)(4) sterilization cycle within its validated state may go undetected for substantial periods if your firm places too much reliance on the final quality control test for sterility to identify a sterility assurance problem. It is also essential to note that any positive sterility test result represents a serious CGMP issue that requires a comprehensive investigation into the cause and extent of the problem, and prompt review of the qualification status of your (b)(4) sterilization process.\nThis is a repeat violation from your 2019 and 2021 inspections.\n2. Your firm failed to have, for each batch of controlled-release dosage form, appropriate laboratory determination of satisfactory conformance to the specifications for the rate of release of each active ingredient (21 CFR 211.167(c)).\nYou failed to provide adequate data demonstrating your drug products, (b)(4), have a (b)(4) of the active ingredient. For example, you claim your (b)(4) lasts for up to (b)(4) and that your (b)(4) products have (b)(4) effect for (b)(4). Your release and stability data for dissolution does not provide data that drug (b)(4). Drug products should not be released without appropriate determination of conformance to final specifications and intended use. There is a lack of assurance of appropriate quality and that your drug will have the intended effect it purports to possess.\nIn your response, you state that you estimated the therapeutic duration and that you will remove (b)(4) claims until you perform adequate studies. Your response is inadequate because you did not provide a retrospective assessment of your drug products on the U.S. market within expiry to identify and take appropriate action on any product quality or patient safety risks.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nYour firm manufactures (b)(4) sterilized, (b)(4). You lacked adequate scientific rationale to demonstrate that your drug manufacturing processes are appropriately validated, reproducible, and controlled to consistently yield drug products of uniform character and quality. For example, you increased the commercial production batch size and released drug product without appropriate validation. You also failed to include critical process parameters in your batch records.\nIn your response, you plan to revalidate manufacturing processes and include more detailed production steps. Your response is inadequate because you failed to provide a detailed plan or supportive documentation for adequately validating your drug production process.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies include intensive monitoring and testing throughout each significant process stage to characterize intra-batch variation and evaluate batches to determine whether an initial state of control has been established.\nSuccessful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle. See FDA’s guidance document Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nThis is a repeat violation from your 2019 and 2021 inspections.\n4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\nContract Testing Laboratories\nYour quality unit (QU) did not exercise its responsibility to oversee your contract testing laboratory to ensure the appropriate finish product testing was being conducted. For example, you failed to ensure your contract testing laboratory completed the method validation protocol for (b)(4). The Method Validation Report did not identify potential impurities of (b)(4) referenced in the method validation protocol. You did not adequately ensure the executed test method was suitable to monitor all potential impurities.\nIn your response, you provided an impurity method that did not adequately identify and characterize the potential impurities of your drug products. Your response is inadequate because the method validation protocol should include all potential impurities with the scientific justification for which ones would be included in the test method. You did not commit to performing a retrospective assessment of all the product lots currently on the market within expiry once new method validations are completed.\nIn addition, your contract testing laboratory was conducting a single dissolution test point for your drug products without scientific justification that a single time point demonstrates a consistent drug absorption over an extended period of time.\nYour response states that the (b)(4) label claims were removed. Your response is inadequate because you did not provide sufficient scientific justification to support inadequately testing your finished drug product.\nYour firm’s quality systems are inadequate. See the FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nContract Manufacturing Organizations\nYour firm utilizes a contract manufacturing organization (CMO) to manufacture your prescription sterile (b)(4) drug product, (b)(4). You stated to our investigators that you received a batch of (b)(4) from (b)(4). You received this drug product without performing an evaluation of (b)(4). You do not have adequate procedures to ensure that the sterile (b)(4) produced for your firm met appropriate quality attributes.\nIn your response, you provide documentation indicating that the CMO of (b)(4) is (b)(4) and provided documentation of an audit performed at this facility. Your response is inadequate because your QU did not ensure the drug product was manufactured in accordance with CGMP requirements.\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nFDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the FD&C Act, 21 U.S.C. 374(a)(4) to your CMO of (b)(4) Injection USP), (b)(4). After multiple follow-up requests, your CMO failed to respond to these attempted communications or otherwise provide the requested records or other information. It is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your CMO failed to respond to the section 704(a)(4) records requests and associated communication attempts, FDA placed all drugs and drug products manufactured by your CMO on Import Alert 66-79. Drugs manufactured by facilities on Import Alert 66-79 are subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that all drugs from their facility appear to be adulterated under section 501(j) because they have been manufactured, processed, packed, or held in any factory, warehouse, or establishment and the owner, operator or agent of such factory, warehouse, or establishment delays, denies, or limits an inspection, or refuses to permit entry or inspection.\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nUnapproved Drugs\nYour (b)(4) products, (b)(4), as well as your (b)(4) injection product are listed in FDA’s electronic Drug Registration and Listing System (eDRLS) as “Export Only.” However, information obtained during the inspection of your firm indicates that your firm plans to distribute these products commercially in the United States. Please be advised that, based on review of the product labeling collected during the inspection of your firm and the labeling that your firm submitted to FDA’s eDRLS, these products are new drugs within the meaning of section 201(p) of the FD&C Act and require FDA premarket approval under section 505 of the FD&C Act [21 U.S.C. 355]. Distribution of an unapproved new drug in the United States is prohibited under section 301(d) of the FD&C Act [21 U.S.C. 331(d)].\nWe encourage you to contact FDA’s Office of New Drugs at ONDCommunications@fda.hhs.gov for assistance with the application process for your unapproved drug products.\n503B Registration\nUnder section 503B(b) of the FD&C Act, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FD&C Act [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FD&C Act [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements in section 582 of the FD&C Act [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FD&C Act are met. However, outsourcing facilities must comply with other applicable provisions of the FD&C Act, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding CGMP requirements.2,3\nDrugs Manufactured for Importation into the United States\nDrug products imported into the United States must comply with all applicable requirements under the FD&C Act and the corresponding regulations set forth in Title 21 of the Code of Federal Regulations. These requirements include compliance with labeling requirements, firm registration and drug listing, and adherence to CGMP. Facilities that manufacture drug products and drug components intended for importation into the United States are subject to inspection by the FDA to determine compliance with these regulatory standards. For drugs requiring NDA or ANDA approval, the application must be submitted to and approved by the FDA’s Center for Drug Evaluation and Research (CDER) prior to importation, as required by section 505(a) of the FD&C Act and 21 CFR part 314.\nDrugs Manufactured for Exportation out of the United States\nDrug products exported from the United States under section 802 of the FD&C Act, must comply with applicable requirements under the FD&C Act, including those specified in section 802(f) [21 U.S.C. § 382(f)]. Under this provision, a drug may not be exported if it is not “manufactured, processed, packaged, and held in substantial conformity with current good manufacturing practice requirements.” Furthermore, a drug is considered adulterated under section 501(a)(2)(B) of the FD&C Act [21 U.S.C. § 351(a)(2)(B)] if the methods, facilities, or controls used in its manufacture, processing, packaging, or holding do not conform to CGMP standards.\nWe therefore encourage you to review your manufacturing processes to ensure that unapproved new drugs intended for export comply with CGMP requirements. Non-compliance with these requirements prevents your ability to export these drugs under section 802(f) of the FD&C Act [21 U.S.C. § 382(f)].\nRepeat Violations at Facility\nIn previous inspections from September 10 to 27, 2019, and August 5 to 23, 2021, FDA cited similar CGMP violations. You proposed specific remediation for these violations in your response. Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate.\nCGMP Consultant Recommended\nBecause you failed to correct repeat violations, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3009963974 and ATTN: Kevin Maguire.\nSincerely,\n\u002FS\u002F\nJill P. Furman\nDirector\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_______________\n1 The terms combination product and drug are used interchangeably in this letter.\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FD&C Act.\n3 For additional information, please see FDA’s “Information for Outsourcing Facilities” webpage, available at https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Finformation-outsourcing-facilities. Furthermore, FDA’s Compounding Quality Center Of Excellence (CQCOE) supports outsourcing facilities’ efforts to improve the quality of drugs they produce through training, research and engagement activities with FDA and other supporting stakeholders. For additional information on the CQCOE, please visit https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fhuman-drug-compounding\u002Fcompounding-quality-center-excellence.","Advanced Pharmaceutical Technology","advanced-pharmaceutical-technology-692576-03142025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fadvanced-pharmaceutical-technology-692576-03142025","2026-10-26T08:07:50.58707+00:00","2025-03-18","692576","Drugs","Mr. Frank M. Bardani","2026-08-19T16:55:57.953+00:00","VIA UPS","320-25-55","2025-03-14",{"id":313,"raw":314,"subject":317,"body_html":318,"body_text":319,"firm_name":320,"letter_id":321,"created_at":101,"fei_number":19,"letter_url":322,"updated_at":323,"action_type":22,"case_status":23,"posted_date":104,"marcs_cms_no":324,"product_type":306,"closeout_date":19,"issuing_office":95,"recipient_name":325,"body_fetched_at":326,"delivery_method":109,"recipient_title":19,"reference_number":327,"action_taken_date":328,"medical_device_id":19,"response_letter_date":19},22198,[92,315,316,95,317,13,13,13],"\u003Ctime datetime=\"2026-11-03T05:00:00Z\">11\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026\">Nanjing Hanxin Pharmaceutical Technology Co. Ltd.\u003C\u002Fa>","Request for Records\u002FCGMP\u002FAPI\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-19\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Bob Bao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Nanjing Hanxin Pharmaceutical Technology Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Building C5, No. 9, Weidi Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Xianlin University Town\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nanjing Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jiangsu Sheng\u003C\u002Fspan>, \u003Cspan>210046\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>November 3, 2026\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-27-19\u003C\u002Fp>\u003Cp>To Mr. Bob Bao:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant deviations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility and provides you the opportunity to address them. Promptly address any deviations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the deviations in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any deviations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Deviations were documented during review of your drug manufacturing facility, Nanjing Hanxin Pharmaceutical Technology Co. Ltd., FDA Establishment Identifier (FEI) 3015142388. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>Your facility was registered with the United States FDA as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our November 18, 2025 request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for APIs.\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>The following deviations were identified during our review. As a reminder, this is not an all-inclusive list of deviations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure of your quality unit to exercise its responsibility to ensure the APIs manufactured at your facility are in compliance with CGMP.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm is a manufacturer of \u003Cstrong>(b)(4)\u003C\u002Fstrong> APIs, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> APIs. These APIs are for use in further processing to produce sterile drug products and for pharmaceutical compounding operations. Based on the records and information you provided, your quality unit (QU) failed to adequately qualify your suppliers of critical raw materials for the manufacturing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> API at your facility.\u003C\u002Fp>\u003Cp>Your firm was \u003Cstrong>(b)(4)\u003C\u002Fstrong> based upon an acceptable FDA inspection. Since then, your firm \u003Cstrong>(b)(4)\u003C\u002Fstrong> API. However, in your response to our records request for quality information on drugs you produced, you did not provide any documentation with regard to the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong> API at your facility. FDA sent a subsequent request for additional information, regarding \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing operations at your facility. Your response indicated that after November 2025, the \u003Cstrong>(b)(4)\u003C\u002Fstrong> production was moved to a subsidiary of your company, \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your firm qualified \u003Cstrong>(b)(4)\u003C\u002Fstrong> as your supplier for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a critical starting material to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> API for U.S. distribution. FDA conducted an inspection in \u003Cstrong>(b)(4)\u003C\u002Fstrong> and concluded the drugs manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong> are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B), because of their methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP. Drugs manufactured at \u003Cstrong>(b)(4)\u003C\u002Fstrong> were placed on IA 66-40. See FDA Warning Letter \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> issued to \u003Cstrong>(b)(4)\u003C\u002Fstrong> for further details.\u003C\u002Fp>\u003Cp>Your oversight of your suppliers is deficient. FDA is also concerned that identifying your firm and not the actual manufacturer of \u003Cstrong>(b)(4)\u003C\u002Fstrong> API may have been an attempt to circumvent safeguards associated with the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and may pose a risk to consumers of receiving substandard \u003Cstrong>(b)(4)\u003C\u002Fstrong> APIs.\u003C\u002Fp>\u003Cp>For manufacturers whose drugs are placed on IA 66-40 for failure to conform to CGMP within the meaning of section 501(a)(2)(B), FDA has evidence that the drugs listed in the import alerts appear to be adulterated. You are responsible for ensuring that the drugs you receive and distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up to date information regarding the import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A summary of your systemic corrective action and preventive action (CAPA) plan to remediate the supplier qualification program and prevent use of unsuitable material suppliers.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>o A complete and final review of each lot and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fli>\u003Cli>Your stability report and data to support the claimed retest date for all of your APIs intended for U.S. market.\u003C\u002Fli>\u003Cli>A list of all drugs you distributed in the last three years, and the name of the original supplier\u002Fmanufacturer, or supplier of starting material, such as crude API.\u003C\u002Fli>\u003Cli>For any lots of APIs identified as being produced from materials from a non-compliant supplier\u002Fmanufacturer, notify your customers in writing, and provide copies of these notifications in response to this letter. Include lot identification and recommended actions in your notifications.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Importation of Unapproved Drugs -\u003C\u002Fstrong> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your facility lists various APIs under its manufacturer registration that were not referenced in your response to the 704(a)(4) records request but were active under your registration at the time the request was issued, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Please be advised that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is not an API permissible for use in human drug compounding under sections 503A or 503B of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the causes of any deviations and implementing corrective and preventative measures to ensure future and sustained compliance so that these deviations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs offered for import into the United States from your firm on Import Alert 66-40 on June 22, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any deviations.\u003C\u002Fp>\u003Cp>Failure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Nanjing Hanxin Pharmaceutical Technology Co. Ltd., located at Building C5, No. 9, Weidi Road, Xianlin University Town, Nanjing, Jiangsu into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015142388 and ATTN: Compliance officer Joan Johnson in the subject line of the email. If you have information that you believe demonstrates that your drugs do not deviate from the FD&amp;C Act, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA post warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-19\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Bob Bao\n\nRecipient Title\n\nGeneral Manager\n\nNanjing Hanxin Pharmaceutical Technology Co. Ltd.\n\nBuilding C5, No. 9, Weidi Road\n\nXianlin University Town\n\nNanjing Shi\n\nJiangsu Sheng, 210046\n\nChina\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nNovember 3, 2026\nWARNING LETTER\nReference number: 320-27-19\nTo Mr. Bob Bao:\nThis warning letter advises you of significant deviations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility and provides you the opportunity to address them. Promptly address any deviations described herein without delay, including ensuring that appropriate resources are allocated to fully address them and prevent their recurrence. This is not intended to be an all-inclusive list of the deviations in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any deviations may result in regulatory action without further notice.\nFDA Review\nDeviations were documented during review of your drug manufacturing facility, Nanjing Hanxin Pharmaceutical Technology Co. Ltd., FDA Establishment Identifier (FEI) 3015142388. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nYour facility was registered with the United States FDA as a manufacturer of active pharmaceutical ingredients (APIs). FDA has reviewed the records you submitted in response to our November 18, 2025 request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.\nThis warning letter summarizes significant deviations from Current Good Manufacturing Practice (CGMP) for APIs.\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your APIs are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThe following deviations were identified during our review. As a reminder, this is not an all-inclusive list of deviations at your facility.\nFailure of your quality unit to exercise its responsibility to ensure the APIs manufactured at your facility are in compliance with CGMP.\nYour firm is a manufacturer of (b)(4) APIs, including (b)(4) APIs. These APIs are for use in further processing to produce sterile drug products and for pharmaceutical compounding operations. Based on the records and information you provided, your quality unit (QU) failed to adequately qualify your suppliers of critical raw materials for the manufacturing of (b)(4) API at your facility.\nYour firm was (b)(4) based upon an acceptable FDA inspection. Since then, your firm (b)(4) API. However, in your response to our records request for quality information on drugs you produced, you did not provide any documentation with regard to the manufacture of (b)(4) API at your facility. FDA sent a subsequent request for additional information, regarding (b)(4) manufacturing operations at your facility. Your response indicated that after November 2025, the (b)(4) production was moved to a subsidiary of your company, (b)(4).\nYour firm qualified (b)(4) as your supplier for (b)(4), a critical starting material to manufacture (b)(4) API for U.S. distribution. FDA conducted an inspection in (b)(4) and concluded the drugs manufactured by (b)(4) are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B), because of their methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP. Drugs manufactured at (b)(4) were placed on IA 66-40. See FDA Warning Letter (b)(4)1 issued to (b)(4) for further details.\nYour oversight of your suppliers is deficient. FDA is also concerned that identifying your firm and not the actual manufacturer of (b)(4) API may have been an attempt to circumvent safeguards associated with the (b)(4) and may pose a risk to consumers of receiving substandard (b)(4) APIs.\nFor manufacturers whose drugs are placed on IA 66-40 for failure to conform to CGMP within the meaning of section 501(a)(2)(B), FDA has evidence that the drugs listed in the import alerts appear to be adulterated. You are responsible for ensuring that the drugs you receive and distribute are manufactured in compliance with all relevant CGMP requirements for drugs. Up to date information regarding the import alerts can be found at the following FDA website: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fcms_ia\u002Fialist.html.\nIn response to this letter, provide:\nA summary of your systemic corrective action and preventive action (CAPA) plan to remediate the supplier qualification program and prevent use of unsuitable material suppliers.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\no A complete and final review of each lot and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\nYour stability report and data to support the claimed retest date for all of your APIs intended for U.S. market.\nA list of all drugs you distributed in the last three years, and the name of the original supplier\u002Fmanufacturer, or supplier of starting material, such as crude API.\nFor any lots of APIs identified as being produced from materials from a non-compliant supplier\u002Fmanufacturer, notify your customers in writing, and provide copies of these notifications in response to this letter. Include lot identification and recommended actions in your notifications.\nImportation of Unapproved Drugs - (b)(4)\nYour facility lists various APIs under its manufacturer registration that were not referenced in your response to the 704(a)(4) records request but were active under your registration at the time the request was issued, including (b)(4). Please be advised that (b)(4) is not an API permissible for use in human drug compounding under sections 503A or 503B of the FD&C Act.\nConclusion\nAs previously stated, you are responsible for investigating and determining the causes of any deviations and implementing corrective and preventative measures to ensure future and sustained compliance so that these deviations and any others do not occur.\nFDA placed all drugs offered for import into the United States from your firm on Import Alert 66-40 on June 22, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any deviations.\nFailure to address any deviations may also result in the FDA continuing to refuse admission of articles manufactured at Nanjing Hanxin Pharmaceutical Technology Co. Ltd., located at Building C5, No. 9, Weidi Road, Xianlin University Town, Nanjing, Jiangsu into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015142388 and ATTN: Compliance officer Joan Johnson in the subject line of the email. If you have information that you believe demonstrates that your drugs do not deviate from the FD&C Act, include that information for our consideration.\nFDA post warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_____________________\n1 (b)(4)","Nanjing Hanxin Pharmaceutical Technology Co. Ltd.","nanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fnanjing-hanxin-pharmaceutical-technology-co-ltd-734913-11032026","2026-11-17T01:02:34.878331+00:00","734913","Mr. Bob Bao","2026-11-17T01:02:34.679+00:00","320-27-19","2026-11-03",{"id":330,"raw":331,"subject":336,"body_html":337,"body_text":338,"firm_name":339,"letter_id":340,"created_at":341,"fei_number":19,"letter_url":342,"updated_at":343,"action_type":22,"case_status":23,"posted_date":344,"marcs_cms_no":345,"product_type":306,"closeout_date":19,"issuing_office":335,"recipient_name":346,"body_fetched_at":347,"delivery_method":309,"recipient_title":19,"reference_number":19,"action_taken_date":348,"medical_device_id":19,"response_letter_date":19},2953,[332,333,334,335,336,13,13,13],"\u003Ctime datetime=\"2021-12-21T14:20:00Z\">12\u002F21\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-14T05:00:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangdong-kemei-pharmaceutical-technology-co-ltd-612090-12142021\">Guangdong Kemei Pharmaceutical Technology Co. Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jack Chen\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Guangdong Kemei Pharmaceutical Technology Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2,4, No.16 (#6 Plant), Jiye Road, 3rd &amp; 4th Floor\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Songgang Songxia Industrial Park\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shishan Foshan\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>528225\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter \u003C\u002Fstrong>320-22-07\u003C\u002Fp>\n\n\u003Cp>December 14, 2021\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Chen:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as IMC WASH-FREE HAND SANITIZER. This drug product was declared to be manufactured at your facility, Guangdong Kemei Pharmaceutical Technology Co. Ltd, FEI 3017086967, at 2,4, No.16 (#6 Plant), Jiye Road 3rd &amp; 4th Floor, Songgang Songxia Industrial Park, Shishan Foshan, China. Following an attempt to import IMC WASH-FREE HAND SANITIZER into the United States, it was detained and refused admission at the border.\u003C\u002Fp>\n\n\u003Cp>The results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\u003C\u002Fp>\n\n\u003Cp>In addition, IMC WASH-FREE HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), (x) and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), (x) and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulteration Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>IMC WASH-FREE HAND SANITIZER, declared to be manufactured at your facility, is labeled to contain 75% of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average 35% ethanol volume\u002Fvolume (v\u002Fv) and an average of 32% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&amp;C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\u003C\u002Fp>\n\n\u003Cp>Methanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\u003C\u002Fp>\n\n\u003Cp>On December 15, 2020, FDA notified the public of the methanol contamination of your hand sanitizer drug products at the following webpage: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\">https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>After several unsuccessful attempts to contact you, FDA contacted your firm’s consignees to discuss marketed action.\u003C\u002Fp>\n\n\u003Cp>On December 23, 2020, one of your firm’s consignees, Shane Erickson Inc., recalled one lot of Wash-Free Hand Sanitizer (50ml, 100ml and 300ml size bottles) and one lot of Thrifty White Pharmacy Wash-Free Hand Sanitizer due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website: shane-erickson-inc-dba-innovative-marketing-consultants-issues-voluntary-nationwide-recall-wash-free\u003C\u002Fp>\n\n\u003Cp>On January 14-15, 2021, FDA received correspondence from your firm stating you were not the manufacturer of IMC brand products and that you had given your “FDA certificates” to this third-party that likely manufactured the contaminated hand sanitizer products.\u003C\u002Fp>\n\n\u003Cp>On January 25, 2021, FDA held a teleconference with your firm. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market that were labeled as or declared as manufactured by your firm, Guangdong Kemei Pharmaceutical Technology Co. Ltd. Your firm agreed to support the recall of IMC hand sanitizer products. However, to date, your firm has not committed to recall.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A detailed investigation into how the drug product described above, which was declared to be manufactured at your facility and which was labeled as containing ethanol, was substituted in part or in whole with methanol.\u003C\u002Fli>\n\t\u003Cli>A list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\u003C\u002Fli>\n\t\u003Cli>A list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\u003C\u002Fli>\n\t\u003Cli>Copies of the complete batch records for all batches distributed to the U.S.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>The substitution and contamination with methanol in a drug product declared to be manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&amp;C Act.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranding Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>IMC WASH-FREE HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), and because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic. Examples of claims observed on the IMC WASH-FREE HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“WASH-FREE HAND SANITIZER… Drug Facts…Purpose…Antiseptic…Use(s) to help reduce bacteria on skin…Directions…Apply a small amount in you palm and rub hands together briskly until dry…”\u003C\u002Fp>\n\n\u003Cp>This topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&amp;C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your IMC WASH-FREE HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>We note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\u003C\u002Fp>\n\n\u003Cp>Section 505G of the FD&amp;C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&amp;C Act, drugs that were classified as Category III for safety and effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\u003C\u002Fp>\n\n\u003Cp>However, IMC WASH-FREE HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&amp;C Act for marketing without an approved application under section 505.\u003C\u002Fp>\n\n\u003Cp>According to the product label, IMC WASH-FREE HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 75% v\u002Fv. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrated that IMC WASH-FREE HAND SANITIZER contains ethanol in a concentration that is less than the 75% v\u002Fv stated on its product label and less than the amount of ethanol described in the 1994 TFM. Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidance setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analyses also demonstrated that batches of IMC WASH-FREE HAND SANITIZER contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\u003C\u002Fp>\n\n\u003Cp>Additionally, this methanol-containing drug product, IMC WASH-FREE HAND SANITIZER, is misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&amp;C Act, 21 U.S.C. 352(j), (a), (e), (x), and (ee).\u003C\u002Fp>\n\n\u003Cp>It is misbranded under section 502(j) of the FD&amp;C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\u003C\u002Fp>\n\n\u003Cp>This hand sanitizer is misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, IMC WASH-FREE HAND SANITIZER is labeled to contain ethyl alcohol 75% v\u002Fv. However, FDA laboratory analysis of batches of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&amp;C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result . . .” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a).\u003C\u002Fp>\n\n\u003Cp>The failure of this product to list methyl alcohol (methanol) as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&amp;C Act, 21 U.S.C 352(e)(1)(A).\u003C\u002Fp>\n\n\u003Cp>IMC WASH-FREE HAND SANITIZER is also misbranded under section 502(x) of the FD&amp;C Act, 21 U.S.C. 352(x) because the product label fails to disclose a complete domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\u003C\u002Fp>\n\n\u003Cp>Lastly, this product is misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee) because IMC WASH-FREE HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&amp;C U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&amp;C Act 21 U.S.C. 355.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\n\n\u003Cp>Additionally, we note that under 21 CFR 201.61(a), “[t]he principal display panel of an over-the-counter drug in package form shall bear as one of its principal features a statement of identity of the commodity.” Under section 505G(a)(3) of the FD&amp;C Act and the 1994 TFM, the statement of identity for health-care antiseptic drug products, a category that included consumer antiseptic rub drug products, must contain “the established name of the drug, if any” (59 FR 31442). Currently, there is no established name for consumer antiseptic rub drug products that have the active ingredient ethyl alcohol and are formulated as a gel. However, we recommend that you include the name “alcohol gel” as part of the statement of identity that appears on the principal display panel of the label for IMC WASH-FREE HAND SANITIZER which will allow consumers to make an informed decisions regarding your topical antiseptic.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on January 7, 2021, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&amp;C Act. Drugs and drug products that appear to be adulterated may be detained or refused admission without physical examination.\u003C\u002Fp>\n\n\u003Cp>All drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&amp;C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\u003C\u002Fp>\n\n\u003Cp>If you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please identify your response with FEI 3017086967 and ATTN: LaKeesha Foster Sifontes.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFrancis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>cc:\u003Cbr>\nRegistered US Agent\u003Cbr>\nVizocom ICT LLC\u003Cbr>\n860 Jamacha Rd. Ste. 104\u003Cbr>\nEl Cajon, CA 92019\u003C\u002Fp>\n\n\u003Cp>________________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: \u003Cem>\u003Cstrong>Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19)\u003C\u002Fstrong>\u003C\u002Fem> on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&amp;C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution of hand sanitizer products manufactured at your facility, a review of the purported formulations on the drug product’s labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&amp;C Act.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jack Chen\n\nRecipient Title\n\nCEO\n\nGuangdong Kemei Pharmaceutical Technology Co. Ltd.\n\n2,4, No.16 (#6 Plant), Jiye Road, 3rd & 4th Floor\n\nSonggang Songxia Industrial Park\n\nShishan Foshan\n\n528225\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-22-07\n\nDecember 14, 2021\n\nDear Mr. Chen:\n\nYour firm is registered as a human drug manufacturer. The U.S. Food and Drug Administration (FDA) conducted testing of a consumer antiseptic hand rub drug product (also referred to as a consumer hand sanitizer), labeled as IMC WASH-FREE HAND SANITIZER. This drug product was declared to be manufactured at your facility, Guangdong Kemei Pharmaceutical Technology Co. Ltd, FEI 3017086967, at 2,4, No.16 (#6 Plant), Jiye Road 3rd & 4th Floor, Songgang Songxia Industrial Park, Shishan Foshan, China. Following an attempt to import IMC WASH-FREE HAND SANITIZER into the United States, it was detained and refused admission at the border.\n\nThe results of the FDA laboratory testing of a batch of this product detained at the border demonstrate that this drug product declared to be manufactured at your facility is adulterated within the meaning of section 501(d)(2) of the Federal Food, Drug, and Cosmetic Act (FD&C Act or the Act), 21 U.S.C. 351(d)(2), in that a substance was substituted wholly or in part therefor. In addition, this product is adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)), in that the substitution demonstrates that the quality assurance within your facility is not functioning in accordance with Current Good Manufacturing Practice (CGMP) requirements.\n\nIn addition, IMC WASH-FREE HAND SANITIZER is an unapproved new drug introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a), and is misbranded under sections 502(j), (a), (e), (x) and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), (x) and (ee). Introduction or delivery for introduction of such products into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a). These violations are described in more detail below.\n\nAdulteration Violations\n\nIMC WASH-FREE HAND SANITIZER, declared to be manufactured at your facility, is labeled to contain 75% of the active ingredient ethyl alcohol (ethanol). However, FDA laboratory testing of a batch of this product detained at the border found that the drug product contained an average 35% ethanol volume\u002Fvolume (v\u002Fv) and an average of 32% methanol v\u002Fv. Therefore, this hand sanitizer drug product is adulterated under section 501(d)(2) of the FD&C Act in that the active ingredient, ethanol, was substituted wholly or in part with methanol, a dangerous chemical when in contact with human skin or ingested.\n\nMethanol is not an acceptable ingredient for hand sanitizers and should not be used due to its toxic effects. Skin exposure to methanol can cause dermatitis, as well as transdermal absorption with systemic toxicity. Substantial methanol exposure can result in nausea, vomiting, headache, blurred vision, permanent blindness, seizures, coma, permanent damage to the nervous system, or death. Although all persons using these products on their hands are at risk, young children who accidentally ingest these products, and adolescents and adults who drink these products as an alcohol (ethanol) substitute, are most at risk for methanol poisoning.\n\nOn December 15, 2020, FDA notified the public of the methanol contamination of your hand sanitizer drug products at the following webpage: https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-safety-and-availability\u002Ffda-updates-hand-sanitizers-consumers-should-not-use\n\nAfter several unsuccessful attempts to contact you, FDA contacted your firm’s consignees to discuss marketed action.\n\nOn December 23, 2020, one of your firm’s consignees, Shane Erickson Inc., recalled one lot of Wash-Free Hand Sanitizer (50ml, 100ml and 300ml size bottles) and one lot of Thrifty White Pharmacy Wash-Free Hand Sanitizer due to potential presence of undeclared methanol (wood alcohol), as noted on the following FDA website: shane-erickson-inc-dba-innovative-marketing-consultants-issues-voluntary-nationwide-recall-wash-free\n\nOn January 14-15, 2021, FDA received correspondence from your firm stating you were not the manufacturer of IMC brand products and that you had given your “FDA certificates” to this third-party that likely manufactured the contaminated hand sanitizer products.\n\nOn January 25, 2021, FDA held a teleconference with your firm. We recommended you consider removing all of your firm’s hand sanitizer drug products currently in distribution to the U.S. market that were labeled as or declared as manufactured by your firm, Guangdong Kemei Pharmaceutical Technology Co. Ltd. Your firm agreed to support the recall of IMC hand sanitizer products. However, to date, your firm has not committed to recall.\n\nIn response to this letter, provide the following:\n\nA detailed investigation into how the drug product described above, which was declared to be manufactured at your facility and which was labeled as containing ethanol, was substituted in part or in whole with methanol.\n\nA list of all raw materials used to manufacture all of your hand sanitizer drug products, including the suppliers’ names, addresses, and contact information.\n\nA list of all batches of any hand sanitizer drug products shipped to the United States by your firm, and a full reconciliation of all material you distributed.\n\nCopies of the complete batch records for all batches distributed to the U.S.\n\nThe substitution and contamination with methanol in a drug product declared to be manufactured in your facility demonstrates that the quality assurance within your facility is not functioning in accordance with CGMP requirements under section 501(a)(2)(B) of the FD&C Act.1\n\nUnapproved New Drug and Misbranding Violations\n\nIMC WASH-FREE HAND SANITIZER is a “drug” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), and because it is intended to affect the structure or any function of the body. Specifically, this product is intended for use as a consumer topical antiseptic. Examples of claims observed on the IMC WASH-FREE HAND SANITIZER product label and labeling that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product include, but may not be limited to, the following:\n\n“WASH-FREE HAND SANITIZER… Drug Facts…Purpose…Antiseptic…Use(s) to help reduce bacteria on skin…Directions…Apply a small amount in you palm and rub hands together briskly until dry…”\n\nThis topical antiseptic product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), because it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. New drugs may not be introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a), unless they are lawfully marketed under section 505G of the FD&C Act (which is not the case for this product, as further described below) or other exceptions not applicable here. No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for this drug product, nor are we aware of any adequate and well-controlled clinical studies in the published literature that support a determination that your IMC WASH-FREE HAND SANITIZER drug product is GRASE for use under the conditions suggested, recommended, or prescribed in its labeling. Accordingly, this product is an unapproved new drug marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\n\nWe note that over-the-counter (OTC) topical antiseptic products had been the subject of rulemaking under the Agency’s OTC Drug Review. In particular, such products were addressed in a tentative final monograph (TFM) entitled “Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Tentative Final Monograph for Health-Care Antiseptic Drug Products,” Proposed Rule, 59 FR 31402 (June 17, 1994) (1994 TFM), as further amended by “Safety and Effectiveness of Consumer Antiseptics; Topical Antimicrobial Drug Products for Over-the-Counter Human Use; Proposed Amendment of the Tentative Final Monograph; Reopening of Administrative Record,” Proposed Rule, 81 FR 42912 (June 30, 2016)(Consumer Antiseptic Rubs Proposed Rule). Over the course of these rulemakings, three active ingredients (benzalkonium chloride, ethyl alcohol (ethanol), and isopropyl alcohol) were classified as Category III for use in consumer antiseptic rub products, meaning that additional safety and effectiveness data are needed to support a determination that a drug product containing one of these active ingredients would be GRASE for use as a consumer antiseptic rub.\n\nSection 505G of the FD&C Act addresses nonprescription drugs marketed without an approved application. Under section 505G(a)(3) of the FD&C Act, drugs that were classified as Category III for safety and effectiveness in a TFM that is the most recently applicable proposal or determination for such drug issued under 21 CFR Part 330 – and that were not classified as Category II for safety or effectiveness – are not required to have an approved application under section 505 in order to be marketed, as long as they are in conformity with the relevant conditions of use outlined in the applicable TFM, including the active ingredient, and comply with all other applicable requirements.\n\nHowever, IMC WASH-FREE HAND SANITIZER does not conform to the 1994 TFM, as further amended by the 2016 Consumer Antiseptic Rubs Proposed Rule, nor any other TFM, proposed rule, or final rule, and do not meet the conditions under section 505G(a)(3) of the FD&C Act for marketing without an approved application under section 505.\n\nAccording to the product label, IMC WASH-FREE HAND SANITIZER purportedly contains the active ingredient ethyl alcohol 75% v\u002Fv. However, as previously discussed, FDA laboratory analyses of a batch of this product detained at the border demonstrated that IMC WASH-FREE HAND SANITIZER contains ethanol in a concentration that is less than the 75% v\u002Fv stated on its product label and less than the amount of ethanol described in the 1994 TFM. Such a product does not conform with the TFM or the applicable requirements, nor is it consistent with the formulations described in the guidance setting forth FDA’s temporary policies for hand sanitizers during the COVID-19 public health emergency.\n\nFDA laboratory analyses also demonstrated that batches of IMC WASH-FREE HAND SANITIZER contain significant concentrations of the undeclared ingredient methyl alcohol (methanol). Use of methanol as an active ingredient is not in conformance with the 1994 TFM, nor is methanol included in the formulations described in FDA’s Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) Guidance for Industry. Furthermore, methanol is not acceptable as an inactive ingredient in hand sanitizers. As previously discussed, methanol has significant and sometimes fatal toxic effects and, therefore, does not meet the requirements under 21 CFR 330.1(e) that a product’s inactive ingredients be safe and suitable.\n\nAdditionally, this methanol-containing drug product, IMC WASH-FREE HAND SANITIZER, is misbranded under sections 502(j), (a), (e), (x), and (ee) of the FD&C Act, 21 U.S.C. 352(j), (a), (e), (x), and (ee).\n\nIt is misbranded under section 502(j) of the FD&C Act, 21 U.S.C. 352(j), because it is dangerous to health when used according to its labeling as a hand sanitizer. As previously stated, skin exposure to methanol could lead to systemic absorption, and substantial methanol exposure can potentially result in, among other things, blindness, permanent nervous system damage, and even death.\n\nThis hand sanitizer is misbranded under section 502(a) of the FD&C Act, 21 U.S.C 352(a), because its labeling is false or misleading. As noted above, IMC WASH-FREE HAND SANITIZER is labeled to contain ethyl alcohol 75% v\u002Fv. However, FDA laboratory analysis of batches of this product demonstrate that the product contains a concentration of ethyl alcohol (ethanol) that is less than what is stated on the product label and contains a significant concentration of methyl alcohol (methanol), an ingredient that is not declared on the product label. Section 201(n) of the FD&C Act, 21 U.S.C. 321(n), provides that “in determining whether the labeling or advertising is misleading there shall be taken into account . . . not only representations made or suggested . . . but also the extent to which the labeling or advertising fails to reveal facts material in the light of such representations or material with respect to consequences which may result . . .” Thus, the misleading representation of the concentration of the active ingredient ethyl alcohol (ethanol), and the failure of the product label to disclose the presence of the methyl alcohol (methanol) in the product, causes this product to be misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a).\n\nThe failure of this product to list methyl alcohol (methanol) as an ingredient on its label also causes it to be misbranded under section 502(e)(1)(A) of the FD&C Act, 21 U.S.C 352(e)(1)(A).\n\nIMC WASH-FREE HAND SANITIZER is also misbranded under section 502(x) of the FD&C Act, 21 U.S.C. 352(x) because the product label fails to disclose a complete domestic address or domestic telephone number through which the responsible person may receive a report of a serious adverse event with such drug.\n\nLastly, this product is misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee) because IMC WASH-FREE HAND SANITIZER is a nonprescription drug subject to section 505G of the FD&C U.S.C. 355h, but does not comply with the requirements for marketing under that section and is not the subject of an application approved under section 505 of the FD&C Act 21 U.S.C. 355.\n\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\n\nAdditionally, we note that under 21 CFR 201.61(a), “[t]he principal display panel of an over-the-counter drug in package form shall bear as one of its principal features a statement of identity of the commodity.” Under section 505G(a)(3) of the FD&C Act and the 1994 TFM, the statement of identity for health-care antiseptic drug products, a category that included consumer antiseptic rub drug products, must contain “the established name of the drug, if any” (59 FR 31442). Currently, there is no established name for consumer antiseptic rub drug products that have the active ingredient ethyl alcohol and are formulated as a gel. However, we recommend that you include the name “alcohol gel” as part of the statement of identity that appears on the principal display panel of the label for IMC WASH-FREE HAND SANITIZER which will allow consumers to make an informed decisions regarding your topical antiseptic.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, we strongly recommend engaging a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. We also recommend that the qualified consultant perform a comprehensive audit of your entire operation for CGMP compliance and that the consultant evaluates the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations associated with your drug products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. Note that FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-78 on January 7, 2021, as the methods used in and controls used for the manufacture, processing, packing, or holding of these products do not appear to conform to current good manufacturing practices within the meaning of section 501(a)(2)(B) of the FD&C Act. Drugs and drug products that appear to be adulterated may be detained or refused admission without physical examination.\n\nAll drugs and drug products manufactured by your firm may remain listed on this import alert until there is evidence establishing that the conditions that gave rise to the appearance of the violation have been resolved, and the Agency has confidence that future entries will be in compliance with the FD&C Act. This may include an inspection prior to the Agency considering the appearance of adulteration to be addressed.\n\nIf you decide you want to manufacture drugs for the United States in the future, request a Regulatory Meeting to discuss corrective actions.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot do so within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov.\n\nPlease identify your response with FEI 3017086967 and ATTN: LaKeesha Foster Sifontes.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\ncc:\n\nRegistered US Agent\n\nVizocom ICT LLC\n\n860 Jamacha Rd. Ste. 104\n\nEl Cajon, CA 92019\n\n________________________________\n\n1 Due to an increased demand for alcohol-based hand sanitizers during the COVID-19 pandemic, FDA published the Guidance for Industry: Temporary Policy for Preparation of Certain Alcohol-Based Hand Sanitizer Products During the Public Health Emergency (COVID-19) on March 19, 2020, and subsequently updated the guidance several times, most recently on February 10, 2021. This guidance communicates the Agency’s temporary policy that we do not intend to take action against firms for CGMP violations under section 501(a)(2)(B) of the FD&C Act if such firms prepare alcohol-based hand sanitizers for consumer use (or for use as a health care personnel hand rub) during the public health emergency, provided certain circumstances described in the guidance are present. These circumstances include preparation of hand sanitizer products using only the ingredients and formulas set forth in the guidance. In addition to the violative sample results detailed above that demonstrate the substitution of hand sanitizer products manufactured at your facility, a review of the purported formulations on the drug product’s labeling further indicates that this product is not prepared consistent with FDA’s temporary policy set forth in the guidance. Therefore, this product does not fall within the Agency’s temporary policy not to take action against firms manufacturing hand sanitizer products for violations of section 501(a)(2)(B) of the FD&C Act.","Guangdong Kemei Pharmaceutical Technology Co. Ltd.","guangdong-kemei-pharmaceutical-technology-co-ltd-612090-12142021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fguangdong-kemei-pharmaceutical-technology-co-ltd-612090-12142021","2026-10-26T08:08:51.101706+00:00","2021-12-21","612090","Mr. Jack Chen","2026-08-20T02:18:43.767+00:00","2021-12-14",17,{"510k":351,"classification":352,"enforcement":353,"event":354,"event_backfill":355,"pma":356,"warning_letter":357},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]